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Staphylococcus aureus is a Gram-positive human pathogen of significant clinical importance. 
The development of resistance to numerous classes of clinically important antibiotics has 
exacerbated the need for the development of novel therapeutic modalities for the treatment of 
serious, drug-resistant S. aureus infections.  
 
One approach for developing new therapies is the discovery of anti-virulence compounds. 
Virulence in S. aureus is mainly regulated by the agr quorum sensing system. The agr system 
is a master regulator of staphylococcal virulence and utilises the thiolactone macrocyclic 
peptide, auto-inducing peptide (AIP) as the signal molecule. The agr system is based around 
two divergent promoters, agrP2 and agrP3. The agrP2 promoter drives expression of the agr 
operon, which consists of 4 genes, agrB, agrD, agrC and agrA. AgrB and AgrD are responsible 
for the synthesis of AIP. AgrD is the pre-pro-peptide of AIP and is processed in part by the 
membrane bound cysteine protease AgrB, a process which ultimately forms the thiolactone 
macrocycle within the AIP molecule. Inhibitors of AgrC and AgrA have been studied 
extensively, however at present, there remains limited study of inhibitors of AgrB 
 
This thesis describes research towards the development of inhibitors of AgrB through the 
production of analogues of the natural product ambuic acid. This represents the first study of 
analogues of ambuic acid as inhibitors of staphylococcal virulence. These analogues include 
the synthesis of a (-)-enantiomer of a truncated ambuic acid analogue and the production of a 
range of ketal analogues. In addition, the attempted synthesis of a range of silyl ether analogues 
was also carried out, unfortunately, it was only possible to synthesise one analogue. 
 
In addition, the full chemical synthesis of a cyclopropyl isostere of the epoxide within a 
truncated ambuic acid analogue was established. This isostere was produced to determine 
whether the epoxide is required for inhibition of the putative target AgrB in an effort to advance 




The anti-agr activity of ambuic acid has been fully characterised in vitro. Ambuic acid was 
found to be a potent inhibitor of staphylococcal agr activity utilising a bioluminescent S. aureus 
reporter. In addition, ambuic acid was found to cause a reduction in the level of expression of 
the staphylococcal exotoxin α-haemolysin. Furthermore, utilising a bioluminescent S. aureus 
reporter strain which is incapable of synthesising AIP, but capable of sensing exogenous AIP 
(designed for the characterisation of inhibitors of AIP sensing), ambuic acid was found to have 
no effect. This suggests that ambuic acid inhibits the synthesis of AIP rather than the sensing 
of AIP. 
 
The testing of the synthesised analogues has been carried out in vitro using the bioluminescent 
S. aureus agr-activity reporter and pharmacological paramaters such as IC50 were determined. 
The majority of compounds were found to be potent inhibitors of agr activity, with the majority 
of compounds found to have IC50 values of < 10 µM. Surprisingly, the cyclopropyl isosteric 
analogue was found to be a potent inhibitor of agr activity, suggesting that the epoxide is not 
required for agr-inhibitory activity. 
 
These data, taken together represent the first study of analogues of the natural fungal product 
ambuic acid as inhibitors of staphylococcal virulence. In addition, these data show that these 
analogues are promising inhibitors of agr-activity and the production of further analogues 
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Like the dust that settles all around me 
I must find a new home 
The ways and holes that used to give me shelter 
Are all as one to me now 
But I, I would search everywhere 
Just to hear your call 
And walk upon stranger roads than this one 
In a world I used to know before. 
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1.1 Chapter outline 
. 
This chapter describes the organism Staphylococcus aureus, its pathogenicity, mechanisms of 
antibiotic resistance, incidence of infection, human impact and its worldwide burden on 
healthcare.  With the establishment of S. aureus as a pathogen of significant clinical importance 
and the great need for new therapeutic strategies for treating staphylococcal infections, the 
virulence of S. aureus and its potential as a target for the development of novel therapeutic 
modalities is outlined. This includes discussion of the staphylococcal agr quorum sensing 
















1.2 Staphylococcus aureus 
Staphylococcus aureus is a Gram-positive bacterium that is both a human commensal and a 
pathogen.1 S. aureus colonisation is common (about 30 % of the global population) and most 
often asymptomatic, typically localised to the skin, anterior nares and gastrointestinal tract.1-5 
Despite the frequent occurrence of S. aureus in the normal human microbial flora, the 
bacterium is an opportunistic pathogen and is a common cause of nosocomial infection.6-7 The 
major route of transmission of infection is direct contact, mediated by skin-to-skin contact and 
contact with contaminated objects.6, 8-9 
 
S. aureus infection is typically associated with individuals whom through a number of factors 
are at a higher risk. These risks include loss of the normal skin barrier (from recent surgery or 
injury) and underlying health conditions such as acquired immune deficiency syndrome and 
diabetes.6, 8 Persistent host colonisation by S. aureus is also an increased risk factor, notably 
nasal carriage.2, 10-11  
 
The exquisite ability of S. aureus to be both part of the commensal microbial flora and an 
opportunistic pathogen is due to the tight regulation of a broad array of virulence factors (such 
as exo-toxins) that are dependent on local bacteria population density and environment.12 
 
In recent times, strains of methicillin-resistant S. aureus (MRSA, as discussed in greater detail 
in section 1.3) have received significant media attention, notably as a nosocomial pathogenic 
agent.7, 13  
 
1.3 The pathology and epidemiology of S. aureus 
The S. aureus infection can clinically present with a broad range of severity. Infection can take 
the form of mild skin infections, such as boils, impetigo and cellulitis to more invasive and 
severe infections, such as endocarditis, bacteraemia, pneumonia, osteomyelitis and sepsis.2, 14-
20 Furthermore, diseases mediated by staphylococcal toxins are also known, which include food 
poisoning, scalded skin syndrome and toxic shock syndrome (TSS).21-23 The most severe of 
these diseases are often fatal. 
 
S. aureus infections are often caused by inoculation of an injury such as a surgical incision by 
the host’s own commensal bacteria. Wertheim et al. found that the risk of S. aureus bacteraemia 
13 
 
in hospital is 3-fold more likely in S. aureus carriers than non-carriers.24 Further studies by von 
Eiff et al. found the blood and anterior nares bacterial isolates are identical in 82 % of the study 
group, thus indicating that endogenous colonisation is a significant risk.25 Healthcare workers, 
whose hands have been contaminated with staphylococci from their own reservoir or that of an 
infected patient is another source of S. aureus infection.8  
 
Initial infection usually causes localised minor pathology, such as the formation of an abscess, 
the most severe of which may require drainage.8 This can complicate the recovery from 
surgery.26 Further complications can arise if the infection is caused by a strain of MRSA. 
Systemic dissemination of the bacteria, away from the site of initial infection can lead to 
endocarditis, bacteraemia and sepsis.17, 27 
 
Numerous other factors can predispose an individual to an increased risk of developing more 
severe S. aureus infections. These include acquired immunodeficiency syndrome (AIDS), 
diabetes, disorders of neutrophils, intravenous drug use, chronic hepatitis C and cancers.6, 28-29 
This can lead to severe soft-tissue infections such as necrotising fasciitis, causing extensive 
necrosis of the fascia and subcutaneous tissue, often requiring amputation, if it has not already 
proved fatal.30 
 
Although typically associated with infections arising from within healthcare settings, S. aureus 
is also known to cause disease in otherwise healthy individuals. A well-documented example 
is toxic shock syndrome (TSS). The introduction of super-absorbent tampons containing cross-
linked carboxymethylcellulose, manufactured by Rely Ltd was linked to a spike in cases of 
TSS in otherwise healthy women.31 Numerous studies failed to attribute this to a direct increase 
in the production of toxic shock syndrome toxin-I (TSST-I), the super-antigen causative agent 
of TSS.23, 31 However, it was suggested the composition of the tampon was the cause, and that 
it may act as a reservoir for TSST-I, allowing it to cross the vaginal mucosa, causing TSS.31 
TSS is a severe acute disease and is characterised by hypotension and fever, which can also 
lead to multisystem organ failure.32 
 
At present, the vast majority of MRSA cases are hospital-acquired (HA-MRSA) and since the 
1960s, it has been considered a healthcare related pathogen, with a high incidence.33 However, 
there has been a recent emergence of strains of community-acquired MRSA (CA-MRSA), 
which can spread rapidly among otherwise healthy individuals.6 One of the strains, known as 
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S. aureus USA300, postulated to have emerged during the early 1990s is an increasingly 
common cause of CA-MRSA infections.34 Many cases have emerged in different 
demographics, including military trainees, prison inmates and American football teams.6, 35 A 
study of the St. Louis Rams during the 2003 American football season found 5 of the 58 players 
had MRSA infections, typically at abrasion sites from falling.35 Further to soft tissue infections, 
CA-MRSA infections have also been found to cause sepsis and necrotising pneumonia.33 These 
more severe cases account for up to 4 % of CA-MRSA infections.36 
 
Although the most pronounced CA-MRSA epidemic has been in the U.S, it is a global issue.6, 
36  There has been a rapid spread of CA-MRSA across the globe, with cases reported throughout 
North America, South America, Europe and Australia.6 Furthermore, CA-MRSA is also an 
issue in Scandinavian countries where MRSA cases have typically been low.6  
 
In the industrialised world, the approximate incidence of S. aureus bacteraemia is 10-30 per 
100,000 person years.1, 37 For example, in Denmark, there has been a gradual increase (from 3 
to 20 per 100,000 person years) in observed cases from the 1950s to the 1990s, which is 
concurrent with an exponential increase in hospital admissions and invasive surgeries in 
Denmark.1, 38 There has also been an increase in the contribution of MRSA to the incidence of 
S. aureus bacteraemia.1 A study in Quebec, Canada found an increase from 0 to 7.4 cases per 
100,000 person years between 1991 and 2005. 1, 39 During the same study period, cases of 
methicillin sensitive S. aureus (MSSA) bacteraemia remained relatively stable. 39 These 
findings have also been replicated in studies from the United Kingdom and North America. 1, 
40-41 Furthermore, in the United States of America, the observed increase in MRSA bacteraemia 
has been largely linked to CA-MRSA, with strains such as S. aureus USA300 being particularly 
prevalent.1, 42 
 
Infective endocarditis (IE) also presents a strain on global healthcare, with estimates suggesting 
that incidence ranges between 1.5 to 6 per 100,000 person years (in the USA and Europe 
between 1970-2000).1, 43 Of these cases, S. aureus was found to cause 16-34 % of IE.1, 43 During 
the period of study, no relative change in the prevalence of an individual bacterial species was 
noted. More current studies have shown that there has been an increase in the incidence of IE, 
the driving force of which has been an increase in S. aureus causing IE.1 Furthermore, S. aureus 
IE was found to have an increased mortality rate, relative to other pathogens.1, 44 S. aureus is 
also a substantial risk in prosthetic valve endocarditis.1 The total annual incidence of prosthetic 
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valve IE is 0.8-3.6 %; of these, S. aureus is the causative agent of 23-33 % of cases.1 The 
greatest risk of developing prosthetic valve IE is during the first 12 months after heart valve 
replacement surgery (greater for mechanical in the first 3 months, greater risk over the whole 
12 months for porcine).1, 45 Various studies have estimated the mortality rate of S. aureus IE to 
be between 22-66 %, higher than other causative agents of IE.1 
 
As previously discussed, S. aureus can cause skin and soft tissue infections (SSTIs) ranging in 
severity from abscesses, impetigo and cellulitis to life-threatening conditions, such as 
necrotising fasciitis. In recent years, the importance of S. aureus as a causative agent of SSTIs 
has grown, exacerbated by a global epidemic of CA-MRSA SSTIs.1, 36, 46 Studies have shown 
that CA-MRSA is not merely causing cases of SSTIs, but increasing the incidence.1 A study 
between 1993-2005 found an increase in presentation of SSTIs in emergency departments in 
the USA from 1.2 million to 3.4 million annually.47 Pallin et al. noted that this rise was 
‘contemporaneous’ with the emergence of CA-MRSA. Although they cannot determine a 
causality between the two factors, they are concerned that CA-MRSA may be causing more 
disease, instead of replacing other causative agents.1, 47 At the start of the study, treatment of 
SSTIs with drugs specific for CA-MRSA (such as trimethoprim 1.2/sulphamethoxazole 1.3, 
[Figure 1.2]) was rare, but by the end of the study (2005), treatment of clinical presentation of 
SSTIs with such drugs was commonplace.47 
 
Figure 1.2. Trimethoprim (1.2)/ sulphamethoxazole (1.3) (co-trimoxazole), administered together 
 
With the growing incidence of CA-MRSA, several studies have shown that there are distinct 
differences between CA-MRSA and both HA-MRSA and MSSA.48 These distinct differences 
are believed to have enabled CA-MRSA to spread within the wider community, not just 
localised to the heathcare setting. One of the major differences between HA-MRSA and CA-
MRSA is the possession of different antibiotic resistance profiles.48 Notably, differences in the 
SCCmec cassette, which causes resistance to β-lactams (described in greater detail later in this 
chapter), can distinguish CA-MRSA and HA-MRSA. HA-MRSA strains typically belong to 
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SCCmec groups I, II and II, whereas CA-MRSA isolates typically carry SCCmec IV or V.48 
Type IV is known to not carry any resistance genes with the exception of those required for the 
resistance to β-lactams.49 It is believed that this means SCCmec IV within strains of CA-MRSA 
confers a lower fitness burden. This is particualry important in an environment where antibiotic 
challenge is less common, i.e. outside of a healthcare environment where resistance genes are 
not always required.50 In addition, CA-MRSA strains are typically resistant to a narrower 
spectrum of antibiotics when compared to strains of HA-MRSA.36 The level of resistance to 
antibiotics in CA-MRSA has also been shown to be lower than in HA-MRSA, for example, 
Cheung et al. found the MIC of oxacillin to be 50 fold lower for the CA-MRSA strain USA300 
than the HA-MRSA strain MRSA252.51 This lower level of resistance could also be due to the 
lower level of exposure to antibiotic outside of the hospital environment. 
 
In addition to their difference in antibiotic expression profiles, CA-MRSA strains have been 
shown to have increased virulence relative to HA-MRSA strains. The CA-MRSA strain LAC 
has been shown to be more virulent in a mouse infection model than HA-MRSA strains such 
as MRSA252.52 Furthermore, the increased level of virulence of CA-MRSA strains relative to 
HA-MRSA may be explained by an increase in expression of virulence factors, such as toxins. 
Studies have also shown that there is increased level of expression of agr (a master regulator 
of staphylococcal virulence, described in more detail later in this chapter), which may lead to 
an increase in the observed levels of virulence factor production.51 
 
Thus, it is clear that for S. aureus, both MSSA and MRSA strains present a clear burden on 
global healthcare systems. The development of antibiotic-resistant S. aureus species such as 
strains of MRSA and vancomycin-resistant S. aureus (VRSA) are a further complicating 
factors.6 MRSA is a leading cause of death by an infectious agent within the USA and, as 
highlighted above, the recent emergence of CA-MRSA has further compounded this issue.46 
The data presented here provide a compelling case for the need of new therapies for the 
treatment of S. aureus infections. 
 
 
1.4 S. aureus and antibiotic resistance 
Prior to Alexander Fleming’s discovery of penicillin, bacterial infection often proved fatal 
meaning that even a simple injury, if it became infected could be imminently life-threatening.6 
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Indeed, the first patient to be treated with penicillin, a police constable called Albert Alexander 
had developed sepsis after pricking his hand on roses whilst gardening. Antibiotics are one of 
the few drugs within pharmaceutical sciences which can be described as Paul Ehrlich’s famous 
‘magic bullet’ (Zauberkugel) due to their ability to kill a microbial infective agent, whilst 
having minimal effect on the host.  
 
Antibiotics are crucial to modern medicine, critical to invasive surgery and chemotherapies. 
However, poor stewardship of antibiotics has led to the development of widespread antibiotic 
resistance in a range of species. These include; MRSA, VRSA, extensively drug-resistant 
(XDR) Mycobacterium tuberculosis and clindamycin-resistant Clostridium difficile.6, 53-54 
These present a significant global burden on health services. Indeed, the World Health 
Organisation (WHO) global report on anti-microbial resistance presents MRSA as an antibiotic 
resistant pathogen of international concern.55 
 
In addition to the development of bacterial resistance to antibiotics, there has been a reduction 
in the research and development of novel antimicrobial therapies. Between the 1940 and 1990, 
there was a huge surge in the discovery and the development of antibiotics.56 Companies were 
striving for scientific breakthrough, identifying new chemical entities and novel modes of 
action (MOA) in an aim to secure patents, a great financial incentive.56 As resistance was 
encountered, replacement of drugs with a subsequent new generation of antibiotics was 
possible.56 However in more recent years, the pharmaceutical industry has moved away from 
the production of new antibiotics towards more profitable therapeutics, primarily due to the 
huge financial investment required to bring a new drug to market.56-57  The current situation 
has been described as ‘the perfect storm’, with a dramatic increase in untreatable antibiotic-
resistant infections and a limited pipeline of novel antibiotics coming to market.57 
 
1.4.1 Antibiotics used for treatment of S. aureus infections 
Fleming’s discovery (1928) and the exploitation of penicillin by Florey and Chain (1939) 
ushered in the antibiotic era, whereby previously fatal infections could be easily treated.6, 58 
With the exception of Salvarsan (1.4, Figure 1.3), discovered by Ehrlich in 1910, which was 





Figure 1.3. Salvarsan (1.4) 
 
Penicillin describes a number of antibiotics which are produced by the moulds of Penicillium 
spp. and fall into a family of antibiotics called β-lactams. These compounds are based around 
a core structure, consisting of a fused thiazolidine and β-lactam bi-cyclic ring system and a 
variant side chain 1.5 (Figure 1.4).60 The penicillins include penicillin G 1.6 (for intravenous 
use), penicillin V (oral) 1.7, and benzathine penicillin 1.8 (intramuscular) (Figure 1.4).61-63 

















Figure 1.4. Structures of numerous penicillins. 1.5 General structure of penicillin, 1.6 penicillin G, 1.7 penicillin 
V and benzathine penicillin 1.8 
Penicillins are bactericidal, meaning they kill actively growing and dividing bacteria. They 
inhibit the synthesis of the bacterial cell wall, specifically the biosynthetic step involved in the 
cross-linking of peptidoglycan, resulting in structural weakness.60 The target enzymes are 
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transpeptidases, also known as penicillin binding proteins (PBPs). 60, 64 S. aureus synthesises 
cell wall during normal growth and division. The cell wall is a polymer made up of repeating 
N-acetylglucosamine (NAG) 1.9 and N-acetylmuramic acid (NAM) 1.10 subunits, which forms 
the ‘backbone’ of the peptidoglycan (Figure 1.5, 1.11).64 Peptide side chains branch off NAM 
within the backbone (Figure 1.5).64 In S. aureus, these peptide chains are branched penta-
peptide chains consisting of L-Ala-γ-D-Glu-L-Lys(Gly)5-D-Ala-D-Ala (Figure 1.5).
64 
Elongation of the NAM-NAG glycan chain is carried out by PBPs which have transglycosylase 
activity, which involves the transfer of the disaccharide-pentapeptide (as described above) from 
membrane-bound lipid-II, adding it to the polysaccharide chain (Figure 1.5).64-65 Cross-linking 
of the ‘strands’ is achieved through a transpeptidation reaction, wherein the terminal D-Ala is 
displaced by the terminal glycine of the pentaglyl side-chain on the L-Lys (Figure 1.5).64 PBPs 
are crucial to the survival of S. aureus as unproductive formation of peptidoglycan cell wall 





Figure 1.5. A. Transglycosylation between individual NAG 1.9 and NAM 1.10 subunits, forming the NAG-NAM 
dimer 1.11, a polymer of which forms the glycan backbone of peptidoglycan. B. Transpeptidation, allowing for 
cross-linking between two peptidoglycan strands giving the polymer the strength required to function as the cell 
wall. Cross-linking occurs with the displacement of the terminal D-Ala by the terminal amino of the pentaglyl side 
chain. 
 
β-lactam antibiotics inhibit the synthesis of the cell wall of S. aureus through inhibition of the 
transglycolase-transpeptidase PBP2.65 Indeed transglycolase-transpeptidase enzymes are 
called PBPs because of their known binding of penicillins.66 It is thought that β-lactam 
antibiotics mimic the natural substrate of the transpeptidase domain, the terminal portion of the 
peptidyl chain (D-Ala-D-Ala) (Figure 1.5).66-67 Both the natural peptidoglycan substrate and β-
lactam acylate a catalytic serine within the active site of the transpeptidase active site of the 
PBP.66 The  natural peptidoglycan-enzyme acyl species can react with a second peptidoglycan 
chain (terminal glylyl) forming the desired peptidoglycan cross-link (Figure 1.5).66 The acyl 
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intermediate formed with the β-lactam, cannot undergo this second step, thus inhibiting the 





Figure 1.6. The structures of glycopeptides. vancomycin 1.12, general structure of teicoplanin 1.13, telavancin 





There are other classes of antibiotics that target the cell wall. For example, the glycopeptides, 
including vancomycin 1.12 (Figure 1.6), disrupt the synthesis of the cell wall of S. aureus.65 
Vancomycin is widely used to treat serious infections, caused by S. aureus.65 The most widely 
used members of the glycopeptides are vancomycin 1.12 and the lipoglycopeptide analogue 
teicoplanin 1.13 (Figure 1.6).68 Semi-synthetic lipoglycopeptide analogues telavancin 1.14, 
dalbavancin 1.15 and oritavancin 1.16 are also in clinical use (Figure 1.6).68 These compounds 
are known to bind to D-Ala4-D-Ala5 of lipid-II monomer, acting as a ‘substrate binder’, 
preventing the key transglycosylation step catalysed by PBP2, and consequently disrupting 
peptidoglycan synthesis (Figure 1.6).65, 68 Although the lipid-II monomer is expressed in the 
vast majority of bacterial species, the activity of glycopeptides is limited to Gram-positive 
species.68 This is due to the physiochemical properties of glyopeptides preventing them from 














Figure 1.7. The peptidic antibiotic daptomycin 1.17.  
 
Daptomycin 1.17 (Figure 1.7) is a cyclic peptide antibiotic, used for the treatment of S. aureus 
bacteraemia and IE.65 It is also commonly used to treat MRSA infections, and bacteria that are 
resistant to vancomycin.65, 69 Daptomycin 1.17 is known to target the S. aureus cell 
membrane.65, 70 
 
Daptomycin requires calcium for bactericidal activity, forming an active Ca2+-daptomycin 
complex, with coordination of the Ca2+ ion by an aspartate and several carbonyls within the 
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peptidic backbone.65, 70-71 The Ca2+-daptomycin complex behaves as a cationic peptide upon 
interaction with the cell, it undergoes oligomerisation forming cell-wall permeable micelles, 
which then interact with the negatively charged phosphate head groups of phosphatidyl 
glycerol.65 This leads to disruption of the phospholipid bilayer resulting in membrane 
permeabilization, leakage of ions, membrane depolarisation and ultimately death of the 
bacterial cell.65  
 
In addition to targeting the synthesis of bacterial cell wall components, antibiotics interfere 
with key bacterial life processes. This includes the inhibition of protein synthesis, through the 
inhibition of both the 30S and 50S ribosomal subunits. Inhibitors of the 30 S subunit include 
tetracyclines, such as tetracycline 1.18 and tigecycline 1.19 (Figure 1.8).65 The 
aminoglycosides, such as neomycin 1.20 and gentamicin 1.21 (Figure 1.9) are also known 
inhibitors of the 30S subunit.65 Inhibitors of the 50S subunit include linezolid 1.22 and 








Figure 1.8. Tetracyclines, tetracycline 1.18  and tigecycline 1.19. 
 
Tetracyclines are bacteriostatic antibiotics.72 They function through binding near to the mRNA 
codon recognition site of the amino acyl-tRNA (aa-tRNA).65, 73-74 In fact, Mg2+ within the 
ribosome forms a complex with tetracycline and is stabilised by a further six intramolecular 
contacts with residues within the 16S rRNA, which effectively disrupts binding of the aa-
tRNA, leading to dissociation and cessation of protein synthesis.65, 72, 74 
 
Aminoglycosides are the only known bactericidal ribosome binding antibiotic.65 They function 
by blocking initiation of translation at ribosomes and causing a 10-fold increase in 
mistranslation of RNA, from < 1 per 1,000 amino acids to ~1 in 100.65, 75 Davis et al. suggest 
that the bactericidal effect comes from the production of defective membrane proteins, leading 




Figure 1.9. Examples of aminoglycosides, neomycin B 1.20  and gentamicin C2 1.21. 
 
Inhibitors of the 50S subunit include linezolid 1.22, an oxazolidinone, which binds at the 
peptidyl transfer centre of the ribosome, which results in disruption of peptide backbone 
formation.65 Like linezolid 1.22, chloramphenicol 1.23 also disrupts peptidyltransferase 
through interference with the amino acyl terminal of aa-tRNA.65 
 
 
Figure 1.10. Inhibitors of the ribosomal 50S subunit linezolid 1.22 and chloramphenicol 1.23. 
 
Protein synthesis can also be interrupted through the disruption of the transcription machinery. 
Rifampicin 1.24 (Figure 1.11) targets the β-subunit RNA polymerase (encoded by the rpoβ 
gene).65 76 Rifampicin is known to sterically block transcriptional elongation.77 Rifampicin is 
bactericidal due to its high affinity binding and RNA polymerase inhibitory activity, arresting 
transcription, a key life process.77 
 
The replication of bacterial DNA is another essential process that is targeted by antibiotics. 
Fluoroquinolones, such as ciprofloxacin 1.25 (Figure 1.12) have been used previously for the 
treatment of S. aureus infections.78 Fluoroquinolones have two main targets within the bacterial 
cell, these are DNA gyrase and topoisomerase IV.65, 79 DNA gyrase is a type-II topoisomerase, 
consisting of four individual subunits (2 GyrA and 2 GyrB) and induces negative supercoils 
into the double stranded circular genomic DNA during DNA replication.79-80 This prevents the 
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accumulation of positive supercoils ahead of the advancing replication fork.79-80 The 
accumulation of positive super coils exerts considerable stress on the DNA and can lead to 
double-strand breakage, fatal for the bacteria.79-81 Topoisomerase IV is the second target of 
fluoroquinolones.79 It is a tetramer (2 ParC and 2 ParE subunits) and shares homology with 
DNA gyrase.79 Like DNA gyrase, topoisomerase IV carries out relaxation of the circular 
genomic bacterial DNA during replication and when disrupted, contributes further to bacterial 
cell death.79  
 
Figure 1.11. The RNA polymerase inhibitor rifampicin 1.24 
 
For both gyrase and topoisomerase IV, the production of double-stranded DNA is cruicial to 
the activity of the enzyme. If too many unregulated double-stranded breaks breaks occur this 
can lead to cell death. Aldred states that quinolones capitalise on this and convert both gyrase 
and topoisomerase into cellular toxins, through inhibition, leading to an increase in the number 
of enzyme-DNA cleavage complexes, this increases the risk of double stranded DNA breaks.81  
 
 






1.4.2 Mechanisms of S. aureus antibiotic resistance 
Naturally, S. aureus is susceptible to almost all antibiotics.6 Poor stewardship of antibiotics has 
led to the development of widespread antibiotic resistance. Antibiotics impose a significant 
selection pressure on S. aureus and hence an evolutionary driving force. Evolution drives 
resistance as those bacteria adapted to survive (resistant to antibiotics) are selected for.  
 
The resistance to antibiotics occurs through a number of mechanisms. These include, but are 
not limited to, mutation leading to alteration of the antibiotic target binding site, an increase in 
the level of expression of efflux pumps and reduced cell envelope permeability.65 
 
Within a few years of the introduction of the penicillin β-lactam (early 1940s) antibiotics, 
resistant strains were being observed clinically. This highlights the ease by which S. aureus 
can develop resistance to antibiotics. These resistant strains of S. aureus were found to be 
expressing a β-lactamse enzyme which can specifically hydrolyse the β-lactam moiety, critical 
to its bactericidal activity.65 The β-lactamase which causes resistance to penicillins in S. aureus 
is BlaZ, (encoded by blaZ) which contains a key catalytic serine residue (Figure 1.13).65 This 
serine residue is utilised for hydrolysis of the β-lactam moiety, rendering the penicillin 
molecule inactive (Figure 1.13).65, 82  
 
Figure 1.13. BlaZ catalysed opening of the β-lactam ring of penicillin antibiotics. 
 
BlaZ is an extracellular enzyme and is produced when the cell is exposed to a β-lactam 
antibiotic.82 Its expression is controlled by two regulatory genes, the blaI repressor and the 
blaR1 anti-repressor.82 Studies suggested that upon exposure to β-lactams and binding of a β-
lactam to the known transmembrane receptor/signal transducer BlaR1, BlaR1 undergoes rapid 
autolytic cleavage.83 Zhang et al. indicated that the un-cleaved BlaR1 is a prometalloprotease, 
which upon autolytic activation can then cleave the BlaI repressor (Figure 1.14). This removes 
BlaI from its intergenic operator between blaZ and blaR1 (Figure 1.14).82-84 This allows for 
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transcription of blaZ and expression of the BlaZ β-lactamase, allowing for resistance.83 De-
repression of blaR1 is necessary, as once cleaved, it can no longer transmit a signal, thus to 
ensure longevity of the signal, the continual production of BlaR1 is required.83 
 
blaZ is carried on the transposon Tn552, which is often on a large β-lactamase/heavy-metal 
resistance plasmid.65, 85 This is a mobile genetic element, which allows for the transmission of 
resistance genes. 
 
Figure 1.14. The regulation of the synthesis of the BlaZ β-lactamase in S. aureus. Briefly, a penicillin antibiotic 
binds the membrane bound BlaR1 receptor/signal transducer, which then undergoes rapid autolytic cleavage. 
After autolytic activation, active BlaR1 can cleave the BlaI repressor, preventing binding to it’s intergenic operator 
region. This allows for expression of blaR1, blaI and blaZ. blaZ encodes the BlaZ β-lactamase, which can then 
hydrolyse the β-lactam heterocycle within penicillin molecules. 
 
As previously outlined, within a few years of the introduction of penicillins for clinical use, 
resistance was observed. To counter this, second generation semi-synthetic penicillins were 
introduced in 1959.64 This second generation include oxacillin 1.26 and methicillin 1.27 
(Figure 1.15).64 However, within two years, cases of MRSA were being observed clinically.86 
This sudden emergence of resistance was due to the acquisition of the mecA gene, which 
encodes a PBP, called PBP2a, the transpeptidase domain of which is not potently inhibited by 
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β-lactams.64 This allows for the synthesis of peptidoglycan even in the presence of methicillin. 
Studies have shown that the active site of the PBP2a transpeptidase has a more closed 
conformation than the normal PBP2, occluding access by active β-lactams.64 PBP2a is still able 
to efficiently catalyse the crosslinking of peptidoglycan, despite the closed conformation of the 
active site and the ~ 1000 Å3 size of the two peptidoglycan subunits.64 It is suggested that the 
protein undergoes a significant conformational change during catalysis.64 
 
Figure 1.15. Second generation semi-synthetic penicillins oxacillin 1.26  and methicillin 1.27. 
 
The mecA is within the chromosome of all MRSA strains and is part of a mobile genetic 
element called SCCmec, a genomic island, transferred between cells due to the action of 
cassette chromosome recombinases A and B (ccrA and ccrB), both encoded within SCCmec.82, 
85, 87 These are site specific recombinases and can excise the cassette and integrate it at a specific 
site within the chromosome.87 Integration of SCCmec into the genome of S. aureus at the 
attBscc locus (near the S. aureus origin of replication) is sufficient to convert drug sensitive 
MSSA into the drug-reistant nosocomial pathogen MRSA, which is resistant to the majority of 
β-lactam antibiotics.49  SCCmec elements are diverse in nature and have been characterised 
into 13 types.88  These are based on different combinations of five mec complexes (A, B, C1, 
C2 and E) and nine distinct ccr complexes (1-9).88 SCCmec also contain mecR1 and mecI, both 
of which regulate the expression of mecA.85 MecR1, in the presence of a β-lactam antibiotics 
cleaves the MecI repressor, which is bound to the operator of the mecA promoter, this allows 





Figure 1.16. The β-lactamase suicide inhibitor clavulanic acid 1.28 which is used in conjunction with amoxicillin 
1.29 as a means to extend its spectrum. 
 
With the development of resistance to β-lactams by S. aureus, attempts have been made to 
circumvent this. These include the development of so-called suicide inhibitors of β-lactamases 
including clavulanic acid 1.28, which has been used in conjunction with amoxicillin 1.29 to 
extend its spectrum of activity in the era of antibiotic resistance (Figure 1.16).89 Furthermore, 
the development of further β-lactam antibiotics which are chemically more resistant to β-
lactamases, these include carbapenems 1.30 and cephalosporins 1.31 (Figure 1.17).90-91 
 
Figure 1.17. General structure of carbapenems 1.30 and cephalosporins 1.31. 
 
Resistance to glycopeptides including vancomycin has also been observed.65 By the end of the 
1990s, MRSA strains had become the most common cause of S. aureus infections and the most 
common therapy for these infections were glycopeptide antibiotics, predominantly 
vancomycin.92 The development of vancomycin resistance in S. aureus is thought to be 
polygenic and requires the development of mutations in a number of genes in cell wall 
biosynthesis.93 This resulted in the development of vancomycin intermediate-resistant S. 
aureus (MIC= 4-8 µg/mL) and vancomycin-resistant S. aureus (MIC= >16 µg/mL).93 
Vancomycin resistance is caused by the vanA operon, part of the transposon Tn1546, originally 
part of a vancomycin resistant enterococci conjugative plasmid.93 The vanA operon consists of 
seven genes (vanA, vanH, vanX, vanS, vanR, vanY and vanZ) and is regulated by a two 




As described earlier, vancomycin binds to the D-Ala4-D-Ala5 of newly synthesised peptide 
pre-cursors, required for the synthesis of peptidoglycan. In contrast, the vanA operon allows 
for the synthesis of a D-Ala4-D-lactate peptidoglycan precursor, which cannot be bound by 
vancomycin.93 This yields a peptidoglycan that is not susceptible to glycopeptide 
interference.93 The production of the D-Ala4-D-lactate precursor is carried out by VanA 
(catalyses the D-Ala4-D-lactate ester bond formation) and VanH (forms D-lactate).93 VanX 
hydrolyses the D-Ala-D-Ala bond and VanY is capable of removing D-Ala-D-Ala which has 
already been attached to the larger pentapeptide peptidoglycan precursor (Figure 1.18).93 
Together, the vanA operon produces a cell wall resistant to glycopeptide antibiotics. 
 
Figure 1.18. Schematic of how resistance to vancomycin develops in S. aureus, adapted from Mcguinness et al.93 
 
Resistance to antibiotics that target the 30S ribosomal subunit has also been observed. 
Resistance to tetracyclines has been observed through two main mechanisms. Firstly, through 
efflux which is mediated by two tetracycline efflux pumps TetA(K) and TetA(L).65 The efflux 
pumps use a proton gradient as the driving force for tetracycline efflux. The TetA(K) pump is 
encoded on the plasmid pT181 and is integrated into the SCCmecIII cassette of numerous 
MRSA strains.65 In addition to efflux pumps, mechanisms of ribosomal protection have also 
been observed.65 These include TetO/M, which resemble elongation factor-G, it does not 
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function as an elongation factor, but instead helps displace tetracyclines from the ribosomal 
active site.65 
 
Resistance to aminoglycosides, such as neomycin and gentamicin, which also inhibit the 30S 
ribosomal subunit has also been recorded. This typically occurs through the expression of 
enzymes, again encoded by mobile genetic elements, which chemically modify 
aminoglycosides.65 Modification prevents binding of the drug to the ribosome, rendering it 
useless. The gene aaC-aphD encodes an acetyltransferase-phosphotransferase (carried on 
transposon TN4001) can lead to resistance against both neomycin and gentimycin.65 
 
Resistance to linezolid 1.22 and chloramphenicol 1.23, antibiotics which target the 50S 
ribosomal subunit has also been seen.65, 85 Chloramphenicol resistance occurs through the 
inducible expression of the chloramphenicol acetyltransferase enzyme, which is carried on the 
pC221 plasmid.85 The acetylation of chloramphenicol to produce acetyl-chloramphenicol 1.32 
prevents binding to the 50S subunit of the ribosome (Figure 1.19). In addition to 
chloramphenicol acetyltransferase, 23S rRNA methyltransferase, which methylates A2503 of 
23S rRNA, causing resistance to chloramphenicol.94 The methyltransferase can also confer 
resistance to linezolid.85  
 
Figure 1.19. Acetyl-chloramphenicol 1.32, produced by the chloramphenicol acetyltransferase enzyme. 
 
As described above, S. aureus has also developed resistance to a broad spectrum of antibiotics. 
It is hardly surprising that resistance should arise, given the stringent selection pressure 
conferred on S. aureus by antibiotics. Those organisms which are not adapted die and those 
which survive can pass on their genes to the subsequent generation. One could argue that 
resistance is merely a product of evolution and could be deemed to be inevitable. In addition, 
mobile genetic elements further compound the issue and aid in the development of resistance. 
This, taken with the evidence above provides a compelling case for the development of new 
therapeutic strategies for the treatment of antibiotic resistant S. aureus infection. These 
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strategies would need to disrupt the organism sufficiently to ease infection, whilst applying 
minimal selective pressure. This could be carried out by the targeting of non-critical bacterial 
life processes. One such avenue of therapy could be the development of anti-virulence 
compounds, with the goal of ‘disarming’ the bacteria, aiding the perturbation of infection.  
 
1.5 The virulence of S. aureus 
As described previously, S. aureus can exist as both a commensal bacterium and an 
opportunistic pathogen. The ability of S. aureus to fulfil both roles is due to its exquisite 
regulation of expression of an arsenal of virulence factors. These virulence factors and their 
regulatory elements are known as accessory genes and are not essential for normal bacterial 
growth.12 The accessory genes fulfil numerous roles, including tissue adhesion, evasion of the 
immune system and injury to the host tissues and cells.95  The pathogenesis of S. aureus is a 
complex process, requiring the coordination of both extracellular and integral cell wall 
proteins, each of which is key for different stages of infection, such as cell wall adhesins, e.g. 
protein A and the fibronectin binding proteins required for early stage infection and the 
production of toxins in later infection.96 The majority of these accessory genes encode bacterial 
cell wall surface and secreted proteins.97 Together, these allow the bacteria to fulfil the 
functions described above and are collectively known as the virulon.97 
 
In the late 1980s, a number of studies described the global regulator, the accessory gene 
regulator (agr) as an overarching regulator of the S. aureus virulon that regulates the expression 
of numerous staphylococcal exoproteins.97-100 In addition to the agr system, S. aureus has 
numerous other virulence regulatory systems such as the Sae (S. aureus exoprotein expression) 
two-component response system, which in conjunction with agr drives the expression of 
numerous exoproteins such as alpha-toxin, coagulase (activates prothrombin), Panton-
Valentine leucocidin (cytotoxin that destroys leukocytes) and TSST-1.12, 101-102 Another major 
regulator of staphyclococcal virulence is SarA, a cytoplasmic DNA binding protein that can 
enhance expression of α, β and δ toxins, through direct effect and/ or up-regulation of agr 
activity.96  
 
1.5.1 The staphylococcal agr system 
Recsei et al. identified the agr system through insertion of an erythromycin resistance cassette 
between the purB and ilv loci.98 They noted a 50 fold decrease in the expression of α, β and δ 
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haemolysins and TSST-1.98 Furthermore, the staphylococcal agr system has been shown to 
regulate the expression of numerous exoproteins, a list of which is surmised in (Table 1.1).97 It 
acts as a ‘molecular switch’, driving expression of a range of toxins and repressing the 
expression of integral cell wall proteins during the post-exponential growth phase of S. 
aureus.96 This aids in the dissemination of biofilms and the propagation of infection. 
 
The staphylococcal agr system is a quorum sensing (QS) system.103  QS is a phenomenon 
where bacteria can produce, sense and respond to small extracellular signal molecules in a cell 
density dependent manner.104 This allows the bacteria to employ community-wide behaviours, 
such as virulence, bioluminescence and swarming through co-ordination of gene expression.104-
106 QS systems utilise a range of chemical signal molecules. Despite these differences in signal 
molecule chemistry and overall mechanism of each system, they all function based on similar 
principles.104 At low bacterial population densities, the signal molecules diffuse away and are 
therefore present at very low concentrations, thus are not detected.104 At a higher bacterial cell 
population densities, the signal molecule reaches a sufficient concentration due to the 
cumulative production (autoinduction), which in turn allows for the detection and subsequent 
response to the signal molecule.104 The signal molecules are all recognised by either membrane 
bound or cytoplasmic receptors and upon recognition of signal molecule, its production is 
upregulated.104 
 
Table 1.1. Some of the genes regulated by the agr system 
Gene Product Reference 
Directly regulated by agr   
agrBDCA Agr B, D, C and A 107 
rna-III RNA-III and δ-toxin 108 
   
Indirect Regulation   
Toxins   
tst TSST-1 98 
hla α-haemolysin 98 
hlb β-haemolysin 98 
hlgBC γ-haemolysin 109 
hld δ-haemolysin 98 
seb Enterotoxin B 110 
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sec Enterotoxin C 111 
sed Enterotoxin D 110 




sak Staphylokinase 98 
lip Lipase  
splA-F Spl proteases 112 
aur Aureolysin 113 
ssp Staphylococcal serine proteases 113 
scp Staphylococcal cysteine proteases 113 
   
Immunomodulation   
psmα1-4 Phenol soluble modulin-α 1-4 114 
psmβ1-2 Phenol soluble modulin-β1-2 114 
scn Staphylococcal complement inhibitor 115 
   
Down-regulated   
Surface proteins   
spa Protein A 98 
fnbA/B Fibronectin-binding protein A/B 116 
coa Coagulase 117 
   
Regulators   
rot Rot transcription factor 118 
 
Both Gram-negative and Gram-positive bacteria utilise QS systems.104 Gram-negative bacteria 
use small molecules such as acyl-homoserine lactones 1.33, which can diffuse across both the 
outer and inner membranes and bind to cytoplasmic receptors which can regulate gene 
expression (Figure 1.20).104 
 
In contrast, Gram-positive bacteria generally use peptide signal molecules called auto-inducing 
peptides (AIPs).104 These are produced and secreted by bacteria and bind to a membrane bound 
histidine kinase which, as part of a two-component signal transduction cascade can regulate 




Figure 1.20. General structure of an N-acyl-homoserine lactone 1.33. 
 
Thus, in S. aureus, the agr system is based around two promoters, P2 and P3 which drive two 
divergent transcripts (Figure 1.21).103 P3 drives expression of RNAIII, a master regulator of 
staphylococcal virulence.119 P2 drives expression of the agr operon, which consists of four 
genes, agrB, agrD, agrC and agrA which encode the components of the agr system. 
 
AgrB and AgrD are responsible for the synthesis of the signal molecule AIP, a thiolactone 
macrocyclic (macrocycle of 5 amino acids) peptide 1.34 (AIP-I)(Figure 1.21). AgrD is the 
precursor to AIP and is synthesised as a pre-pro-peptide consisting of a core AIP sequence 
flanked N-terminally by an amphipathic helical region and C-terminally by an hydrophilic 
region.120 In S. aureus, the core AIP sequence is 7-9 amino acids in length (Table 1.2) and can 
be divided into four distinct groups, each with their own corresponding agr system, 
differentiated by primary amino acid sequence.121 AIPs have strong cognate agr agonistic 





Figure 1.21. (A) The staphylococcal agr system: AgrD, the precursor to AIP is processed by the membrane bound 
cysteine protease AgrB and MroQ, a putative signal endopeptidase, releasing mature AIP. AIP can subsequently 
bind to AgrC, a canonical histidine kinase receptor, allowing auto-phosphorylation, recruitment of AgrA and 
subsequent phosphotransfer. Once phosphorylated, AgrA, can drive expression of both the P2 and P3 transcripts. 
(B) Structure of AIP-I 1.34 containing the key 5-membered thiolactone macrocycle. 
 
The N-terminal region of AgrD is required for localisation to the inner leaflet of the membrane, 
to bring AgrD proximal to AgrB, a membrane bound cysteine protease, recognition of which 
is carried out by the C-terminal region of AgrD.120 AgrB (Figure 1.22) catalytically excises the 
C-terminal region of AgrD, forming a thioacyl-enzyme intermediate between a key catalytic 
cysteine (Cys77) within AgrB and the terminal methionine of the processed AIP sequence 
(Figure 1.22 and Figure 1.23).120 The thio-acyl intermediate then undergoes an intramolecular 
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trans thio-esterification reaction with the thiol of an absolutely conserved cysteine internal to 
the pre-AIP molecule (Figure 1.22). This process forms the 5-membered thiolactone 
macrocycle and releases the macrocyclic pre-AIP molecule from AgrB, restoring the active 
site.122-123 All staphyclococcal AIP molecules contain this thiolactone macrocycle, with the 
exception of the sub-species of Staphylococcus intermedius, Staphylococcus 
pseudointermidius, which has a lactone macrocycle 1.35, formed between the terminal 
carboxyl and an internal serine residue (Figure 1.24).120  
 
The thiolactone pre-AIP molecule is then translocated to the outer leaflet of the membrane 
where the N-terminal amphipathic helix is removed by the putative CAAX metalloprotease 
MroQ (Figure 1.23).124 The result of these processes is the secretion of the mature AIP signal 
molecule into the extracellular milieu (Figure 1.21). 
 
Table 1.2. The primary amino acid sequences of AIP S. aureus AIPs. AIP I-IV where AIP-I and AIP-IV only 
differ by one amino acid. Highlighted the absolutely conserved cysteine residue, critical for the formation of the 
thiolactone macrocycle. 
S. aureus AIP 
  
Primary Amino Acid Sequence 
AIP-I  Y S T C D F I M 
AIP-II G V N A C S S L F 
AIP-III   I N C D F L L 
AIP-IV  Y S T C Y F I M 
 
The mature AIP molecule from each agr group has its own distinct structure (Figure 1.25). 
AIPs are between 7-9 amino acids in length and contain a thiolactone macrocycle comprising 
of 5 amino acids and an N-terminal tail region of either 2 or 4 residues. The thiolactone 
connection is made between a conserved cysteine residue, 5 residues from the C-terminus of 
the AIP sequence and the terminal carboxylic acid (Figure 1.25). 
 
Mature, extracellular, mature AIP can bind to AgrC, a canonical histidine kinase receptor, 
consisting of 5-6 transmembrane regions with a C-terminal histidine kinase domain, which 
exists as a homodimer within the membrane of S. aureus.103, 121, 125 Upon the binding of cognate 
AIP, that is, AIP of the same agr group, the AgrC receptor undergoes auto-phosphorylation in-
trans, allowing for recruitment and subsequent transfer of phosphate to AgrA (Figure 1.21).125 
39 
 
The phosphorylated AgrA subsequently binds to promoters P2 and P3 in order to drive the 
expression of the agr operon and an upregulation of toxin production, mediated by RNA-III.119 
This leads to up-regulation of agr activity, through the ‘self-synthesis’ of components, one of 




Figure 1.22. The proposed mechanism for the formation of AIP-I by AgrB. Nucleophilic attack at the methionyl 
carbonyl by the absolutely conserved Cys84 (part of an ion pair with His77) within AgrB leads to lysis of the 
amide bond, liberating the C-terminal AgrB recognition region. Attack at the thiolacyl intermediate as part of an 
intra-molecular thiolesterification , carried out by an absolutely conserved cysteine, 5-residues internal to the AIP 
sequence (summised as a concerted mechanism above) leads to the formation of the thiolactone macrocycle and 
restoring the active site of AgrB. 
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Both the P2 and P3 promoters exhibit basal transcriptional activity, at a higher level for the P2 
transcript.126 This allows for low level production of AIP. At low population densities, this is 
insufficient for agr activation, however, when the population density reaches the threshold 
level, activation of the agr system occurs.126 
 
Figure 1.23. The full primary amino acid sequences of AgrD from each of the staphylococcal agr groups 
highlighting the cleavage sites.and the product of each cleavage. 
 
The final major component of the agr system is the main effector molecule, RNA-III, a master 
regulator of staphylococcal virulence.119, 127 RNA-III is 514 nucleotides in length and is one of 
the largest known small regulatory RNA that functions through an anti-sense mechanism, by 
complementary base pairing with target mRNAs.127 These leads to downstream effects on the 
expression of accessory genes such as superantigens and cytotoxins (Table 1.1).97 Moreover, 





Figure 1.24. The AIP signal molecule of the S. intermedius sub-species S. pseudointermedius 1.35, with an 
atypical lactone macrocycle. 
 
The result of agr activation leads to an overall increase in virulence factor expression, the 
arsenal of weapons by which S. aureus can propagate infection and a decrease in surface 
proteins (Table 1.1), which leads to the breakdown of biofilms allowing the bacteria to spread 
infection to distal sites within the host. 
 
1.5.2 The different agr groups of S. aureus 
As previously discussed, S. aureus has four distinct agr groups, I-IV, each with their own 
distinctive AIP molecule (1.34, 1.36, 1.37, 1.38, Figure 1.25). The cognate AIP is a potent 
agonist at the corresponding AgrC receptor whereas non-cognate AIPs act as potent 
competitive antagonists. Notably, AIP-II acts as an inverse agonist at the AgrC1 receptor.128 
Studies have shown that a single dose of non-cognate AIP can block murine abscess formation 





Figure 1.25. The thiolactone AIP molecules endogenous to S. aureus. AIP-I 1.34, AIP-II 1.36, AIP-III 1.37 and 
AIP-IV 1.38. 
 
The agr operon, agrBDCA contains a variable region including the 3’ end of both agrB and 
agrD, as well as the 5’ end of agrC.121, 130 This suggests that variation in AIP structure (agrD) 
requires concurrent changes in AgrB and AgrC to retain auto-inducing activity.121 Variation in 
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the nucleotide sequence between groups is most notable within agrD, the precursor to AIP, 
which is unsurprising given different agr groups produce different signal molecules (Figure 
1.25)130 Further variance is seen within the C-terminal two thirds of AgrB, potentially involved 
in the processing of AgrD, which again enables recognition of cognate AgrD.130 AgrC also 
exhibits N-terminal divergence, with variation in the receptor domain, notably within 
extracellular loops I and II, which have been found by Jensen et al. to be necessary for the 
exquisite differentiation between AIP-I and IV, which differ by only a single amino acid.121 
 
1.6 The agr systems of other species 
Analogous agr systems are present within other Gram-positive species, including coagulase 
negative staphylococci, clostridia, listeria, lactococci and enterococci. 
 
1.6.1 Staphylococci 
Apart from S. aureus, the most clinically relevant staphylococcal species is Staphylococcus 
epidermidis, which like S. aureus is an opportunistic pathogen but also a commensal of skin 
microbial flora.131 S. epidermidis is a leading cause of medical implant/device infections.131 
The fundamentals of the agr system are conserved between S. aureus and S. epidermidis.131 
However, unlike S. aureus, which is an invasive pathogen, S. epidermidis infection is typically 
associated with chronic biofilm associated infections, which are the primary mechanism of 
pathogenesis.131 In S. epidermidis, agr activity differs to S. aureus in relation to the genes 
regulated. For example, in S. epidermidis, agr upregulates adhesins including polysaccharide 
intercellular adhesion (encoded by the icaADBC locus) that facilitate biofilm formation.132 
S. intermedius is another staphylococcal species that utilises an agr system. In fact, S. 
intermedius which is part of the normal commensal flora of dogs, is often associated in causing 
SSTIs in humans who have been exposed to dogs, for example after surgery.133 S. intermedius 
infection can be invasive, leading to systemic infection.134 As mentioned previously, S. 
pseudointermedius utilises a unique AIP 1.35 containing a 5-amino acid lactone macrocycle 
between an internal serine residue and the terminal carboxyl. Ji et al. have shown that the 
lactone macrocycle is important for the activity of the AIP.135 Replacement of the serine with 
a cysteine, to produce a thiolactone analogue of 1.35, 1.39 afforded an AIP molecule with weak 




Figure 1.26. The lactone AIP of S. pseudointermedius 1.35 and the thiolactone analogue 1.39. 
1.6.2 Enterococci 
The enterococci, such as Enterococcus faecalis also use agr-like QS systems to facilitate their 
pathogenesis. E. faecalis is a commensal bacteria found in the gastro-intestinal tract and is also 
an opportunistic pathogen.136 Pathogenesis in E. faecalis involves colonisation of host tissues 
and the formation of biofilms, which requires the expression of numerous surface proteins.136 
 
E. faecalis uses the fsr system to regulate virulence.137 Encoded within the fsr locus, it consists 
of four genes, fsrA, fsrB, fsrD and fsrC.138 The signal molecule of the fsr system is gelatinase 
biosynthesis activating pheromone (GBAP) 1.40 (Figure 1.27), consisting of 11 amino acids 
and is synthesised as a precursor, encoded within the fsrD gene in a manner similar to AIP 
within S. aureus.138 GBAP, when produced, binds to FsrC, which is then phosphorylated 
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enabling activation of FsrA, the response regulator, which through activity as a transcription 
regulator, drives expression of the fsr cassette and numerous other loci, including gelE-sprE.139 
gelE and sprE encode gelatinase and serine protease and are both positively regulated by Fsr 
activity.139 Gelatinase is a type II metalloprotease that targets, fibrin, collagen, fibrinogen, 
haemoglobin and a number of complement proteins.139 Furthermore, gelatinase activates an 
autolysin which is important in biofilm formation.139 Gelatinase is also known to activate 
protease-activated receptor 2 (PAR2), causing chronic inflammation within the intestines of a 
mouse model.139 Serine protease, encoded by sprE is a glutamyl endopeptidase and also 
contributes to the pathogenesis of E. faecalis.139 
 
Figure 1.27. The signal molecule of the E. faecalis Fsr system, GBAP 1.40 
 
1.6.3 Clostridia 
Clostridia are Gram-positive bacteria that cause a wide range of diseases, such as botulism and 
gas gangrene. In order to cause these diseases, Clostridia produce an array of toxins such as 
the botulinum toxin. Clostridia use an agr-like system, which is known to play a crucial role 
in the pathogenesis of several clostridial species including Clostridium botulinum and 
Clostridium perfringens.140 However, less is known about the agr-like system of Clostridia 
than the staphylococcal agr system. Some species of clostridia, such as C. botulinum have two 
copies of the agrBD genes, required for the synthesis of the signal molecule.140 
 
Three clinically relevant species of Clostridia are C. perfringens, C. botulinum and Clostridium 
difficile. C. perfringens is a causative agent of food poisoning and gas gangrene, mediated 
through the production of an arsenal of toxins, including proteases which digest host tissue, to 
provide a pool of amino acids for the bacteria.140 Knock-out/targeted mutagenesis on agr genes 
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within C. perfringens have been shown to have effects on toxin production and thus implicated 
in regulation of toxin production.140 
 
C. botulinum produces an array of toxins, including some neurotoxins which are amongst the 
most harmful known.140 In their 2015 review, Darkoh et al. state that all recently studied 
genomes of C. botulinum contained ‘putative homologues’ of the agr system, and within ten 
of these genomes, analysis found two copies of agrB and agrD.140 AgrD mutants have been 
found to have disrupted neurotoxin production.140 
 
Lastly, C. difficile, is a nosocomial pathogen and one of the leading causes of hospital-
associated diarrhoea worldwide.141 Multi-drug resistant C. difficile can cause infection in the 
gut after the local microbiota have been disrupted by broad-spectrum antibiotics, due to the 
loss of competition for nutrients.141 This bacterium relies on two toxins, named toxin A and B 
for pathogenesis.140-141 A 2015 study found that C. difficile utilises a QS system for the 
regulation of toxin production, mediated through a small thiolactone that can be detected in 
stools of C. difficile patients.141 The authors noted that C. difficile QS system offers novel 
















1.7 The agr system as a pharmacological target 
The clinically important organisms discussed above depend on agr-like systems for the 
production of their virulence weaponry. There has been some success in the disruption of 
individual virulence factors. Human antibodies against S. aureus α-haemolysin have been 
previously shown to have therapeutic potential for the treatment of infection.142 Furthermore, 
a reduction in virulence factor production has also been attributed to improved prognosis for 
S. aureus infection.143 This makes the development of a broad range inhibitor of virulence a 
promising new avenue for the production of new therapies. With a focus on S. aureus, 
inhibition of one of the major global regulators of virulence, the agr system presents the 
opportunity to develop unique classes of potential therapeutic agents. 
 
Inhibitors of the agr system have been previously studied and will be discussed herein. The 
agr system presents several viable targets for novel inhibitors. Inhibitors of AgrC and AgrA 
have been studied previously and will be discussed herein. Furthermore, the potential of AgrB 
to be utilised as a drugable target will also be discussed. 
 
1.7.1 Inhibitors of AgrC 
AgrC, as discussed earlier, is the sensor of the agr system, recognising the AIP signal molecule. 
Numerous inhibitory strategies have been studied, which will be discussed here. 
 
One such inhibitor-discovery strategy is the production of pan-group AIP analogues as direct, 
competitive inhibitors of the AgrC histidine kinase receptor. An example being when a mouse 
challenged with an agr group I murine infection model was dosed with AIP-II there was a 
reduction in abscess formation.123 This reduction was comparable to that of an agr knock-out 
control.123 Numerous studies have shown that small changes to the structure of cognate AIP 
led to conversion of the molecule to an antagonist of the AgrC receptor.144-145 This further 
highlights the exquisite selectivity of AgrC for the cognate AIP ligand. The AIP-I analogue 
(Ala5)-AIP-I 1.41 (Figure 1.28), has been identified as a potent global inhibitor of AgrC, with 
nM potency against all four agr groups.143  
 
An additional family of inhibitors of AgrC are the solonamides. These compounds were first 
identified by Mansson et al. from over 500 samples of marine bacteria collected as part of a 
global research expedition.146 These bacteria were investigated to determine whether they were 
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a potential source of compounds with the ability to disrupt agr QS.146 They recorded agr 
interference in a number of ways, such as enhanced expression of spa, the gene encoding 
protein A, with reduced expression of hla (α-haemolysin) and rna-III.146 A marine 
Photobacerium was found to produce compounds which interfered with agr activity, and 
bioactivity guided fractionation resulted in the isolation of two novel cyclic depsipeptides 
called solonamide A 1.42 and solonamide B 1.43 (Figure 1.29).146  
 
The solonamides were found to be active against S. aureus 8325-4 and the CA-MRSA strain 
USA300.146 Specifically, solonamide B was found to reduce the expression of hla and rna-III 
whilst causing a concurrent increase in spa expression, whereas solonamide A caused an 
increase in spa expression, with only marginal depression of expression of hla and rna-III.146 
Importantly, neither of the compounds inhibited bacterial growth.146 Further studies suggested 
that the target of the solonamides is AgrC, since no effect on rna-III expression was observed 
with bacteria expressing a constitutively active (R238H) AgrC receptor.147 Nielsen et al. note 
that there was a ‘tendency towards dose-dependency’ when cells were treated with cognate 
AIP and solonamide B, which suggested competitive inhibition.147 
 
Figure 1.28. (Ala5) AIP-I 1.41, a potent inhibitor of AgrC 
 
The finding that solonamide B may be a competitive antagonist is hardly surprising, given the 
structural similarity between solonamides (Figure 1.29) and AIPs (Figure 1.25). This was first 
noted by Mansson et al. in their manuscript first identifying the solonamides.146 The 
solonamides are cyclized by a 3-hydroxy fatty acid forming a lactone with the terminal 
carboxyl of the amino acid chain (Figure 1.29). The difference in anti-agr activity between 
solonamide A and B is postulated to be due to the change in length of the fatty acyl chain, with 
the increased hydrophobicity of solonamide B being correlated to its improved potency.146 
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Non-competitive inhibitors of the AgrC receptor have also been reported. Murray et al. 
described the synthesis and testing of a range of analogues of 3-oxo-C12-HSL (N-(3-
oxododecanoyl)-L-homoserine lactone) 1.44 analogues (Figure 1.30).148 3-oxo-C12-HSL is a 
known signal molecule utilised for QS by the Gram-negative bacteria Pseudomonas 
aeruginosa.148 Gram-negative bacteria utilise small, non-peptidic signal molecules such as 
HSLs that can freely diffuse across the bacterial membrane and bind to either cytoplasmic or 
inner membrane bound receptors, the downstream effects of which can alter the expression of 
numerous genes.149 In P. aeruginosa, 3-oxo-C12-HSL activates the transcriptional regulator 
LasR, which drives expression of numerous genes implicated in exotoxin production and 
exoenzyme production.148 3-oxo-C12-HSL is also known to inhibit the growth of some Gram-
positive bacteria and at sub-lethal concentrations, it has been shown to disrupt the production 
of S. aureus exotoxins.148, 150 
 
Figure 1.29. The Solonamides, (A 1.42 and B 1.43) known inhibitors of AgrC 
 
Murray et al. synthesised a range of 3-oxo-C12-HSL (1.44), tetramic acid (1.45) and tetronic 
acid (1.46) analogues and tested their anti-bacterial and anti-virulence activities (Figure 
1.30).148 The most potent of these, 3-tetradecanoyltetronic acid 1.47 (Figure 1.30) showed 
promising in vivo activity, reducing nasal colonisation and bacterial arthritis in a mouse urine 
infection model.148 It was found that these compounds act as non-competitive inhibitors, as 
negative allosteric modulators of the AgrC receptor.148 Unfortunately, the scope for the use of 
these compounds for their anti-virulence properties is limited, due to the small therapeutic 
window between anti-virulence activity and undesired growth inhibitory activity. For example, 





Figure 1.30. Compounds from the Murray et al. study. 3-oxo-C12-HSL 1.44, tetranoic acid derivatives 1.45, a 
tetronic acid analogue 1.46 and the compound found to be an highly potent inhibitor of AgrC, 3-
tetradecanoyltetronic acid 1.47. 
 
1.7.2 Inhibitors of AgrA 
AgrA has also been investigated as a target for novel anti-virulence compounds. Sully et al. 
identified the synthetic small molecule Staphylococcus aureus virulence inhibitor (savirin) 
1.48 as a potent inhibitor of AgrA through a high-throughput screen (Figure 1.31).151 Molecular 
docking identified a binding pocket for savirin on AgrA.151 Docking studies, carried out by 
Sully et al. suggested that savirin occupies a binding pocket adjacent to the DNA binding motif 
of AgrA which allows it to inhibit funciton.151 Specific inhibition of AgrA by savirin was 
elucidated through the production of a reporter strain, where plasmid encoded AgrA is 
produced constitutively, which drives activation of agr::P3 lux in the absence of any other agr 
components.151 Savirin was found to inhibit constitutive bioluminescence without any adverse 
effects on bacterial growth.151 Furthermore, electrophoretic mobility shift assay (EMSA) 
confirmed inhibition of AgrA by savirin.151 
 
Figure 1.31. The synthetic AgrA inhibitor savirin 1.48. 
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Although savirin proved to be an effective inhibitor of AgrA in S. aureus, when it was tested 
in S. epidermidis, it proved ineffective in vitro and in silico.151 Thus variation in the amino acid 
sequence of AgrA between S. aureus and S. epidermidis (agr group II) is suggested as the 
reason for this.151 Indeed, it was noted that one of the key intermolecular contacts, Tyr229 in 
AgrA of S. aureus is replaced by Phe in AgrA of S. epidermidis.151 The ineffectiveness of 
savirin to act in S. epidermidis suggests that inter-group variation in the structure of AgrA could 
prove problematic in the development of a broad spectrum inhibitor of AgrA. 
 
1.7.3 The potential of AgrB as an anti-virulence target 
As discussed above, promising inhibitors of both AgrC and AgrA have been previously studied. 
AgrB remains the least studied component of the agr system as a potential pharmacological 
target. Like AgrC and AgrA, AgrB has considerable cross-group amino acid sequence 
variation. However it is predicted that all AgrB variants share both structural and mechanistic 
features.120 This is enforced by studies which found high levels of homology of hydropathy 
profiling amongst AgrB homologs as well as absolute conservation of Cys84 and His77 
residues, which together form the putative active site.120, 152 Thus, the conservation of structure 
and function of AgrB and its homologues in different species makes AgrB an attractive target 
for a broad-spectrum inhibitor of virulence. 
 
Figure 1.32. The highly functionalised epoxycyclohexenone ambuic acid 1.1, produced by species of the 
Pestalotiopsis fungi. 
 
In their 2009 paper, Nakayama et al. carried out a screen of fungal extracts for the modulation 
of the GBAP-mediated QS system.153 Through this screen, they found that ambuic acid 1.1 
(Figure 1.32), an epoxy cyclohexenone with known anti-fungal properties, as an inhibitor of 
fsr QS.153-154 Nakayama et al. demonstrated that ambuic acid 1.1 inhibited the biosynthesis of 
GBAP, as well as the biosynthesis of AIP-I in S. aureus and cyclic peptide QS signal molecules 
in Listeria innocua.153 Furthermore, a database search based on the amino acid sequence of 
AgrB found several molecules comparable to AgrB in a range of Gram-positive bacteria.153 In 
addition, studies have confirmed inhibition of AIP biosynthesis in the clinically relevant MRSA 
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strain S. aureus USA300, as well as reducing ulcer formation in a mouse murine model of 
MRSA infection.155  In addition, Todd et al. utilised mass-spectrometric methods to measure 
the effects of ambuic acid 1.1 on the production of AIP-I in S. aureus USA300 and a strain 
wherein AIP-I synthesis was deregulated.155 They observed inhibition of AIP-I production in 
both the constitutively active strain and USA300 (IC50 2.5 ± 0.1 µM).
155 They also screened 
ambuic acid against a further 11 strains/ species, eight of which showed IC50 values of < 25 
µM.155 Two-thirds of the strains with an IC50 of > 25 µM were S. epidermidis strains which 
were of the agr groups II and III.155 
 
These findings make ambuic acid 1.1 a promising broad-spectrum-inhibitor of Gram-positive 
virulence. The finding of further AgrB homologues in a number of Gram-positive species 
further increases the potential scope of ambuic acid 1.1. 
 
1.8 Ambuic acid 
1.8.1 Known bioactivities of ambuic acid 
Ambuic acid 1.1, a highly functionalised epoxy cyclohexenone, is produced as a secondary 
metabolite by species of tropical endophytic fungi of the Pestalotiopsis and Monochaetia.154 
Pestalotiopsis microspore is one of the most common of these organisms and is one of several 
related organisms which have been isolated from the stems and leaves of economically 
important tropical crops such as mangos and guavas.154 These fungi are weak, plant 
pathogens.154 The fungal-produced ambuic acid has been shown to have biological activity 
against several phytopathogenic Fusarium sp., including Diplodia natelensis and 
Cephalosporium gramineum.154 The biological function of ambuic acid may be as a protectant 
against other species of fungi or may play a role in fungus-plant relationships.154 
 
 
Figure 1.33. Acyl ambuic acid derivative 1.49. 
The acyl ambuic acid derivative 1.49 (Figure 1.33) has been shown to inhibit the inter-cellular 
signal molecule nitric oxide (NO).156 NO is produced by the oxidation of L-arginine by a group 
54 
 
of enzymes called nitric oxide synthases (NOS). Overproduction of NO is attributed to several 
diseases including cancers and chronic inflammation, thus, NOS inhibitors or scavengers of 
the NO radical could potentially become new therapeutics.156 
 
Furthermore, ambuic acid 1.1 has shown anti-proliferative activity against the human ovarian 
cancer cell line A2780 and the cisplatin resistant line A2780CisR with IC50 values of 10.1 µM 
and 17 µM respectively.157 
 
Studies have also reported that ambuic acid 1.1 and acyl derivative 1.49 have mild growth 
inhibitory activity against S. aureus, with IC50 values of 43.9 µM and 27.8 µM respectively.
158 
However, at present, work undertaken within the Chan and Williams laboratory (discussed in 
Chapter 4), no growth inhibition was observed with ambuic acid, even at concentrations far in 
excess of those reported by Ding et al..158 
 
1.8.2 The potential mode of action of AgrB inhibition by ambuic acid 
AgrB is a putative cysteine protease, with Cys 84 and His77 forming the proposed active site 
of the enzyme.120 Broadly, cysteine proteases are a distinct family of proteases that hydrolyse 
peptide bonds utilising the thiolate of a deprotonated cysteine residue as the nucleophile for 
attack at the carbonyl of a peptide bond (Figure 1.34).159 The catalytic mechanism of the clan 
CA family of cysteine proteases is one of the most extensively studied.160 Briefly, cleavage of 
the peptide bond depends on the thiolate-imidazolium ion pair, formed between a cysteine and 
histidine residue within the active site of the protease (Figure 1.34).160 Thiolate attack at the 
carboxyl of the target peptide bond within the substrate leads to the formation of a tetrahedral 
oxyanion intermediate, the amine of which can receive the proton from the imidazolium ion, 
forming a thioacyl enzyme-substrate intermediate, releasing the amino fragment (Figure 
1.34).160 Subsequent hydrolysis of this thioester intermediate releases the remaining portion of 
the substrate and re-generates the active site, ready for further catalysis.160 The improved 
nucleophilicity of the sulphur atom in cysteine compared to that of oxygen in serine (within 
serine proteases) negates the requirement for a full triad of catalytic residues Within serine 
proteases, the triad is typically formed by the Ser, His and Asp residues, where the aspartate is 






Figure 1.34. The general mechanism of cysteine proteases. Attack at the carbonyl of the peptide bond by the thiol 
within cysteine, this leads to release of the amino portion of the peptide substrate, forming a thiolacyl substrate-
enzyme intermediate. This can then undergo subsequent hydrolysis, releasing the carboxylic acid segment and 
restoring the active site of the enzyme. 
 
Thus, in S. aureus Group I the Cys84 and His77, which form the putative active site of AgrB 
are able to catalyse the processing of AgrD, eventually forming the key thiolactone macrocycle 
of AIP.120  
 
The cysteine proteases are common in nature and are required for a diverse array of functions. 
They are known to play important roles in a number of pathologies and as such, inhibitors have 
been widely studied.159 Disorders involving cysteine proteases and several classes of inhibitor 
are discussed at greater depth in chapter 3. 
One class of cysteine protease inhibitors is the epoxysuccinates 1.50 and 1.51 which are able 
to irreversibly alkylate the key active cysteine within the active site, via the epoxydione 
electrophilic warhead (Figure 1.35). They form a thioether, thus irreversibly alkylating the 
enzyme.162 Alkylation occurs through nucleophilic attack at either carbon of the epoxide 
heterocycle, resulting in opening of the strained ring (Figure 1.35).162 This results in inhibition 





Figure 1.35. Examples of epoxysuccinates (1.50 and 1.51) and their mode of inhibition of cysteine proteases. 
 
At present, the mechanism by which ambuic acid 1.1 attenuates staphylococcal agr-mediated 
virulence remains unknown. However, the presence of the epoxide may be a clue for how 
ambuic acid functions as an AgrB inhibitor. It is postulated that ambuic acid covalently 
modifies the key Cys84 within AgrB, forming a thioether drug-enzyme covalent complex 






























1.9 Aims and objectives 
 
The work outlined in this thesis focuses on the synthesis and biological characterisation of 
novel anti-virulence compounds for the treatment of serious multi-drug resistant S. aureus 
infection. To this end, the aims of this thesis are outlined below. 
 
- The synthesis of a range of analogues of the natural product ambuic acid in order to 
investigate their inhibitory activity towards the agr-mediated quorum sensing system. 
 
- The synthesis of a cyclopropyl isostere of the epoxide electrophilic centre within 
ambuic acid to determine how modification alters the anti-virulence activity. 
 
- The in vitro biological characterisation of the synthesised analogues in vitro. 
 
The approach for the completion of these research aims will be outlined briefly here. 
 
1.9.1 The synthesis of analogues of ambuic acid 
 
The synthesis of analogues of the natural fungal product ambuic acid 1.1 has been carried out. 
These analogues were based on the truncated, racemic ambuic acid analogue 1.52 which was 
found to show promising anti-virulence activity at the onset of this work (Figure 1.37). 
 
Figure 1.37. Ambuic acid 1.1 and the truncated racemic analogue 1.52 of which enantioselective syntheses have 
been carried out. 
 
The synthesis of analogues broadly followed the synthetic strategy utilised by Jung et al. in 
their total synthesis of ambuic acid, which has been strategically modified by Dr Leonardo 
Baldessarre, formerly of the Williams/Chan group.163 This synthesis involves the production 
of a key, chiral Diels-Alder adduct intermediate 1.53 produced from reaction of ketal 1.54 with 
cyclopentadiene 1.55 in the presence of chiral (R)-(+)-o-tolyl-CBS-oxazaborolidene catalyst 
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1.56 (Scheme 1.1). The Diels-Alder adduct is capable of imparting stereoselectivity on 




Scheme 1.1. Proposed conditions for the Diels-Alder reaction between ketal 1.54 and cyclopentadiene 1.55 in the 
presence of chiral catalyst 1.56 to generate the key, chiral Diels-Alder adduct 1.53. 
 
Subsequent transformations involved the installation of an allyl group through Stille cross-
coupling to give 1.57. The epoxide was installed using hydrogen peroxide in the presence of 
Na2CO3 to afford the epoxide 1.58 (Scheme 1.2). The epoxide was taken into a 
hydroxymethylation procedure, first pioneered by Mehta et al. giving alcohol 1.59.164 The 
lower ketone was enantioselectivly reduced to the corresponding alcohol utilising DIBAL-H, 
using a procedure adapted from Jung et al affording diol 1.60 (Scheme 1.2).163 A retro Diels-
Alder reaction was utilised to dismantle the adduct to give the quinolone derivative 1.61 which 
was then followed by an ozonolysis and a Wittig reaction to yield the final compound 1.62 








Scheme 1.2. Proposed route to the truncated ambuic acid analogue 1.62. (a) Pd(PPh3)4, allyltributyl stannane, µW 
radiation; (b) 1 N H2SO4; (c) H2O2, NaHCO3 (aq.); (d) formaldehyde, DBU; (e) DIBAL-H; (f) TBSCl, imidazole; 
(g) Ph2O, heat; (h) O3, dimethylsulphide then Ph3P=C(Me)CO2t-Bu. 
 
Analogues of 1.62 were also synthesised. These included 1.63, the corresponding (-)-
enantiomer of 1.62. The synthesis of ether analogues of the primary alcohol, shown as general 
structure 1.64 was also attempted. In addition, a range of silyl ether analogues based on the 
general structure 1.65 and a range of ketal analogues based on the general structure 1.66 was 









Figure 1.38. The target compounds to be synthesised. 1.63, the corresponding (-)-enantiomer of 1.62, the general 
structure of ether analogues 1.64, the general structure of the silyl ether analogues 1.65 and the ketal analogues 
general structure 1.66. 
 
The route to (-)-enantiomer 1.63 was established. This required the enantioselective production 
of the Diels-Alder adduct 1.67, produced from ketal 1.54 in a reaction with cyclopentadiene 
1.55 in the presence of (S)-(-)-o-tolyl-CBS-oxazaborolidene catalyst 1.68. The adduct 1.67 
confers stereoselectivity on subsequent chemical transformations through steric occlusion of 
the undesired enantiomer (Scheme 1.3).  
 
The final, (-)-compound 1.63 was to be produced in a similar fashion to the (+)-enantiomer 
1.62. A Stille coupling was to be utilised to install the allyl chain to afford 1.69 (Scheme 1.4). 
Following the installation of the epoxide moiety, giving 1.70 a hydroxymethylation procedure 
adapted from Mehta et al. will be utilised to provide alcohol 1.71.164 The lower ketone was 
then reduced using a procedure adapted from Jung et al., to the corresponding secondary 
alcohol 1.72.163 The Diels-Alder adduct was to be dismantled to yield 1.73 which was followed 




Scheme 1.3. Conditions to be used to produce (-)-adduct 1.67, a key intermediate in the synthesis of target 
molecule 1.63. The adduct 1.67 is formed in Diels-Alder reaction between ketal 1.54 and cyclopentadiene 1.55 in 
the presence of (S)-(-)-o-tolyl-CBS-oxazaborolidene catalyst 1.68. 
  
Ether analogues of the primary alcohol 1.64 were to be synthesised through a modified 
Williamson ether synthesis to install the desired functionality. Diol 1.60 (Scheme 1.2) was to 





Scheme 1.4. Proposed route to the (-)- enantiomer of truncated ambuic acid analogue 1.63. a) Pd(PPh3)4, 
allyltributyl stannane, µW radiation; b) 1 N H2SO4; c) H2O2, NaHCO3 (aq.); d) formaldehyde, DBU; e) DIBAL-
H; f) TBSCl, imidazole; g) Ph2O, heat; h) O3, dimethylsulphide then Ph3P=C(Me)CO2t-Bu.  
 
Silyl ether analogues 1.65 were to be produced from a key diol intermediate 1.74 which is 
produced through dismantling of the t-butyl dimethyl silyl ether within 1.62. Diol 1.74 was 
subsequently taken into a number of reactions with a range of silyl chlorides to generate a range 
of silyl ethers based on general structure 1.65 (Scheme 1.5).  
 
 
Scheme 1.5. Proposed route to silyl ether analogues based on structure 1.65. 
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The diol 1.74 was to be utilised for the synthesis of numerous ketal analogues based on the 
general structure 1.66. The synthesis of ketals was undertaken through the reaction of the key 
diol intermediate 1.74 with desired symmetric ketone in the presence of catalytic p-toluene 
sulfonic acid (Scheme 1.6). 
 
 
Scheme 1.6. Proposed route to ketal analogues 1.66 
  
1.9.2 The synthesis of a cyclopropyl isostere of ambuic acid 
 
The synthesis of a cyclopropyl isostere 1.75 (Figure 1.39) of the epoxide within a truncated 
ambuic acid analogue was to be carried out. This was done to determine whether the epoxide 
is required for inhibition, potentially as an electrophilic warhead, irreversibly alkylating the 
key catalytic cysteine within AgrB. 
 
Figure 1.39. The target cyclopropyl compound 1.75. 
 
The key step in this synthesis of cyclopropyl target 1.75 is the enantioselective installation of 
the cyclopropyl ring through conjugate addition of methylene at the α,β-unsaturated system of 
key dione intermediate 1.76. The approach used for this was a modified Corey-Chaycovsky 
cyclopropylation reaction, in which activated sulphur ylide trimethyl sulphoxonium iodide 1.77 
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Scheme 1.7. Proposed reaction to install the cyclopropyl ring in a reaction of 1.76 with trimethylsulphoxonium 
iodide 1.77 in the presence of base giving cyclopropane 1.78. 
  
Upon the optimisation of this key synthetic step, the synthesis of the final analogue 1.75 was 
to be carried out. The production of the compound 1.75 broadly follows the synthesis of 
analogues 1.62, outlined above. The proposed route to the final compound is outlined in 
(Scheme 1.8). Briefly, after the successful installation of the cyclopropyl ring and the 
verification that it has the desired stereochemistry, by Nuclear-Overhauser effect spectroscopy 
(NOESY), the primary alcohol was installed using a procedure adapted from Mehta et al. and 
Jung et al. to yield alcohol 1.79 (Scheme 1.8).163-164 Following this, the alcohol was 
subsequently protected as the corresponding t-butyldimethyl silyl ether 1.80, before a retro 
Diels-Alder reaction was carried out to dismantle the Diels-Alder adduct to afford the quinone 
derivative 1.81. Quinone 1.81 was then to be taken into an ozonolysis and Wittig olefination 




Scheme 1.8. Proposed route to the desired cyclopropyl compound 1.75. a) trimethylsulphoxonium iodide, base; 



















1.9.3 The microbiological evaluation of the synthesised analogues 
 
After the synthesis of the analogues outlined briefly above, their in vitro agr-inhibitory activity 
was to be assessed. The anti-virulence properties of ambuic acid 1.1 were to also be fully 
determined. 
 
The agr-inhibitory properties of the test compounds was to be assessed through the use of a 
bioluminescent reporter, EJM82, produced by Dr Ewan Murray of the Williams/Chan group. 
This reporter will be described in greater detail in Chapter 4. Briefly, a methicillin-sensitive S. 
aureus SH1000 strain with a native agr system has been modified at the attB ectopic locus with 
insertion of agrP3::luxABCDE. This allows for a real-time, bioluminescent readout of agr 
activity. If a high level of bioluminescence is observed, this is indicative of a high level of 
activity. A reduction in bioluminescence correlates to a reduction in agr activity, indicative of 
inhibition. Ambuic acid 1.1 and the synthesised analogues were to be assessed for anti-
virulence activity using this reporter to establish pharmacological parameters, such as IC50.  
 
In addition to the use of the bioluminescent reporter strain described above, the phenotypic 
effect of compounds on toxin (α-haemolysin) and AIP-I production was to be assessed. The 
effect on toxin production was determined through Western blot analysis, wherein S. aureus is 
grown ± treatment with test compounds. The spent growth media was then collected and the 
secreted α-haemolysin levels were assessed.  
 
To investigate whether the test compounds have an effect on AIP-I production, a reporter strain, 
ROJ143 was utilised. This strain has a Δagr background with agrP3::luxABCDE and 
agrP2agrC1agrA and has previously been utilised by Jensen et al..121 The bacterium is 
incapable of producing AIP-I, but is capable of sensing AIP-I and like the EJM82 strain 
(described above), the sensing of AIP-I produces a bioluminescent signal. As these cells cannot 
produce AIP-I, exogenous AIP-I is therefore required to elicit a response from these cells. Thus, 
filtered, cell-free media from S. aureus strains with an intact agr system exposed to the desired 
test compound was used to treat the ROJ143 cells. If the compound inhibits the production of 




The methods outlined here were utilised to determine if ambuic acid and the synthetic 
analogues proposed above are potent inhibitors of agr mediated virulence, particularly if they 
are acting through the inhibition of the biosynthetic enzyme AgrB. 
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2.1 Chapter outline 
 
The synthetic route to a number of unique ambuic acid analogues is outlined in this chapter. 
The synthetic route for the production of the silyl ether 1.62 is discussed. The development of 
a route for the enantioselective production of 1.63, the corresponding (-)-enantiomer of 1.62 is 
also discussed. The attempted production of ether analogues of the primary alcohol, as well as 
the successful assembly of other silyl ethers, illustrated by the general structures 1.64 and 1.65, 
respectively is also described. Finally, the synthesis of a number of unique ketal-based 
analogues of the general structure 1.66 is outlined. 
 




2.2.1 Ambuic acid 
As outlined in Chapter 1, ambuic acid 1.1 is a highly functionalised epoxy cyclohexenone 
produced by a number of species of endophytic fungi with several documented bioactivities.154  
As such, several total chemical syntheses of ambuic acid have previously been published by Li 
et al., Mehta et al. and Jung et al., and these will be discussed herein.163, 167-168 
 
 
Figure 2.2. Ambuic acid 
 
2.2.2 Li synthesis of (±)-ambuic acid 
The total synthesis of (±)-ambuic acid has previously been carried out by Li et al. as part of 
their published synthesis of the quinone epoxide dimer torreyanic acid 2.1.167 Since both 
ambuic acid 1.1 and the related compound jesterone 2.2 were isolated from the same fungal 
species, they suggested a biosynthetic route to 2.1 is likely to involve oxidative dimerization 
of these intermediates 1.1 and 2.2.167  
 
 
Figure 2.3. The quinone epoxide dimer torreyanic acid 2.1 and the related compound jesterone 2.2 
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The Li synthesis of ambuic acid focuses on the enantioselective formation of epoxide 2.3 from 
the quinone monoketal 2.4.167 Initially, Li et al. found poor formation of epoxide 2.3 directly 
from 2.4 with an observed yield of < 40% after 20 h.167 In addition, to a poor yield, they found 
the direct epoxidation of 2.4 afforded poor enantioselectivity.167 To alleviate this they, 
generated alcohol 2.5 through a 2-step procedure, i.e. oxidative cleavage of the terminal alkene 
within 2.4 by a Lemieux-Johnson oxidation, followed by a subsequent reduction reaction.167 
The authors generate alcohol 2.5 to facilitate the enantioselective epoxidation through directing 
group effects.167 They found an improved outcome of the epoxidation when alcohol 2.5 was 
used as the substrate, with a good yield and enantioselectivity observed.167 
 
 
Scheme 2.1. Li synthesis of ambuic acid. (a) NaIO4, OsO4, THF/H2O, 1.5 h, 62%; (b) BH3. tBuNH2, MeOH/H2O, 
0 ºC, 20 min, 76%; (c) Ph3COOH, NaHMDS, L-DIPT, 4 Å MS, toluene, -40 ºC, 50 h, 91%; (d) (i) Dess-Martin 
periodinane, DCM, 35 min, (ii) Ph3P=C(Me)CO2t-Bu, DCM, -78 - -5 ºC, 4 h, 94 %; (e) (E)-tributyl-1-
heptenylstannane, Pd(PPh3)4, toluene, 110 ºC, 2 h, 94%; (f) TBAF/ acetic acid (1:1), THF, 20 h, 76%; (g) 48% 





Dess-Martin oxidation of the alcohol within 2.3 and subsequent Wittig olefination generated 
the t-butyl ester 2.6.167 Stille cross-coupling allowed for installation of the heptene chain which 
was followed by deprotection of both the ketal and the TBDPS silyl ether yielded 2.7.167 
 
With the production of 2.7, the authors proceed with the production of ambuic acid. Reduction 
of ketone 2.7 afforded a mixture of enantiomers 2.8 and 2.9 in a 1.2:1 ratio.167 Li et al. 
attempted to alleviate this through the use of a range of borohydride reagents but did not find 
an improvement in the reaction outcome in terms of selectivity.167 Final hydrolysis of the t-
butyl ester yielded (+)-ambuic acid 1.1.167 
 
2.2.3 Mehta synthesis of ambuic acid 
Mehta et al. presented a simplified method relative to the Li method for the production of 
racemic (±)-ambuic acid 1.1.168 The key intermediate in the Mehta synthesis is the epoxy 
cyclohexenone 2.10 produced from the readily available endo-Diels-Alder adduct 2.11 
(Scheme 2.2).168 
 
Scheme 2.2. (a) 10% (w/v) Na2CO3, 30% H2O2, acetone, 0 ºC, 92%; (b) 35% formaldehyde, DBU, THF, rt., 0 ºC, 
30 min, 95%; (c) TBSCl, imidazole, DMAP, DMF, 0 ºC, 90%; (d) 35% formaldehyde, DBU, THF, rt., 36 h, 80%; 
(e) NaBH4, MeOH, -5 ºC, 84%; (f) Ph2O, 220 ºC, 96%; (g) NaBH4, MeOH, -5 ºC, 10 min, 75%; (h) PPTS (2 eq.), 
2,2-dimethoxypropane, rt., 5 h, 92%; (i) TBSOTf, 2,6-lutidene, DCM, 0 ºC, 15 min, 95%; (j) PPTS (0.4 eq.), 
MeOH, rt., 2 h, 78%; (k) TEMPO, O2, CuCl, DMF, rt., 3 h, 90%; (l) acetic anhydride, pyridine, DMAP, DCM, 0 
ºC, 2.5 h, 98%. 
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In their 2004 paper, Mehta et al. describe the transformation of Diels-Alder adduct 2.11 to 
epoxy cyclohexenone 2.10 (Scheme 2.2).164 They observed that the epoxide 1.58 is formed in 
a stereo- and chemo-selective manner through the use of hydrogen peroxide.164 
Hydroxymethylation with formaldehyde and DBU and subsequent silyl protection gave 2.12 
in a regio and stereo-selective manner.164 A second hydroxymethyl group was then installed 
under the same conditions giving 2.13.164 Mehta et al. suggested that the adduct, as well as the 
newly installed primary alcohol allows for stereoselective reduction of the ketone using NaBH4 
to give desired endo-alcohol 2.14.164 With the successful production of 2.14, the Diels-Alder 
adduct was then dismantled through heating to produce the desired epoxy cyclohexenone 
2.10.164  
 
With the successful production of epoxy cyclohexenone 2.10, the subsequent step was the 
reduction of the ketone to the corresponding alcohol 2.15 (Scheme 2.2).168 Mehta et al. found 
that the hydride addition occurred on the opposite face of the ring to the epoxide, generating 
the desired syn alcohol 2.15 as the major product in a ratio of 7:1 of 2.15 to undesired anti-
alcohol.168 The diol was then protected as a cyclic dimethyl ketal and the free secondary alcohol 
as a TBDMS silyl ether giving 2.16.168  
 
The cyclic ketal 2.16 was then dismantled to give the diol 2.17, and the newly deprotected 
primary alcohol was selectively oxidised through the use of TEMPO to give the corresponding 
aldehyde 2.18.168 The secondary alcohol was then protected in the form of an acetate 2.19.168 
The aldehyde functionality was then utilised for Wittig olefination for the installation of the 
heptenyl side chain to afford 2.20 as a mix of E:Z isomers in a 1:2.2 ratio (Scheme 2.3).168  
 
With the successful installation of the heptene chain, Mehta et al. turned their attention to the 
modification of the allyl functionality to allow for the installation of the t-butyl ester moiety. 
Thus, the intermediate 2.20 was treated with OsO4 in a dihydroxylation procedure to give a 
vicinal diol intermediate which was subsequently cleaved with Pb(OAc)4 to give the aldehyde 
2.21 which in turn was taken into a Wittig olefination with the ylide Ph3P=C(Me)CO2t-Bu to 
finally afford the t-butyl ester 2.22 (Scheme 2.3).168  
 
The acetyl group was then hydrolysed to yield a secondary alcohol which was then oxidised to 
the ketone 2.23 with tetra-n-propylammoniumperruthenate (TPAP).168 At this point in the 
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synthesis, Mehta et al. decided that it was appropriate to resolve the issue of the stereochemistry 
of the heptene chain. Mehta et al. postulated that due to the proximal position of the dienone 
chromphore to the double bond within the heptene chain, photochemical mediated E:Z 
equilibration should be possible, and indeed they achieve complete conversion affording the 
desired E isomer 2.24.168 Final deprotection of the ester and silyl ether was achieved through 
the use of 40% HF giving ambuic acid 1.1.168 
 
 
Scheme 2.3. (a) n-C6H13PPh3Br, t-BuOK, diethyl ether, 0 ºC, 75%; (b) OsO4, NMMO, acetone and water, -25 ºC, 
3 h, 40%; (c) Pb(OAc)4, THF, 0 ºC, 1.5 h, 95%; (d) Ph3P=C(Me)CO2t-Bu, DCM, -78 ºC - -5 ºC, 9 h, 65%; (e) 
LiOH, MeOH, 0 ºC, 4 h, 65%; (f) TPAP, NMMO, 4 Å MS, 3 h, 85%; (g) hv, 450 W, I2, chloroform-d, 10 h, 80%; 













2.2.4 Jung synthesis of ambuic acid 
Jung et al. presented a simplified total synthesis of (+)-ambuic acid, when compared to the Li 
and Mehta syntheses outlined above.167-168 Jung et al. utilise a key, chiral Diels-Alder adduct 
intermediate 1.53 prepared through a reaction of cyclopentadiene with 2-iodo-1,4-quinone 
monoketal 1.54 in the presence of a chiral (R)-(+)-o-tolyl-CBS-oxazaborolidene catalyst 1.56 
(Scheme 2.4, Figure 2.4).163  
 
Chiral oxaborolidenes, such as 1.56 have significant utility in organic synthesis. They are 
traditionally used as chiral auxiliary agents to confer enantioselectivity in the reduction of 
ketones with borohydride reagents.169  
 
In a 2002 paper, Corey et al. described a new enantioselective Diels-Alder procedure by 
employing an oxazaborolidene catalyst 1.56 (Figure 2.4).169 Treatment of catalyst 1.56 with 
the strong protic acid, triflic acid generated the strongly Lewis acidic species 2.25 which exists 
at equilibrium with 2.26.169 Through an optimisation study, Corey et al. find that the test Diels-
Alder reaction with cyclopentadiene in the presence of catalyst 1.56 provides excellent 
enantioselectivity (99% of desired exo product).169 
 
Hence, it is anticipated that 2.25 can coordinate with the reaction substrate 1.54 (Figure 2.4). 
Corey et al. suggested hydrogen bonding between the α-proton of the substrate with the oxygen 
within the oxazaborolidene ring of 2.25 (Figure 2.4).169 In this conformation, the aromatic 
group on the oxazaborolidene can undergo a π-π interaction with the α,β unsaturated region of 
















Scheme 2.4. The Jung synthesis of ambuic acid. (a) cyclopentadiene, catalyst 1.56 (20 mol%), DCM, -78 ºC, 1 h, 
94%; (b) Pd(PPh3)4, allyltributyl stannane, THF, 100 ºC, 92%; (c) 1 N H2SO4, acetone, THF, 0 ºC, 94%, (d) H2O2, 
10% (w/v) Na2CO3, 0 ºC, 93%; (e) formaldehyde, DBU, THF, 0 ºC, 90%; (f) DIBAL-H, THF, -78 ºC, 87%; (g) 
TBSCl, imidazole, DMF, 0 ºC, 95%; (h) 1,2-dibromotetrachloroetane, DBU, DCM, 98%; (i) Ph2O, 230 ºC, 81%; 
(j) O3, dimethylsulfide then Ph3P=C(Me)CO2t-Bu, DCM, -40 to -10 ºC, 74%; (k) Pd(PPh3)4, (E)—tributyl-1-







Figure 2.4. (R)-(+)-o-tolyl-CBS-oxazaborolidene 1.56, the equilibrium states when catalyst 1.56 is treated with 
triflic acid and the proposed complex formed between 2.25 and 2.26, adapted from Corey et al..169 
 
Jung et al. found that in their application, (R)-(+)-o-tolyl-CBS-oxazaborolidene 1.56 catalysis 
provided the desired exo-product 1.53 in good enantiomeric excess (95%, Scheme 2.4).163 With 
the successful production of the Diels-Alder adduct 1.53, the subsequent step was to install the 
allyl group through a Stille cross-coupling reaction to give 1.57.163 Treatment with acid gave 
the de-protected ketone 1.76.163 Epoxidation, mediated by hydrogen peroxide and base 
smoothly gave only the exo-epoxide 1.58 (Scheme 2.4).163 Monohydroxymethylation was 
carried out using a protocol previously developed by Mehta et al. to give the alcohol 1.59.163-
164 Jung et al. evaluated a number of reducing agents to selectively give exo-alcohol 1.60 and 
found that DIBAL-H gave the desired product with good regio- and stereoselectivity.163 The 




A key synthetic step in the Jung synthesis was the α-bromination generating bromide 2.28 
(Scheme 2.4).163 They evaluated a range of brominating reagents including N-
bromosuccinimide and elemental bromine. However, they found 1,2-dibromotetrachloroethane 
to be an excellent brominating agent for this application.163 The silyl ether 2.27 was stirred with 
DBU to extract the α-proton allowing for reaction with 1,2-dibromotetrachloroethane to afford 
2.28 in a good yield (98%).163 With the production of 2.28 the Diels-Alder adduct was 
dismantled through heating giving quinone derivative 2.29 (Scheme 2.4).163  
 
Another part of the Jung synthesis which differs significantly from the Li and Mehta 
approaches is the manner in which the t-butyl ester moiety is installed (Figure 2.5). In the Jung 
approach, the t-butyl ester was installed via ozonolysis and subsequent Wittig olefination.163 
In contrast, both the Li and Mehta approaches utilised a dihydroxylation approach to cleave 
the terminal alkene within the allylic side chain, through the use of OsO4 (Figure 2.5).
167-168 
Subsequent cleavage of the vicinal diol by Pb(OAc)4 in the Mehta study and NaIO4 in the Li 
study gave the corresponding aldehyde.167-168 In the Li study, this aldehyde is reduced to the 
primary alcohol for the subsequent synthetic transformations, before Dess-martin oxidation, 
giving hte aldehyde for the Wittig reaction.167 The Li and Mehta syntheses both require more 
synthetic steps to install the t-butyl ester in addition, OsO4, used for the dihydroxylation is 
highly toxic which makes its use undesirable. Both of these are disadvantageous when 


















Figure 2.5. The synthetic approaches employed by (A) Jung et al., (B) Li et al. and (C) Mehta et al. for the 





Jung et al. produce the aldehyde 2.30 (Figure 2.6) precursor for the Wittig-mediated installation 
of the t-butyl ester protected acid moiety in a one-pot ozonolysis procedure (this procedure is 
expanded upon later in this chapter).163 Quinone 2.29 is treated with ozone gas followed by 
dimethyl sulfide giving aldehyde 2.30.163 The aldehyde 2.30 was taken directly into a Wittig 
olefination with Ph3P=C(Me)CO2t-Bu to install the t-butyl ester, thus giving 2.31 (Scheme 
2.4).163 This procedure is an improvement upon those outlined previously in this chapter due 
to its relative simplicity as well as not requiring toxic OsO4. 
 
Figure 2.6. Aldehyde intermediate 2.30 produced by Jung et al. in the ozonolysis procedure. 
 
Next, a Stille cross-coupling with (E)-tributyl-1-heptenyl-stannane allowed for installation of 
heptene right-hand chain giving 2.32.163 This is an improvement when compared to the Mehta 
synthesis which gave a mixture of (E) and (Z) isomers in a ratio of 1:2.2.168 With the successful 
installation of the (E)-heptene chain, subsequent deprotection through the use of dilute HF gave 









2.3 General Synthetic Route 
2.3.1 The synthetic target 
With the exception of ambuic acid 1.1, within the literature there are no documented inhibitors 
of AgrB. Thus, the production of analogues of ambuic acid may provide an interesting avenue 
of research for the investigation into inhibitors of AgrB. 
 
At the outset of this study, the racemate LB75 1.52 (produced by Dr Leonardo Baldassarre) 
was found to be active against agr activity at a comparable level to that of ambuic acid 1.1 
(Figure 2.7) 
 
Figure 2.7. Racemate 1.52 found to be as active as Ambuic acid 1.1 against agr-mediated quorum sensing in S. 
aureus. 
 
As such, it was decided to use enantiomerically pure versions of 1.52 as the scaffold for the 
production of a range of unique ambuic acid analogues. This was done because of the more 
facile nature of the synthetic route, relative to that of ambuic acid. The attempted synthesis and 
synthesis of novel analogues will be discussed herein. 
 
2.2.2 Synthesis target 1.62 
The synthesis of enantiomerically pure 1.62 (Figure 2.8) is based on a modified procedure from 
the total synthesis of (+)-ambuic acid previously carried out by Jung et al. outlined 
previously.163 Dr Leonardo Baldesarre, carried out modification of the Jung et al. procedure to 
produce the (+)-enantiomer 1.62 (LB151) of racemate 1.52. An efficient workflow was 
established by Baldassarre which allows for the production of numerous unique analogues. 
This synthetic approach was utilised in this study as it provided the opportunity to produce 




Figure 2.8. Enantiomerically pure (+)-enantiomer of LB151 1.62  
 
Commercially available 2-iodo phenol 2.33 was treated in an oxidative dearomatization 
reaction with (diacetoxyiodo)benzene in MeOH to yield the quinone derivative 2.34 (Scheme 
2.5). This reaction generally proceeded with reasonable yields, typically with 40-60% 
conversion to the desired product 2.35. This was followed by the formation of the cyclic ketal 
1.54, which was achieved by treatment with ethylene glycol in the presence of BF3Et2O (yields 
typically 70-80%) (Scheme 2.5). However, difficulty was encountered with the stability of 
product 2.34, as well as the quality of commercially available 2-iodo phenol 2.33.  
 
It was noted that there was an apparent batch-to-batch variation in 2-iodo phenol 2.33. 
Differences in the physical appearance of 2-iodo phenol were observed, with variation in colour 
and texture found. The colour variation ranged from being light purple/ pink in some batches 
to white in others. Indeed, this variation in colour is described in technical information provided 
by the supplier.  
 
Texture variation included the compound having an almost free-running crystalline appearance 
to a mildly viscid, fine, powdery appearance. Typically, the light pink/ purple crystals were of 
this viscid nature and were associated with poor reaction outcome.  
 
In addition to apparent batch-to-batch variation in starting material, it was also found that 
quinone derivative 2.34 was unstable. When left at ambient temperature, not in solution, the 
dark red/brown oil was observed to spontaneously sublimate iodine vapour in an exothermic 
manner. This yielded an intractable dark green/black tar. This should be noted for future 






Scheme 2.5. Scheme showing the general synthesis scheme of target 1.62. (a) (diacetoxyiodo)benzene, MeOH, 2 
h, 0 ºC, 55%; (b) BF3Et2O, ethylene glycol, dimethoxyethane, 2 h, -78 ºC, 81%; (c) catalyst 1.56, cyclopentadiene, 
DCM, 15 min, -78 ºC, 88%; (d) Pd(PPh3)4, allyltributyl stannane, THF, 10 min, 110 ºC, 150 W MW radiation, 
68%; (e) 1 N H2SO4, acetone, THF, 30 min, rt., 96%; (f) 10% (w/v) Na2CO3, 30% (v/v non-stab.) H2O2, acetone, 
30 min, 0 ºC, 83%; (g) 37% (w/v) aqueous formaldehyde, DBU, THF, 30 min, 0 ºC, 79%; (h) DIBAL-H, THF, 
30 min, -78 ºC, 43%; (i) TBSCl, imidazole, DMF, 4 h, 0 ºC, 83%; (j) Ph2O, 4 h, 230 ºC, 73%; (k) O3, 
dimethylsulfide, MeOH, -78 ºC, 30 min then Ph3P=C(Me)CO2t-Bu, DCM, 2 h, -40 ºC, 25%. 
 
Attempts were made to circumvent these issues. Firstly, to overcome the issue of the batch-to-
batch variability of 2-iodo phenol, an alternative starting material was considered. Thus, 2-
bromo phenol 2.35 was chosen as a substitute for 2-iodophenol 2.33 as it possesses the required 
functionality for subsequent transformations. In addition, the replacement of iodine with 
bromine, a poorer leaving group may impart stability to 2.36 relative to 2.34. Given that iodine 
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Scheme 2.6. Reaction schemes showing dearomatization of 2-iodophenol 2.33 (A) and 2-bromo phenol 2.35 (B) 
to quinone derivatives 2.34 and 2.36, respectively, followed by the formation of the cyclic ketals 1.54 and 2.37. 
 
Oxidative dearomatization of 2-bromophenol 2.35 proceeded with reasonable yield of the 
product 2.36 (46%) which is comparable to formation of the iodo variant (Scheme 2.6). 
Furthermore, transformation to the cyclic ketal 2.37 proceeded with a good yield of 71% 
(Scheme 2.6). Thus, it appeared that 2-bromophenol is a suitable substitute for 2-iodophenol 
as overall yields of 1.54 and 2.37 in the two-step synthetic procedure are comparable with 
yields of 45% and 33% observed respectively. Furthermore, the costs of 2-iodo phenol and 2-
bromophenol are comparable. In future applications, if issues with 2-iodophenol are 
encountered, 2-bromophenol is a suitable substitute for the synthesis.  
 
Further to the above attempts to improve the stability of 2.34, it should be noted that for future 
work involving this compound, once purified, it should be used directly in the subsequent step. 
Additionally, keeping 2.34 either in solution or cold (keeping the compound in an acetone/dry 
ice bath (-78 ºC)) until it was required was found to be beneficial, with fewer incidences of 





Scheme 2.7. The Diels alder reaction forming the desired adduct 1.53 and the racemic adduct 2.38 as well as the 
(R)-(+)-o-tolyl-CBS-oxazaborolidene catalyst 1.56 
 
With the successful production of both the iodo- and bromo- cyclic ketal compounds, 1.54 and 
2.37, both were both taken forward to the chiral Diels-Alder reaction to produce the adducts 
1.53 and 2.38, respectively (Scheme 2.7). The adducts, 1.53 and 2.38 are produced to impart 
stereoselectivity on subsequent chemical transformations through steric hindrance of formation 
of the undesired enantiomer. The production of the Diels-Alder adduct is a key step in the 






Figure 2.9. The Diels-Alder reaction in the absence of CBS chiral catalyst, generating racemate 2.39 
 
The Diels-Alder reaction between 1.54 (and 2.37 for the bromo analogue) and freshly distilled 
cyclopentadiene 1.55 is the key step in this synthetic route and utilises (R)-(+)-o-tolyl-CBS-
oxazaborolidine 1.56 to selectively generate the desired (+)- adduct 1.53 (Scheme 2.7).163, 170-
171 Due to the achiral nature of starting materials 1.54/2.37 and cyclopentadiene 1.55, the 
reaction in the absence of chiral catalyst would generate a racemate 2.39 (Figure 2.9), which is 
undesirable. 
 
Figure 2.10. The facile equilibrium between species of (R)-(+)-o-tolyl-CBS-oxazaborolidene upon treatment with 
trifluoromethanesulfonic acid 
 
The CBS catalyst 1.56 was activated through the addition of trifluoromethanesulfonic acid, 
producing the chiral and strongly Lewis acidic species 2.25, which exists at facile equilibrium 
with 2.26 (Figure 2.10).170 Acting as a Lewis acid, the Boron within 2.25 can coordinate to the 
carbonyl within either 1.54 or 2.37. This allows for steric occlusion of the superfacial π-orbitals 
of 1.54/2.37, mediated by the bulky tolyl group within 2.25.170 This occlusion prevents 
alignment of the superfacial π-orbitals of the dienophile starting material (either 1.54/2.37) and 
the π-orbitals within cyclopentadiene, preventing formation of the undesired (-)-adduct. This 
procedure produced the desired adduct 1.53 in good yields (60-80%) and good 
enantioselectivity, [α]D
25= -70.3, which is comparable to the literature value reported by Jung 
et al. ([α]D
25 -84.7).163 The bromo variant 2.38 was produced in comparable yield 73%. 
Unfortunately, upon optical rotation analysis, it was found that the bromo adduct 2.38 was a 
racemic mixture. The observed value of [α]D
25= 0.0, indicated racemisation. However, due to 
87 
 
the poor reaction outcome when forming iodo-cyclic ketal 1.54, it was necessary to use 
racemate 2.38 for subsequent steps for the production of the diethyl and cyclohexyl ketal final 
compounds, thus producing racemic diethyl and cyclohexyl ketals. The synthesis of these two 
ketal analogues is outlined later in this chapter. Racemic synthesis followed the same general 
synthetic route as outlined herein. 
 
With the production of adducts 1.53 and 2.38, the subsequent step was to install the allyl chain 
α to the ketone (Scheme 2.8). Stille cross-coupling was utilised for this purpose. Alternatives 
routes such as Suzuki coupling could also have been considered, however Stille coupling was 
employed due to the milder nature of reaction conditions, the diversity of permitted R-groups 
and the successful previous application by Jung et al.163 However, an issue with the Stille 
coupling is the toxicity of the stannane (tin) reagents required.  
 
 
Scheme 2.8. The installation of the allyl group by Stille coupling with iodo 1.53 and racemic bromo 2.38 adduct 
starting materials which afforded 1.57 and racemate 2.40. 
 
Stille coupling utilises palladium(0) to catalyse the coupling of conjugated stannanes to 
electrophilic carbon centres such as an alkyl halide.172-173 Stille coupling proceeds in a three-
step pathway, summarised as follows; oxidative addition, transmetallation and reductive 
elimination (Scheme 2.9).172-174 Briefly, using the iodo compound 1.53 as an example, 
oxidative addition of the alkyl halide (Diels-Alder adduct 1.53) to triphenylphosphine 
palladium(0) catalyst 2.41 generates a palladium(II) species which can undergo 
transmetallation with allyl tributyl stannane 2.42 (Scheme 2.9). The allyl group displaces the 
88 
 
halide through action as a nucleophile (Scheme 2.9). Preceding reductive elimination, trans / 
cis isomerisation occurs to bring to the allyl and starting material within proximity of one 
another for the final reductive elimination step, which releases the desired product 1.57 and 
regenerates the triphenylphosphine palladium(0) catalyst 2.41 (Scheme 2.9). Thus, the Stille 
coupling successfully produced the desired allyl compound 1.57 in a good yield of 68 %. The 
yield observed experimentally in this study is lower than that observed in the Jung et al. 
synthesis, which was found to be 91 %.163 
 
 
Scheme 2.9. The catalytic pathway of Stille coupling; (i) Oxidative addition, (ii) transmetallation and (iii) 
reductive elimination. 
  
The racemic bromo adduct 2.38 was also taken into the Stille reaction with allyl tributyl 
stannane. The reaction also proceeded in a facile nature, however the reaction mixture required 
additional heating with microwave radiation (20 minutes, compared to 10 minutes for iodo 
variant) (Scheme 2.8). The lower efficiency of bromine as a leaving group, relative to iodine 
could be a reason for this. Despite this, the reaction yield of 2.40 proved to be good at 75%, 
compared to 68% in the corresponding iodo route (Scheme 2.8). This shows that the bromo-
route is a viable alternative to the iodo-route. As described above, the allyl compound 2.40, 
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produced from the bromo Stille coupling substrate 2.38 is racemic. This racemate was only 
used for the production of the diethyl and cyclohexyl ketal compounds, the synthesis of which 
is outlined in section 2.6. The synthesis of the racemic ketal analogues follows the synthetic 
route outlined herein. 
 
With the successful production of allyl compound 1.57, the cyclic ketal was cleaved by the 
addition of dilute H2SO4 to afford the de-protected ketone 1.76 in near quantitative yield (96 
%) (Scheme 2.10).  
 
Scheme 2.10. Deprotection of the lower ketone by H2SO4 yielding dione 1.76. 
 
The intermediate 1.76 was taken forward into a modified Juliá-Colonna epoxidation which had 
previously been employed by Jung et al.163 The Juliá-Colonna epoxidation is the oxidation of 
an electrophilic α, β-unsaturated enone by hydrogen peroxide (as the hydroperoxide anion) in 
the presence of a poly-amino acid chains with high α-helical content (typically poly-leucine or 
alanine).175-176 The poly-amino acid chain is thought to act as a catalyst in the Weitz-Sheffer 
(Figure 2.11) epoxidation to produce the desired epoxide in an highly enantioselective 
manner.175-178 However, it is well known that endocyclic enones are not suitable substrates for 
Juliá-Colonna epoxidation with poly-amino acid catalysts.178 Nonetheless, in this case, 
enantioselectivity is ensured through the steric hindrance of formation of the endo-epoxide, 
caused by the Diels-Alder adduct (Scheme 2.11). This yielded the desired epoxide 1.58 in good 
yield (83%) (Scheme 2.11). This yield is comparable to that observed by Jung et al. in their 
total synthesis of ambuic acid (93%).163 
 
 





Scheme 2.11. Installation of the epoxide forming 1.58. 
 
With the successful production of the epoxide 1.58, a mono-hydroxymethylation procedure 
was utilised to install the primary alcohol affording 1.59. A monohydroxymethyation 
procedure, previously used by Jung et al. and Mehta et al. in their synthesis of the 
epoxyquinone (±)-jesterone 2.2, also produced by Pestalotiopsis sp. was used for this 
application. 163, 179 In addition, Mehta et al. had further success with this procedure in their total 
synthesis of the epoxyquinone dimer (±)-torreyanic acid 2.1.164 DBU was used to extract the 
α-proton of 1.58 allowing for reaction with aqueous formaldehyde to furnish 1.59 in a good 
yield (79%, Scheme 2.12). The yield observed experimentally in this study was unfortunately 
lower than those within the literature, Jung et al. and Mehta et al. found yields of 90% and 
92%, respectively.163, 168 
 
Scheme 2.12. Installation of the primary alcohol forming 1.59. 
 
The newly installed primary alcohol within 1.59 was utilised for the stereoselective reduction 
of the adjacent ketone to the secondary alcohol 1.60 (Scheme 2.13). Mehta et al. (2005) 
postulate that regioselectivity of the reaction can be explained through initial coordination of 
aluminium to the carbonyl and hydroxyl group blocking the preferred exo-face (Scheme 2.13) 
thus, favouring hydride delivery to the hindered endo-face, to yield the desired exo-secondary 
alcohol (Scheme 2.13).180 DIBAL-H reduction yielded the desired diol, 1.60 in reasonable yield 
(43%), albeit lower than those previously reported in the literature, Jung et al. reported a yield 
of 87%.163  Diol 1.60 was produced with good enantioselectivity, [α]D
25= -44.4, which is 




Stubborn aluminium salts formed upon the quenching of the reaction with MeOH proved 
problematic during the aqueous workup, due to their poor solubility in the aqueous phase, they 
may be a cause of the lower than expected yield. Notably, they form a viscous paste when 
anhydrous MgSO4 was added as a drying agent. This caused blockage of filters, potentially 
causing the loss of compound. Therefore, dilute HCl was employed to try and aid solvation of 
the aluminium salts. Despite this, yields remained lower than those previously observed in the 
literature.163 
 
Scheme 2.13. Reduction of the lower ketone to the corresponding secondary alcohol. Potential transition state of 
the reduction, adapted from Mehta et al..180 
 
Following the reduction, the primary alcohol of diol 1.60 was protected as a t-butyl dimethyl 
silyl (TBDMS) ether 2.27 (Scheme 2.14). Silylation is a widespread approach for the protection 
of alcohols and has been used broadly in other synthetic applications, including the Jung and 
Mehta syntheses outlined previously in this chapter.163, 168, 181-182 A solution of diol 1.60 in 
DMF was treated with imidazole and TBDMSCl to yield the desired silyl ether 2.28 in an 
excellent yield (83%, Scheme 2.14). 
 
Corey initially postulated that this reaction was catalysed by the formation of a reactive 
imidazole-silicone species (Scheme 2.15). However, in more recent studies, such as Patschinski 






Scheme 2.14. TBDMS protection of primary alcohol as the t-butyl dimethyl silyl ether 
 
In addition to high yields, the removal of silyl ether protecting groups is often facile, typically 
using tetra-n-butylammonium fluoride (TBAF).181 Efficiency of protection and deprotection 
are both highly desirable properties of a protection step. Silyl ether 2.27 was taken forward. 
 
The Diels-Alder adduct was dismantled using a procedure modified from Jung et al. by heating 
2.27 to 230 ºC in Ph2O for 2 h liberating cyclopentadiene and forming 1.61 in good yield (73 
%, Scheme 2.16).163 The yield observed in this study is comparable to the yield observed by 
Jung et al. in their total synthesis of ambuic acid (81 %).163 
 
Scheme 2.15. TBDMSCl protection of a primary alcohol showing the reactive imidazole-silyl species as 
postulated by Corey (1972) to be the catalyst of the reaction.182 
 
The compound 1.61 was treated in an ozonolysis procedure, modified from Jung et al. with a 
reductive workup with dimethylsulfide to convert the terminal allylic alkene into aldehyde 
2.43. The aldehyde 2.43 was then taken into a Wittig reaction with ylide 2.44 to install the t-






Scheme 2.16. Retro Diels-Alder reaction, dismantling of the adduct 2.27 yielding 1.61. 
 
Ozonolysis is the oxidative cleavage of olefins utilising O3 (Scheme 2.17) and was first 
investigated by Harries et al..183 Initial addition of ozone across the olefin generates an 
unstable, 5-membered ‘primary’ ozonide, a melozonide (Scheme 2.18).184-185 Subsequent 
decomposition of the melozonide yields a carbonyl and ‘carbonyl oxide’ (Scheme 2.18).184, 186 
Addition of the ‘carbonyl oxide’ to the carbonyl yields the secondary ozonide, a 1,2,4-
trioxolane, first observed by Rieche et al., an interesting heterocycle with both an ether and 
peroxide linkage (Scheme 2.19).184-185, 187 After ozonolysis, the reaction mix was treated with 
dimethylsulfide, and stirred for 30 minutes, causing lysis of the1,2,4-trioxolane, forming 
formaldehyde, dimethylsulfide and the desired aldehyde 2.43 (Scheme 2.19). 
 
 
Scheme 2.17. Ozone and its resonance structures 
 
The crude aldehyde 2.43 was then taken into a Wittig olefination with ylide 2.44. The Wittig 
reaction initially proceeds through a [2+2] cycloaddition between the aldehyde and ylide 
forming an oxaphosphetane ring (Scheme 2.20). The ring then degrades via reverse [2 + 2] 
cycloaddition to give the desired alkene and triphenylphosphine oxide (Scheme 2.20).188 
Formation of the P=O bond provides an enthalpic driving force for this reaction. This reaction 
proceeds as a stabilised Wittig as the electron withdrawing ester within ylide 2.44 delocalises 
the charge of the carbanion. This stabilises the intermediate, allowing for formation of the 




Scheme 2.18. Ozonolysis, showing formation of the unstable primary melozonide, subsequent degradation and 
formation of the 1,2,3-trioxolane. 
 
The multi-step ozonolysis and Wittig reaction produced the desired t-butyl ester, albeit in poor 
yield (25 %) (Scheme 2.21). Unfortunately, the yield observed in this study is substantially 
worse than those previously observed in the literature. Jung et al. found a good yield of 74 
%.163 The poor yield could be explained by the difficulty in the monitoring of the ozonolysis 
reaction and the formation of the 1,2,4-trioxolane. The only way of monitoring the ozonolysis 
reaction is the observation of a colour change of the solution from colourless to a light blue. 
This may be a cause of the poor yields of the aldehyde 2.43.  
 
 
Scheme 2.19. Reductive workup of ozonolysis with dimethylsulfide, forming formaldehyde, the desired aldehyde 








Scheme 2.20. Mechanism for a Wittig olefination showing [2 + 2] addition, and subsequent degradation of the 
oxaphosphetane forming the olefin and triphenylphosphine oxide 
 
The above synthetic transformations yielded the target compound 1.62 and provided a scaffold 
for the production of a range of unique analogues. Furthermore, this synthetic route provides 
several starting materials for the production of a variety of analogues.  
 
 















2.4 The synthesis of enantiomerically pure (-)-1.63 
2.4.1 The synthetic target 
With the successful production of 1.62, modification of the route was carried out to enable the 
production of unique ambuic acid analogues. It was initially decided to modify the procedure 
outlined above to enantioselectively produce the (-)-analogue 1.63 (Figure 2.12).163 1.63 will 
be produced to determine whether stereochemistry has an effect on the biological activity of 




Figure 2.12. The synthetic target, the (-)-analogue 1.63. 
 
2.4.2 Synthesis of target 1.63 
Broadly, the synthetic route to 1.63 is similar to that of 1.62 with the main modification to the 
procedure being that of alteration of the highly enantioselective Diels-Alder reaction. The 
reaction was modified by utilising (S)-(-)-o-tolyl-CBS oxazaborolidene 1.68 instead of (R)-(+)-
o-tolyl-CBS oxazaborolidene 1.56 catalyst (Scheme 2.22).  
 
Utilisation of (S)-(-)-o-tolyl-CBS oxazaborolidene catalyst 1.68 allows for formation of the 
desired (-)-adduct 1.67 in reasonable yield (56%) with good enantioselectivity observed, 
[α]D
25= +81.4. The (+)-adduct has a value of [α]D
25= -70.3.  Steric occlusion of the suprafacial 
π-orbitals of the reaction substrate 1.54 by the bulky tolyl group within (S)-(-)-o-tolyl-CBS 





Scheme 2.22. The enantioselective Diels-Alder reaction selectively forming the (-)-adduct 1.67 and the chiral 
catalyst 1.63. 
 
With the successful production of (-) Diels-Alder adduct 1.67, the remainder of the synthesis 
of target 1.63 proceeded in a similar manner to the production of 1.62, as outlined previously 
in this chapter. 
 
The allyl group was installed via Stille coupling in a good yield (69%) to furnish 1.69 (Scheme 
2.23). The lower ketone was then de-protected with dilute H2SO4 affording the dione 2.45 in 
an excellent yield (91%). 2.45 was then treated with H2O2 in the presence of Na2CO3 to afford 
the epoxide 1.70 in a good yield (76%). The primary alcohol was then installed α- to the lower 
ketone of 1.70 using DBU and aqueous formaldehyde to provide alcohol 1.71 in a good yield 
(87%, Scheme 2.23). The primary alcohol was then utilised for the reduction of the lower 
ketone to the desired secondary alcohol, yielding the diol 1.72 in adequate yield (57%) with 
good enantioselectivity, [α]D
25= +43.9. The corresponding (+)-diol 1.60 was found to have a 
value of [α]D
25= -44.4. The primary alcohol was then protected as a t-butyl-dimethyl silyl ether, 
affording 2.46 in a good yield (79 %). The Diels-Alder adduct was then dismantled by heating 
2.46 in diphenyl ether to liberate cyclopentadiene giving quinone derivative 1.73 in poor yield 
(38 %, Scheme 2.23). As discussed in more detail in chapter 3, yields observed in this retro 
Diels-Alder reaction were often variable, with poor yields being associated with the formation 
of side products, potentially through thermolysis and/or oxidation. Attempts to improve this 




Figure 2.13. Catalytic complex formed between the activated (S)-(-)-o-tolyl-CBS oxazaborolidene 2.33 (grey) 
and reaction substrate, 2.9 (turquoise). Through action as a Lewis acid, the boron within the CBS catalyst can 
coordinate to the carbonyl, allowing for occlusion of the suprafacial π-orbitals by the bulky tolyl group 
(highlighted) within the catalyst. This prevents orbital alignment of the diene (cyclopentadiene) and the dienophile 
(reaction substrate) and favours formation of the (-)-adduct. 
 
1.73 was taken into the two-step ozonolysis and Wittig procedure, outlined in more detail 
previously in this chapter, producing the target compound 1.63 in 36 % yield. The total yield 
for the production of 1.63 from 2-iodophenol is 0.6 % in an 11 step synthetic route (53 mg of 






Scheme 2.23. The synthesis of target 1.63 from the Diels-Alder adduct 1.67. (a) Pd(PPh3)4, allyltributyl stannane, 
THF, 10 min, 110 ºC, 150 W MW radiation, 69%; (b) 1 N H2SO4, acetone, THF, 30 min, rt., 91%; (c) 10% (w/v) 
Na2CO3, 30% (v/v non-stab.) H2O2, acetone, 30 min, 0 ºC, 76%; (d) 37% (w/v) aqueous formaldehyde, DBU, 
THF, 30 min, 0 ºC, 87%; (e) DIBAL-H, THF, 30 min, -78 ºC, 57%; (f) TBDMSCl, imidazole, DMF, 4 h, 0 ºC, 
79%; (g) Ph2O, 4 h, 230 ºC, 38%; (h) O3, dimethylsulfide, MeOH, -78 ºC, 30 min then Ph3P=C(Me)CO2t-Bu, 













2.5 The attempted synthesis of ether analogues of the primary 
alcohol 
2.5.1 The Synthetic Targets 
With the finding that racemate 1.52 was active against staphylococcal agr mediated quorum 
sensing activity, it was decided to produce a range of analogues of enantiomerically pure 1.62 
to determine how chemical modification of the primary alcohol affects biological activity. 
Initial attempts of derivatisation were to synthesise a range of ether analogues [shown by 
general structure 1.64, (Figure 2.14)] of the primary alcohol (protected as the t-butyl dimethyl 
silyl ether) within 1.62. This was done as a means to explore the chemical space around the 
primary alcohol of 1.52 and the silyl ether of 1.62.  
 
 
Figure 2.14. Racemate 1.52, enantiomerically pure ‘(+)’ enantiomer 1.62 and general structure of the ether 
analogue synthetic target 1.64. 
 
2.5.2 Synthesis- Attempted Williamson Etherification 
Initial attempts at the production of the asymmetric ether employed a modified Williamson 
ether synthesis procedure, one of the oldest named synthetic transformations in organic 
chemistry.189 
 
Compound 1.60 was initially chosen as the substrate for the production of a range of ether 
analogues as it is simpler and less time consuming to produce than quinolone derivative 1.62 
(Figure 2.15). 
 





Scheme 2.24. The Liang et al procedure for the production of an asymmetric ether.190 
 
Initial conditions tested were based on a modified literature procedure from Liang et al. 
(Scheme 2.24), utilised in their synthesis of both 11-α-methoxycurvularin and 11-β-
methoxycurvularin.190 Alcohol 2.47 is treated with NaH and tetra-n-butyl ammonium iodide 
(TBAI) as a phase transition catalyst to install benzyl ether, giving 2.48 (Scheme 2.24). Their 
procedure allows for near quantitative formation of a benzyl ether in the presence of an epoxide, 
thus, it was decided to use their conditions for this application to preserve the epoxide.  
 
The key intermediate 1.60 was stirred with NaH to deprotonate the primary alcohol, in THF in 
the presence of the phase transition catalyst TBAI and bromomethyl cyclohexane in order to 
generate the desired asymmetric ether 2.51 (Scheme 2.25, Table 2.1 condition 1). 
 
 
Scheme 2.25. Attempted synthesis of the methyl cyclohexyl asymmetric ether analogue 2.49 from diol 1.60. 
 
Unfortunately, the modified condition from Liang et al. failed to produce the desired product 









Table 2.1. Conditions trialled for the synthesis of desired asymmetric ether 2.75 
Condition  Solvent Base Other 
1 THF Sodium hydride (excess) TBAI 
2 THF Sodium hydride (excess) 15-Crown-5 ether (1 eq.) 
3 THF Potassium t-butoxide (excess) N/A 
 
The poor reaction outcome could potentially be attributed to the primary alcohol being 
sterically hindered. Thus, modification of the procedure was required. Aspinall et al. report the 
improvement of etherification of sterically hindered alcohols, when sodium hydride was used 
as base, through the use of 15-crown-5 ether 2.50 (Figure 2.16).191 They stated that using 
traditional methods, utilising sodium hydride as base, often leads to outcomes which are 
‘unacceptable’ in terms of yield and timescale.191 Furthermore, these methods often necessitate 
the use of polar aprotic solvents such as DMF or DMSO, which are both problematic in terms 
of toxicity and ease of removal.191 Therefore, 15-crown-5 ether was utilised for this application 
to try and improve the reaction outcome. 
 
Figure 2.16. 15-Crown-5 ether 2.50 and 15-crown-5 ether chelating a sodium cation. 
 
15-Crown-5 ether chelates the sodium cation, aiding its solvation and increasing the availability 
of hydride for deprotonation (Figure 2.16). Additionally, coordination of the sodium cation 
would also prevent it from interacting with the alkoxide which would weaken it as a 
nucleophile.  
 
Starting material 1.60 was stirred with sodium hydride and 15-crown-5 ether, before the 
addition of bromomethylcyclohexane (Table 2.1, condition 2). Unfortunately the reaction 
failed to proceed despite stirring again for several days. 
 
In a final attempt to generate the desired methyl cyclohexyl ether, the strong, non-nucleophilic 
base potassium t-butoxide was used in place of sodium hydride (Table 2.1, condition 3). 
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Unfortunately, this also failed to improve the reaction outcome and even after 2 days of stirring, 
no change in the reaction mixture was observed by TLC. 
 
With the failure of these conditions to produce the desired ether 2.49, it was postulated there 
may be a factor adversely affecting the reaction. One possibility that might account for the poor 
reaction outcome could be the secondary alcohol potentially acting as a hydrogen bond donor 
and bonding with the alkoxide, reducing its nucleophilicity 2.51 (Figure 2.17). 
 
Figure 2.17. Potential six-membered ring formed between the alkoxide and the adjacent secondary alcohol 2.51 
 
To see if this was indeed the case, it was decided to utilise the dione 1.59 as the reaction 
substrate as the ketone is unable to act as a hydrogen bond donor. Thus, dione 1.59 was treated 
as previous (with sodium hydride, 15-crown-5 ether and bromomethylcyclohexane in THF) to 
form the ether 2.52. Post-workup, 1H-NMR and LC/MS analysis revealed that the observed 
product was a diastereoisomeric mixture of the diol 2.53 (Scheme 2.26), indicative of sodium 
hydride-mediated reduction of the ketones. With the failure of Williamson-like etherification, 





Scheme 2.26. The attempted synthesis of methyl cyclohexyl ether 2.52 from dione starting material 1.59. Reaction 
formed undesired diastereoisomeric mix of diol 2.53 
 
2.5.3 Attempted Modification of Hydroxymethylation Step to Install the Ether Directly 
With the difficulties experienced in the production of an ether via a modified Williamson ether 
synthesis, it was decided to attempt to install the ether directly through modification of the 
hydroxymethylation procedure.  
 
 





Hence, the dione 1.58 was treated with DBU followed by 1.5 equivalents of 
benzylchloromethyl ether 2.54 in THF at 0 ºC (Scheme 2.27). It was hoped that the carbanion 
formed when 1.58 is treated with DBU would act as a nucleophile and attack the δ-positive 
carbon adjacent to the chlorine within 2.54. 
 
Initially, the reaction was attempted at 0 ºC with gradual warming to ambient temperature. 
However, Thin-layer chromatography (TLC) failed to show any change in the reaction mixture. 
The reaction was subsequently heated to 90 ºC with 150 W microwave radiation for 30 minutes. 
Unfortunately, this failed to facilitate the formation of 2.55, thus it was heated again for a 
further 90 minutes. No change was observed by TLC or LC-MS. The failure of these conditions 
could be due to steric occlusion of the carbanion, caused by the adduct and/or the size of the 
benzylchloromethyl ether. 
 
2.5.4 Conversion of the Primary Alcohol to a Leaving Group 
With the failure of above model studies, an alternative strategy was required. The conversion 
of the primary alcohol to a leaving group, allowing for nucleophilic substitution with an alcohol 
(forming the desired ether) was deemed to be the next suitable strategy. 
 
Initially, it was decided to produce propyl ether 2.56 (to be converted to the final compound) 
from dione 1.59 in a one pot reaction with a mesylate intermediate 2.57 (Figure 2.18). 
 
 
Figure 2.18. Dione 1.59, the desired propyl ether 2.56 and the mesylate intermediate 2.57 
 
Hence, the intermediate 1.59 was treated with 1.5 equivalents of Et3N and mesyl chloride for 
2 h at -78 ºC using a procedure modified from the literature (Table 2.2, condition 1).192 After 
stirring, an excess of anhydrous propan-1-ol was added and the reaction mixture was stirred 
for 72 h at ambient temperature. After stirring for 72 h, TLC analysis showed a change in 
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reaction mixture and the potential product was purified. However upon analysis by 1H NMR, 
this compound was found to be the mesylate 2.57. 
 
Thus, the mesylate 2.59 was treated with an excess of anhydrous propan-1-ol, which had 
previously been treated with sodium hydride to generate the alkoxide nucleophile in an attempt 
to aid the reaction. Unfortunately, after further stirring, LC-MS analysis failed to show any 
change in the reaction mixture.  
 
Table 2.2. Conditions tested to convert the primary alcohol into a good leaving group 
Condition  Solvent Temperature (oC) Reagents 
1 DCM -78 
Et3N (1.5 eq.), mesyl chloride (1.5 
eq.), propan-1-ol (excess) 
2 DCM 
75, 150 W microwave 
radiation 
Imidazole (1.1 eq.), iodine (1.1 eq.), 
triphenylphosphine (1.1 eq.) 
 
Due to the failure of production of an asymmetric propyl ether with a mesylate intermediate, it 
was decided to convert the primary alcohol into an iodide, 2.58 (Table 2.2, condition 2). This 




Figure 2.19. (A) Mechanism of the Appel reaction, for the conversion of an alcohol to an iodide. The formation 
of the strong P=O bond provides an enthalpic driving force for the reaction. (B) The target iodide 2.58 
 
The Appel reaction is the conversion of an alcohol to a halide using triphenylphosphine and a 
source of halide, for example carbon tetrachloride or elemental iodine (Figure 2.19).193-194 
Initial formation of the phosphonium salt and deprotonation of the alcohol allows for 
subsequent displacement of the iodide by the generated alkoxide (Figure 2.19). Through an 
SN2 mechanism, the iodo ion can react to form the alkyl halide and triphenylphosphine oxide, 
the strong P=O bond formation providing an enthalpic driving force for the reaction (Figure 
2.19). 
 
A procedure was adapted from the literature (Table 2.2, condition 2) to produce the iodide.195 
Alcohol 1.59 was stirred with imidazole (acting as a sink for the HI generated in the reaction, 
forming the imidazolium iodide), triphenylphosphine and iodine (all 1.1 eq.) and the reaction 
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mixture was stirred overnight.195 Unfortunately, no reaction was observed when the reaction 
was monitored by TLC. Thus, the reaction mixture was heated for 2 h at 75 ºC with 150 W 
microwave radiation. Heating the reaction mixture caused the formation of triphenylphosphine 
oxide precipitate, an indicator that the reaction had proceeded. Furthermore a change in the 
reaction mixture was observed by TLC. Thus, workup and purification of the reaction mixture 
was carried out. Unfortunately, it was not possible to purify the iodide, it may have degraded 
during silica gel chromatography. 
 
With the exhaustive testing of numerous synthetic strategies and conditions to produce a range 
of asymmetric ether analogues and the failure of these conditions, it was decided to discontinue 























2.6 Production of silyl ether analogues of the primary alcohol 
2.6.1. The synthetic targets 
With the failure to produce ether analogues, it was decided to produce a range of silyl ether 
analogues of the primary alcohol 1.65 (Figure 2.20). Silyl ether analogues were chosen due to 
the facile nature of their installation.182  
 
 
Figure 2.20. The general structure of a silyl ether synthetic target 1.65. 
 
The incorporation of silicon into small molecular inhibitors is uncommon in medicinal 
chemistry.196-197 As of 2018, no drugs containing silicon were approved in Western Europe or 
the United States.197 The only example of an approved drug containing silicon is silabolin 2.59 
(Figure 2.21) which is used in Eastern Europe.196-197 Silabolin is a steroid used for the treatment 
of muscle wasting disorders which is administered as a trimethyl silyl ether pro-drug.196-197  
 
 
Figure 2.21. The trimethyl silyl ether pro-drug silabolin.2.59 
 
Silyl ethers are typically used as protecting groups and as such have well-defined chemical 
properties.182, 198 The Si-O bond is thermodynamically stable, but under acidic and aqueous 
conditions proves kinetically labile.198 The steric environment around the silicon atom dictates 
the lability of the silyl ether. 198 This property is useful in the design of prodrugs such as 
silabolin, 2.59 as well as in synthetic strategies for the selective protection of alcohols.198 The 
trimethyl silyl ether within silabolin is labile under mildly acidic conditions, whereas more 
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complex silyl ethers such as t-butyldimethyl silyl ethers are more resistant to hydrolysis under 
both mildly basic and acidic conditions.199  
 
The silyl ethers, whilst rare in final compounds of interest within the literature, have been used 
previously to improve the clinical potential of withaferin A 2.60, which is cytotoxic against 
several ovarian cancer cell lines (Figure 2.22).200 Perestelo et al. found the incorporation of 
silyl ethers in 2.61 enhances the pharmacological properties of withaferin A.200 They noted that 
slight modifications on the silyl ether substituent had substantial effects on the compound 
activity.200 For example, the incorporation of a triethyl silyl ether gave improved cytotoxic 
activity against the human  cisplatin resistant ovarian cancer cell line A2780/CP70 when 
compared to the free alcohol 2.60 with IC50 values of 20 nM and 32 nM respectively for the 
silyl ether and free alcohol.200 
 
 
Figure 2.22. Withaferin A 2.60 and general structure of a silyl ether analogue 2.61 reported by Perestelo et al..200 
 
The incorporation of silicon into inhibitors can provide the resulting compound with unique 
medicinal chemical properties.196, 198, 200 Silicon containing compounds have increased 
lipophilicity which could enhance cell penetration.198 Furthermore, silicon is more 
electropositive than carbon, potentially generating an electron deficient centre within the 
compound.196, 198 Within the target structures here (1.65), the incorporation of silicon generates 
an ether with increased polarity compared to an ether with a C-O-C bond. This may prove 
interesting in terms of compound activity. 
 
The previous utilisation of silyl ethers to improve the activity of withaferin A 2.60 and the 
interesting medicinal chemical properties imparted by the inclusion of silicon make this an 
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interesting and novel approach for the design and synthesis of a range of analogues. Thus, the 
synthesis of a focussed range of unique silyl ether analogues will be attempted herein (Figure 
2.23). These analogues will incorporate a range of chemical functionalities, including short 
linear and branched chain alkanes as well as aromatics (Figure 2.23). In addition, the silyl 
ethers were synthesised to explore the chemical space around the silyl ether of 1.62. 
 
 
Figure 2.23. The initial silyl ether analogue 1.62 (LB151), the general target silyl ether structure 1.65 and the 
proposed silyl groups to be incorporated. 
 
Furthermore, with the synthesis of enantiomerically pure 1.62 by Dr Leonardo Baldasarre, the 
production of further silyl ether analogues could provide useful information about the effect on 
biological activity of ambuic acid analogues modified at the primary alcohol. 
 
2.6.2 The synthesis of silyl ether analogues 
The synthesis of the unique silyl ether analogues broadly follows the synthesis of 1.62, which 
has been outlined in detail previously in this chapter. Following the synthetic route, the t-butyl 
dimethyl silyl ether, 1.62 was first cleaved exposing the free alcohol to yield diol 1.74 (Scheme 
2.28). The diol 1.74 was then treated with a silyl chloride in the presence of imidazole to furnish 




Scheme 2.28. Proposed synthetic route to silyl ether analogues. Cleavage of silyl ether of 1.62 followed by 
subsequent reaction to form desired silyl ether. 
 
Initial attempts at deprotection of the TBS-protected primary alcohol utilised 2 equivalents of 
tetra-n-butyl ammonium fluoride (TBAF) (Table 2.3, condition 1). TBAF is a source of the 
fluoride ion which can attack the electron deficient silicon atom within 1.62 cleaving the silyl 
ether. With 4 h stirring at 0 ºC, TLC analysis confirmed consumption of the starting material 
and the formation of a more polar product, indicative of the formation of the desired diol 1.74. 
Unfortunately, following purification by silica gel chromatography, the diol 1.74 was obtained 
in a low yield of 37%. For the production of a range of analogues, an efficient deprotection 
method is required as the production of the substrate for the reaction 1.62 requires a significant 
investment of both reagents and time. To avoid wasting of reagents, the deprotection method 
needs to be as efficient as possible. 
 
Table 2.3. Conditions for the cleavage of the t-butyl dimethyl silyl ether within 1.62 
Condition Solvent Reagents Yield (%) 
1 THF 2 eq. TBAF 37 
2 - 1:2:1 mix of diethyl ether, 
acetic acid and dH2O 
54 
    
Thus, 1.62 was treated with a 1:2:1 mixture of diethyl ether, acetic acid and dH2O to dismantle 
the ether (Table 2.3, condition 2). 1.62 was stirred in the mixture overnight, which produced 




With a more efficient production of diol, the subsequent step is the installation of the silyl ether. 
This was carried out using a standard procedure for installing silyl ethers. Thus, the diol 1.74 
was first stirred with imidazole in DMF before addition of the relevant silyl chloride (Table 
2.4). 
 
Table 2.4. The silyl chlorides used to produce the final silyl ether analogues and their yields 
Target Compound Silyl Chloride Yield (%) 
 
 
23 (4 mg) 
 
 








Upon exposure of the diol 1.74 to dimethylthexyl silyl chloride 2.63 the dimethylthexyl silyl 
ether 2.62 was obtained in a low yield (23 %). In contrast, the production of the t-butyldiphenyl 
silyl ether proved more challenging, with a yield of 6 % of the desired product 2.64 (Table 2.4). 
This poor yield could be attributed to the steric hindrance incurred by the two bulky phenyl 
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groups within silyl chloride 2.65. The amount of compound t-butyl diphenyl silyl ether 2.64 
generated was insufficient to fully characterise by NMR. 
 
The production of ethyl dimethyl and n-butyl dimethyl silyl ethers proved more problematic 
(2.66 and 2.68, respectively) (Table 2.4). Upon reaction of diol 1.74 with the appropriate silyl 
chloride (either 2.67 or 2.69), no change in reaction mixture was observed by either LC-MS or 
TLC. 
 
With the failure of the reaction utilising imidazole as the base, it was decided to investigate 
whether changing the base would improve the reaction outcome. Thus, 2,6-lutidine was used 
as the base for the reaction in an attempt to form the desired  n-butyldimethyl silyl ether 2.68. 
This again failed to cause a change in reaction mixture. Likewise, in an attempt to form the 
ethyldimethyl silyl ether, 2,6-lutidene was again used to try and aid formation of the product 
2.70, again, no change was observed. Thus, pyridine was added to the reaction mixture, which 
again failed to cause a change in the reaction mixture even with stirring overnight. 
 
With the failure of these reactions, it was decided to discontinue with this approach of 
producing analogues. The dimethyl thexyl silyl chloride 2.62 (Figure 2.24) was taken forward 
for characterisation of anti-virulence activity, described in chapter 4. 
 
 









2.7 Ketal analogues 
2.7.1 The synthetic targets 
The production of several ketal analogues, cross-linking the diol of 1.74, may provide some 
valuable pharmacological data about the anti-virulence activity of ambuic acid and the 
synthetic analogues. Firstly replacement of the alcohols, with two ethers, which comprise the 
ketal may yield some interesting information regarding the inhibition of staphylococcal agr-
mediated quorum sensing. Secondly, the formation of a cyclic ketal would impart a level of 
rigidity within the structure of the modified compound, which may alter compound activity. 
 
A family of drugs containing a ketal moiety is the azole anti-fungals, including ketoconazole 
2.70 (Figure 2.25). Ketoconazole 2.70 is a broad spectrum anti-fungal known to inhibit the 
production of steroids, required for correct fungal membrane synthesis.201 Ketoconazole 2.70 
can be used for oral treatment of both superficial and deeper fungal infections.202 In addition, 
ketoconazole is also used for the treatment of systemic Candida albicans infection 
(candidiasis) which can prove fatal.202-203 
 
 
Figure 2.25. The azole anti-fungal drug ketoconazole 2.70 
 
A further example of a drug molecule containing a ketal moiety is topiramate 2.71 (Figure 
2.26). 2.71 is widely used for the treatment of epilepsy and migranes.204-205 In the treatment of 
epilepsy, 2.71 is believed to function through a number of modes of action, including inhibition 
of carbonic anhydrase and increasing the frequency of opening of GABA-mediated chloride 
ion channels.206-207 Compound 2.71 is a fructose derivative, initially synthesised in a study to 
produce compounds for the treatment of hypoglycaemia.204 It was found that 2.71 had no direct 
effect on blood sugar levels however, it was found to have efficacy against several types of 
human seizures.204 The ketals within 2.71 are known to enhance the central-nervous system 
uptake of the compound through masking of the hydrophilic hydroxyl groups within the 






Figure 2.26. The known anti-epileptic and migrane treatment topiramate 2.71 
 
The previous utilisation of the ketal functionality within known drug molecules makes the 
synthesis of ketal analogues a viable route for the production of novel analogues of ambuic 
acid. It was decided to initially produce the dimethyl (2.72), diethyl (2.73) and cyclohexyl 
(2.74) ketals (Figure 2.27). As discussed in section 2.3, the diethyl 2.73 and cyclohexyl 2.74 
ketals were prepared from the racemic Diels-Alder adduct 2.38. Thus, the two ketals 2.73 and 
2.74 are both racemic. 
 
 
Figure 2.27. The structures of the target ketal compounds, dimethyl 2.72, diethyl 2.73 and cyclohexyl 2.74. 
 
2.7.2 The synthesis of the ketal analogues 
The synthesis of the ketal analogues follows a similar route to the production of the silyl ether 
analogues, as discussed above. The diol is produced by the cleavage of the t-butyl dimethyl 
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silyl ether with a 1:2:1 mix of dH2O, acetic acid and diethyl ether. With production of the diol 
1.74, the ketal (given as general structure 1.66) will be installed using a procedure modified 
from Jin et al. (Scheme 2.29 and Scheme 2.30).209 Jin et al. treated 2.75 with a solution of p-
toluenesulfonic acid (0.2 mg/ mL) in acetone at room temperature, which afforded the dimethyl 
ketal 2.76 in a good yield (71 %).209 
 
 
Scheme 2.29. The installation of the dimethyl ketal carried out by Jin et al..209 
 
The dimethyl ketal 2.72 was produced by treating diol 1.74 with acetone and catalytic p-
toluenesulfonic acid (0.2 mg/mL) at 60 ºC. The reaction proceeded smoothly, with formation 
of product observed by LC-MS. The reaction was worked-up and the product was purified 
initially by preparative-TLC, to yield a yellow oil (6 mg, 20 % yield) with recovery of 32 % of 
starting material (confirmed by LC-MS) (Scheme 2.31). HPLC purification yielded 2 mg of 






Scheme 2.30. The proposed synthetic route for the production of ketal analogues. The silyl ether of 1.62 is 
dismantled yielding diol 1.74, followed by installation of the desired ketal forming 2.5 using a procedure adapted 




Scheme 2.31. Production of dimethyl ketal 2.72 from diol 1.74  
 
The racemic diethyl ketal 2.73 was to be produced in a similar manner. Thus, the racemic diol 
2.77 was dissolved in a solution of p-toluenesulfonic acid (0.4 mg/mL) in pentan-3-one and 
heated to 100 ºC (Scheme 2.32). After stirring overnight, TLC analysis of the reaction mixture 
indicated ~50 % conversion of starting material 2.77, with the appearance of a spot of increased 
hydrophobicity. The reaction mixture was worked up and the product 2.73 was purified by 
column chromatography yielding 12 mg of a yellow oil (15 %, Scheme 2.32). The poor yield 
could be attributed to steric hindrance, potentially by pentan-3-one and/or the reaction substrate 
2.77. The diethyl ketal 2.73 was taken forward for biological testing in chapter 4.  
 
 
Scheme 2.32. The production of the diethyl ketal 2.73 from diol 2.77. 
 
The same procedure was also attempted for the installation of the cyclohexyl ketal, to give the 
racemic cyclohexyl ketal 2.74. Thus, the racemic diol 2.77 was dissolved in a solution of p-
toluenesulfonic acid (0.2 mg/mL) in cyclohexanone and heated to 60 ºC. After 2 h of heating, 
no change in the reaction mixture was observed by TLC and LC-MS, thus the reaction was 
raised to 80 ºC for 1 h. Again, no change was observed, so the reaction was heated to 100 ºC 
overnight (Scheme 2.33). No change was observed, so the reaction was worked up in order to 
recover the starting material. The reaction failure could be potentially attributed to steric 






Scheme 2.33. The attempted production of cyclohexyl ketal 2.74 by cyclohexanone method 
 
An alternative route to 2.74 was investigated. A trans-acetalation/ketalation route was 
evaluated in an attempt to improve the reaction outcome. Alternative routes to ketals have been 
studied previously.210-211 Lorette et al. successfully produced a range of dimethyl ketals 
utilising 2,2-dimethoxypropane in place of acetone.211 Thus, it was anticipated that replacement 
of cyclohexanone with 1,1-dimethoxycyclohexane may improve the reaction outcome, 
potentially facilitated by the production of the reactive oxonium ion intermediate (Scheme 
2.34). Hence, the diol 2.77 was dissolved in a solution of p-toluenesulfonic acid (0.4 mg/ mL) 
in 1,1-dimethoxycyclohexane and heated to 60 ºC for 1.5 h with stirring (Scheme 2.35). This 
led to a change in reaction mixture, observed by TLC and LC-MS, with ~80 % conversion of 
starting material. This coincided with the appearance of a spot of increased hydrophobicity 
when analysed by TLC. The product was purified by column chromatography yielding 30 mg 






Scheme 2.34. Proposed mechanism of the trans-acetalation/ketalation reaction. 
 
As described previously in this chapter, both the diethyl 2.73 and cyclohexyl 2.74 ketals were 
synthesised from a racemic preparation of the bromo Diels-Alder adduct 2.38 ([α]D
25= 0.0). 
Optical rotation values of both the diethyl 2.73 and cyclohexyl 2.74 ketals were both [α]D
25= 
0.0, again indicative of the final compounds being racemic. 
 
 





In addition, 1NMR analysis of both the diethyl 2.73 and cyclohexyl 2.74 ketals revealed a 
diastereoisomeric mix of compounds. For the diethyl ketal 2.73, a 1:1 ratio was observed by 
1H NMR (Figure 2.28) and for the cyclohexyl ketal 2.74, a 9:1 ratio was observed (Figure 
2.30).  
 
The 1H NMR of diethyl ketal 2.73 showed duplication of peaks corresponding to protons at 
positions 4 and 5 within the epoxycyclohexenone ring (Figure 2.28 B) each with an integral of 
~0.5 each, suggesting a 1:1 mix of compounds. Additionally, duplication of the signal assigned 
to the α-proton within the ring was observed, with each signal again integrating to ~0.5 protons 
(Figure 2.28 C). Additionally, there is a signal indicative of a CH2 at δ 2.43 (Figure 2.28 A), 
which through the use of COSY 2D NMR, was found to couple to the terminal CH3 at δ 1.06 
(Figure 2.29). The other CH2 is under and adjacent to the methyl peak within the left hand of 
the molecule (Figure 2.28 A). The difference in chemical shift of the CH2 peaks is indicative 








Figure 2.28. 1H NMR of the diethyl ketal 2.73. (A) Full 1H NMR of diethyl ketal 2.73, note the CH2 at 2.43 ppm, 
indicative of one of the CH2 moieties within the diethyl ketal. (B) Magnified region of 1H NMR showing the 
duplication of signals corresponding to the protons within the epoxy cyclohexene ring in ~1:1 ratio, indicative of 




Figure 2.29. Magnified region of the 2D COSY NMR of the diethyl ketal 2.73 showing the CH2 at 2.43 ppm 
coupling to the CH3 peak at 1.06 ppm. Line denotes the correlation. 
 
In the case of the cyclohexyl ketal analogue 2.74, there is again evidence of 1H NMR signal 
duplication for protons within the epoxy cyclohexenone ring as well as the α-proton (Figure 
2.30 B), however in this instance, the integration gives an approximate ratio of 9:1 (Figure 2.30 





Figure 2.30. (A) 1H NMR of the cyclohexy ketal 2.74. (B) Magnified region of 1H NMR showing the duplication 
of signals corresponding to the protons within the epoxy cyclohexene ring in an approximate ratio of 9:1 (by 
integral). (C) Magnified region showing the duplication of the signals corresponding to the α-proton, again in an 
approximate ratio of 9:1. 
126 
 
The trans-acetalation/ketalation approach yielded the desired cyclohexyl ketal in improved 
yield when compared to the previous approach, which had been successfully used for the 
production of the dimethyl 2.72 and diethyl 2.73 ketals. This is pleasing, as the cyclohexyl 
ketal requires a more sterically encumbered substrate (1,1-dimethoxyxyclohexane) when 
compared to the production of the dimethyl (acetone) and diethyl (pentan-3-one) ketals. As 
such, for the future preparation of similar compounds, the trans-acetalation/ketalation approach 
should be used. Dimethyl ketal (2.72), diethyl ketal (2.73) and cyclohexyl ketal (2.74) were 




























This chapter has outlined the attempted synthesis of a range of unique analogues of ambuic 
acid. 
 
Scheme 2.36. The key Diels-Alder reaction providing the key intermediate (+)-adduct 1.53. 
 
The general synthesis of 1.62, utilising an efficient procedure optimised by Dr Leonardo 
Baldessarre has been outlined here. This involved the use of a key Diels-Alder reaction between 
cyclic ketal and cyclopentadiene in the presence of (R)-(+)-o-tolyl-CBS-oxazaborolidine 1.56 
catalyst which afforded the adduct 1.53 in good yield with good enantioselectivity (Scheme 
2.36). With the successful synthesis of adduct 1.53, production of the final compound 1.62 
could proceed. Stille cross-coupling allowed for the installation of the allyl functionality giving 
1.57, epoxidation through the use of H2O2 gave the desired epoxide 1.58 (Scheme 2.37). A 
procedure adapted from Mehta et al. and Jung et al. allowed for the installation of the primary 
alcohol to afford 1.59 (Scheme 2.37).163, 168 The lower ketone was then enantioselectivly 
reduced using a modified procedure from Jung et al. utilising DIBAL-H which afforded diol 
1.60.163 The primary alcohol is then protected as the t-butyl dimethyl silyl ether 2.27. The Diels-
Alder adduct of 2.27 is subsequently dismantled giving the quinilone derivative 1.61 which is 







Scheme 2.37. The route to enantiometrically pure 1.62 which has been carried out in this study. (a) Pd(PPh3)4, 
allyltributyl stannane, THF, 10 min, 110 ºC, 150 W MW radiation, 68%; (b) 1 N H2SO4, acetone, THF, 30 min, 
rt., 96%; (c) 10% (w/v) Na2CO3, 30% (v/v non-stab.) H2O2, acetone, 30 min, 0 ºC, 83%; (d) 37% (w/v) aqueous 
formaldehyde, DBU, THF, 30 min, 0 ºC, 79%; (e) DIBAL-H, THF, 30 min, -78 ºC, 43%; (f) TBSCl, imidazole, 
DMF, 4 h, 0 ºC, 83%; (g) Ph2O, 4 h, 230 ºC, 73%; (h) O3, dimethylsulfide, MeOH, -78 ºC, 30 min then 
Ph3P=C(Me)CO2t-Bu, DCM, 2 h, -40 ºC, 25%. 
 
The compound 1.63, the corresponding (-)-enantiomer of 1.62 has been prepared to determine 
how stereochemistry affects the anti-virulence activity of the compounds. Production was 
mediated through the modification of the key Diels-Alder reaction to produce the (-)-adduct 
1.67. This was carried out using (S)-(-)-o-tolyl-CBS oxazaborolidene catalyst 1.68. This 
provided the adduct 1.67 with good enantioselectivity and reasonable yield (Scheme 2.38). 
With the successful production of adduct 1.67, subsequent transformations yielded the desired 




Scheme 2.38. The chiral Diels-Alder reaction providing the key intermediate, (-)-adduct 1.67 
 
The attempted production of a range of ether analogues was also outlined. Numerous 
approaches to modify a Williamson ether synthesis failed to afford the desired asymmetric 
ether. It was decided to discontinue with this branch of analogues. 
 
The synthesis of numerous silyl ether analogues was attempted. Perestelo et al. suggests that 
the production of a range of silyl ether analogues may be an interesting series of analogues to 
synthesise.200 Unfortunately, the production of several silyl ethers proved problematic and it 









A focussed range of ketal analogues have been synthesised. Dimethyl (2.72), diethyl (2.73) and 
cyclohexyl (2.74) ketals have been successfully synthesised. These were produced from the 
reaction of the diol 1.74 with the desired ketone in the presence of catalytic p-toluenesulfonic 
acid. This procedure afforded the dimethyl and diethyl ketals however failed in the production 
of the more sterically encumbered cyclohexyl ketal. Thus an efficient trans-
acetalation/ketalation route for the production of the cyclohexyl ketal has been established. 
This utilises the 1,1-dimethoxy variant of the ketone as a more reactive substrate for reaction. 
This procedure could be utilised in future applications for the production of further sterically 
encumbered ketals. Furthermore, NMR analysis of the diethyl 2.73 and cyclohexyl 2.74 ketals 
indicated a diasteromeric mixture of compounds in a 1:1 ratio for the diethyl ketal and a 9:1 
ratio for the cyclohexyl ketal.  
 
The successfully synthesised compounds (Figure 2.32) were taken forward for biological 





Figure 2.32. The compounds successfully produced in this chapter to be taken forward for biological testing. The 


















Chapter 3. The total synthesis of a cyclpropyl 




3.1 Chapter outline 
This chapter outlines the synthesis of an isosteric analogue of ambuic acid, in which the epoxide 
moiety is replaced with a cyclopropyl group. The cyclopropyl analogue 1.75 is required to 
elucidate the mode of action of ambuic acid and its analogues. This chapter discuses the 
installation of the cyclopropyl ring and the subsequent chemical transformations to generate 
the desired product 1.75, which is based on the ambuic acid analogue 1.62, the synthesis of 

















3.2.1 AgrB, a cysteine protease 
As previously outlined in chapter 1, AgrB is a putative, membrane-bound cysteine protease 
that is responsible for the removal of the C-terminal region of AgrD, in a process which is 
coupled to the formation of the AIP thiolactone macrocycle. The macrocyclic structure is 
critical for AIP activity.103, 122-123, 152  
 
In summary, AgrD, an AIP pre-pro peptide consists of a core AIP sequence flanked N-
terminally by an amphipathic helix and C-terminally by an AgrB recognition motif consisting 
of hydrophilic residues.120, 122, 212 AgrB catalytically excises the C-terminal recognition region 
of AgrD which yields an enzyme-substrate thioacyl intermediate involving the key catalytic 
Cys77 residue of AgrB.120, 122, 212 Subsequent intramolecular nucleophilic attack of this 
intermediate by an absolutely conserved cysteine within the core AIP sequence generates the 
thiolactone macrocycle,  releases the AgrD thiolactone pro-peptide, and regenerates the active 
site of AgrB (described in greater detail in chapter 1).152  
 
The AgrD thiolactone pro-peptide is then N-terminally processed by the putative CAAX 
metalloprotesae MroQ producing the mature AIP molecule which is then secreted into the 
extracellular milieu124.  
 
3.2.2 Disorders and inhibitors of cysteine proteases 
Cysteine proteases are found extensively in nature and fulfil a wide range of biological roles. 
A number of cysteine proteases have been identified in the genomes of both veterinary and 
human parasites.213 Clan CA (papain family) and Clan CD asparaginyl endopeptidases 
(legumains) are amongst those used by parasites such as metazoan and protozoa.213 Parasites, 
such as Trypanosoma sp. and Plasmodium falciparum utilise cysteine proteases for the 
propagation of infection.214-216 P. falciparum utilises cysteine proteases for a range of functions, 
including the breakdown of haemoglobin and the invasion and rupture of erythrocytes.214 
 
Cysteine proteases are not unique to parasites and examples are found in vertebrates, including 
the human and animal hosts infected by the parasite.213, 217 Mammalian cysteine proteases 
include cathepsins, which are often found at high concentrations within intracellular organelles, 
such as lysosomes for the degradation of unwanted proteins and caspases, which play a key 
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part in apoptosis- controlled cell death.213, 217 More recently, there is a growing field of evidence 
suggesting that cysteine proteases function beyond lysosomes and have a range of pathological 
and physiological functions.217 For example, cathepsin activity is often elevated in the heart 
and arterial walls of patients with cardiovascular disease.217 Furthermore, the loss of function 
of calpain 3 is linked to the onset of limb-girdle muscular dystrophy.159 
 
Due to the importance cysteine proteases play in numerous pathological conditions, inhibitors 
have been widely studied and several have been validated as potential therapeutics.159 Both 
covalent and non-covalent inhibitors of cysteine proteases have been previously studied.162 
Covalent inhibitors of cysteine proteases either acylate or alkylate the key nucleophilic cysteine 
within the active site of the protease target.  
 
3.2.3 Acylating inhibitors 
Examples of inhibitors which acylate the key nucleophilic cysteine of cysteine proteases are 
the aza-peptides 3.1 (Figure 3.1).162, 218 Aza-peptides are peptides wherein one of the amino 
acids has its α-carbon substituted for a nitrogen.162, 219 It is thought that aza-peptides inhibit 
cysteine proteases through ‘direct acylation’ of the key nucleophilic cysteine within the active 
site of the cysteine protease.162 Initial attack at the aza-amino acid carbonyl by the active site 
thiol leads to the formation of a covalent carbazyl intermediate (Scheme 3.1).162 With a natural 
peptide substrate, a thioester is formed (Scheme 3.1).162 Inhibition of the protease by aza-
peptides occurs due to the nature of the carbazyl enzyme-substrate intermediate.162 The 
carbazyl carbonyl is less susceptible to nucleophilic attack by water, i.e. by hydrolysis, due to 
the trigonal geometry and delocalisation of the α-nitrogen lone pair into the carbonyl system.162 
This leads to a slower rate of hydrolysis relative to the ester intermediate formed with the 
natural substrate and subsequent inhibition.162  
 
 





Despite formation of the relatively stable carbazyl intermediate, aza-peptide inhibition can still 
be surmounted by hydrolysis and hence, proteolytic activity can be recovered.162  
 
 
Scheme 3.1. The mechanism of lysis of a peptide bond by a cysteine protease, (A) by forming a thioester 
intermediate  and (B) the mechanism of action of aza-peptide inhibitors of cysteine proteases; note the carbazyl 




3.2.4 Alkylating inhibitors 
 
Figure 3.2. Examples of halomethylketone inhibitors of the coronavirus 3CLpro main protease. 
  
Examples of alkylating inhibitors of cysteine proteases include halomethyl ketones and 
epoxysuccinates.162 The compounds 3.2 and 3.3 (Figure 3.2) are examples of inhibitors of the 
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coronavirus 3CLpro main protease which carry the halomethyl ketone electrophilic warhead 
which facilitates the formation of a thiolether adduct with the key catalytic cysteine within the 
active site of the target protease (Scheme 3.2).220 The resultant thiolether is resistant to 




Scheme 3.2. Mechanism of inhibition of halomethyl ketones alkylating a cysteine protease as suggested by Bacha 
et al..220 
 
Epoxysuccinates (3.4 and 3.5) (Figure 3.3) are a further class of covalent, alkylating inhibitors 
of cysteine proteases which utilise the epoxydione electrophilic warhead to irreversibly modify 
the nucleophilic cysteine within the protease active site (Scheme 3.3).159, 221 Nucleophilic attack 
at either carbon of the epoxide opens the strained 3-membered heterocycle, leading to 
alkylation mediated by the formation of a thiolether and inhibition surmountable only by de 
novo protein synthesis.162 
 
Figure 3.3. Examples of epoxysuccinate inhibitors. 
 
Epoxysucinates have previously been shown to be a useful family of cysteine protease 
inhibitors with the pro-drug E-64d (3.5) having reached phase-III clinical trials for the 




Scheme 3.3. A potential mechanism of inhibition of epoxysuccinates which alkylate the key nucleophilic cysteine 
within the active site. 
  
3.2.5 Is ambuic acid a covalent inhibitor of AgrB? 
Despite the mechanism of ambuic acid attenuation of staphylococcal agr-mediated virulence 
remaining unknown, the presence of the epoxide moiety which is shared with the known family 
of cysteine protease inhibitors such as 3.4 and 3.5 may suggest a potential mode of action. It is 
hypothesised that ambuic acid covalently modifies the catalytic Cys84 in AgrB forming a 
thiolether-bound enzyme-inhibitor covalent adduct (Scheme 3.4). This leads to inhibition of 
AgrB, surmountable only by de novo protein synthesis.  
 
 
Scheme 3.4. A proposed mechanism of inhibition of AgrB by ambuic acid. 
 
 To determine whether ambuic acid and the unique synthesised analogues function in the 
manner proposed in Scheme 3.4, a cyclopropyl isostere 1.75 of a lead analogue 1.62 was 
synthesised. The isosteric replacement of the epoxide with a cyclopropyl ring may go some 
way towards the determination of a mechanism of action for ambuic acid analogues, which is 







3.3 Synthesis of the cyclopropyl analogue 
 
3.3.1 Methods for cyclopropylation 
In order to produce the final cyclopropyl isostere 1.75, a method for the stereoselective 
installation of the cyclopropyl ring was required. Compound 2.27 (Figure 3.4), the synthesis of 
which is outlined in chapter 2 was chosen as the substrate for the cyclopropylation reaction. In 
the synthesis of the epoxide-containing equivalent 1.62, compound 2.27 is the substrate for the 
Julia-Colona epoxidation. Hence, 2.27 was chosen as the point of divergence from the general 
synthesis discussed in chapter 2 to enable the synthesis of the cyclopropyl analogue 1.75. 
 
 
Figure 3.4. Substrate for cyclopropylation 
 
Despite their strained nature, cyclopropyl rings are present in a diverse range of natural 
products such as pheromones and terpenes.222 Hence, synthetic methods to introduce 
cyclopropyl rings have been extensively explored. For example, multiple methods have been 
developed for the installation of cyclopropyl rings, including the Simmons-Smith and Corey-
Chaycovsky reactions.165-166, 223-224 
 
The original Simmons-Smith reaction utilises iodomethylzinc iodide (prepared from CH2I2 and 
elemental zinc) and an olefin for the production of a cyclopropane compound (Figure 3.5).223-
225 Modifications to the procedure which utilise diethylzinc have also been developed and 
remain widely used in synthetic applications.225  
 
 






Despite the discovery of the Simmons-Smith reaction occurring in the 1950s, the exact 
mechanism by which the reaction occurs remains undetermined and is beyond the scope of this 
thesis.225 
 
Figure 3.6. Structures of sulphur ylides dimethylsulfonium methylide 3.6 and dimethylisulfoxonium methylide 
3.7, and their respective precursors, trimethylsulfonium iodide 3.8 and trimethylsulfoxonium iodide 1.77. 
  
In the early 1960s, Corey and colleagues reported the ability of two sulphur ylides; 
dimethylsulfonium methylide 3.6 and dimethylsulfoxonium methylide 3.7 (Figure 3.6) to 
transfer methylene group to a range of unsaturated electrophilic centres, such as C=O, C=S, 
C=N and α,β-unsaturated olefins. Since these early findings, several methods have been 
reported leading to them becoming versatile reagents, suitable for a range of synthetic 
applications.226-227 The ylides 3.6 and 3.7 are prepared from trimethylsulfonium iodide (3.8) 
and trimethylsulfoxonium iodide (1.75) respectively by stirring with a base, typically sodium 
hydride (Figure 3.6).  
 
 
Scheme 3.5. Mechanism of Corey-Chaycovsky epoxidation. 
. 
 In early studies, 3.6 was first found to react with ketones and aldehydes to produce oxiranes 
(Scheme 3.5).165-166 Ylide 3.7 can also react with ketones to give the oxirane (Scheme 3.6 A). 
However in the presence of an electrophilic olefin, such as in an α,β-unsaturated system (e.g. 
an enone), 3.7 will selectively react to give the cyclopropane with no formation of the 
corresponding oxirane (Scheme 3.6 B).165-166, 228-229 However, reaction of 3.6 with an α,β-
unsaturated olefinic system does not give the cyclopropane. Computational studies of the 
reaction mechanism, carried out by Xiang et al. suggested that 3.7 favours the formation of the 
cyclopropyl ring due to the high activation energy of the rate determining, ring closure event 
required for the formation of the oxirane (Scheme 3.6).230 Furthermore, the sulfoxonium may 
delocalise the negative charge of the ylide 3.7, softening it as a nucleophile favouring HOMO-
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LUMO interaction leading to 1,4-conjugate addition at the electrophilic olefin compared to 
direct 1,2 addition.  
 
Scheme 3.6. Mechanism of Corey-Chaycovsky  (A) epoxidation with dimethylsulphoxonium methylide 3.7 and  
the Corey-Chaycovsky (B) cyclopropylation. 
   
3.3.2 Production of the cyclopropyl ring 
Of the above two cyclopropylation reactions, it was decided to install the cyclopropyl moiety 
using a modified Corey-Chaycovsky reaction with dimethylsulfoxonium methylide 3.7. The 
Corey-Chaycovsky procedure allows for the selective cyclopropylation of α,β-unsaturated 
systems, the target in this synthetic application, whereas the Simmons-Smith reaction may react 
with the other alkenes within the reaction substrate 1.76. Furthermore, Corey-Chaycovsky 
cyclopropylation proceeds as a 1,4-addition, akin to the Julia-Colona (Weitz-Scheffer) 
epoxidation described in chapter 2 and it is hoped that the level of conservation of mechanism 
between the two reactions may lead to the cyclopropane product sharing the same endo 
stereochemistry as the epoxide (Scheme 3.7). Additionally, it was hoped that the chiral Diels-
Alder adduct would confer stereoselectivity on the reaction through steric occlusion, 
preventing formation of the non-desired exo- enantiomer.  
 
Scheme 3.7. Installation of the cyclopropyl ring 
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Thus, a procedure by Lee et al. which was used for their installation of a cyclopropyl ring on a 
cyclohexenone was modified for this application (Scheme 3.8).231 Initially 1 eq. of 
trimethylsulfoxonium iodide (1.77) was stirred with 1.1 eq. of NaH in DMSO at -78 ºC to 
generate the active sulphur ylide species 3.7. Then, the substrate 1.76 in DMSO was titrated 
into the methylide suspension (Table 3.1, condition 1). The reaction was monitored by HRMS 
and the correct mass of the desired product 1.78 was observed. However, upon purification, 
the overall yield was < 10 % and upon analysis by 1H-NMR, the isomer 3.9 was found to be 
the major product in a ratio of 85.5:14.5 (ratio calculated by 1H NMR) with the minor product 
being the desired cyclopropane 1.78 (Scheme 3.9, Figure 3.7 A).  
 
 
Scheme 3.8. The Corey-Chaycovsky cyclopropylation reaction as used by Lee et al..231 
 
It was postulated that a small excess of base may be the cause for this isomerisation, so in an 
attempt to alleviate this, 2 eqv. of trimethylsulfoxonium iodide were employed to ensure that 
all NaH within the reaction mixture had reacted (Table 3.1, condition 2). Unfortunately, this 
condition still afforded the isomer in extremely poor yield (Scheme 3.9, Table 3.1).  
 














1 Me3SOI * NaH - DMSO 20-50 <10 
2 Me3SOI NaH - DMSO 20-50 <10 
3 Me3SOI - - THF 20 - 
4 Me3SOI t-BuOK TBAI (cat.) DCM 20 4 
5 Me3SOI n-BuLi - DCM -76-20 - 
6 Me3SOI n-BuLi - DMSO/THF -76-20 16 




Scheme 3.9. The reaction of conditions 1 and 2 from Table 3.1, gave the undesired isomer 3.9 (major product) 
and desired cyclopropane 1.78. 
  
In order to alleviate the problem, it was decided to prepare the dimethylsulfoxonium methylide 
species ex situ (Table 3.1, condition 3). Methylide species 3.7 was prepared by stirring a 
suspension of trimethylsulfoxonium iodide with NaH in THF, before addition of this 
suspension to a solution of substrate 1.76. However, upon addition to 1.76, no change in 
reaction mixture was observed by TLC even with stirring overnight. The reactive methylide 
species may have degraded prior to the addition of 1.76. With the failure of this condition, it 
was decided to continue to prepare the methylide in situ.  
 
In conditions 1-3 (Table 3.1) it was observed that the dimethylsulfoxonium methylide was in 
suspension in the reaction solvent. In an effort to improve the solubility and therefore 
availability of the methylide 3.7 for cyclopropanation, an alternate method was devised. 
Initially, the decision was made to change the reaction solvent to DCM in an attempt to better 
solvate the dimethylsulfoxonium and improve the reaction outcome (Table 3.1, condition 5). 
Unfortunately this condition failed to cause any change in the reaction mixture when monitored 
by TLC and HRMS. 
 
With the failure of the above condition, a procedure developed by Ng et al., which was 
established to eliminate the hazards associated with NaH in a scale-up reaction, was modified 
for use here, wherein NaH is replaced with t-BuOK.232-233 Moreover, the changes made 
included using the solvent DCM in place of DMSO and the use of tetra-n-butylammonium 
iodide (TBAI) as a phase transition catalyst to aid solubility (Table 3.1, condition 4). TBAI had 
been shown to be beneficial in cyclopropanation reactions previously, albeit in aqueous 
systems.233 Unfortunately, the reaction failed to proceed to completion (monitored by TLC) 
and upon analysis, the product again proved to be the isomer 3.9 with a yield of 4%. Again, the 
reaction mixture was observed to be a suspension, even with the addition of TBAI, a possible 
explanation for the undesirable outcome observed in this study. Next, n-BuLi was used as the 
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base to produce the active methylide species (Table 3.1, condition 5). Unfortunately these 
conditions failed to react. 
 
A further method for cyclopropylation utilises a mixture of DMSO/THF as the solvent 
system.233 The procedure was subsequently modified utilising n-BuLi as the base to produce 
the methylide active species from trimethylsulfoxonium iodide (Table 3.1, condition 6). The 
substrate 3.9 was added and the reaction proceeded to completion. It was pleasing to see that 
upon purification, 1H NMR found that the desired cyclopropane 1.78 had been selectively 
formed with no formation of the undesired isomer 3.9. However, the overall yield was still poor 
at 16 %. As there are numerous subsequent steps to convert the cyclopropane 1.78 to the final 
compound, an improvement of the reaction yield was required. 
 
 
Scheme 3.10. The Corey-Chaycovsky cyclopropylation conditions optimised by Thompson et al., utilised in their 
synthesis of sesquiterpenes.  
 
Thompson et al., in their synthesis of marasmane and lactarane sesquiterpenes developed a 
method for cyclopropanation using THF as the reaction solvent (Scheme 3.10). 234 
Cyclopropane 3.10 was prepared through treatment of cyclohexenone 3.11 with 3.7 that had 
been prepared through the reaction of 1.77 with n-BuLi (Scheme 3.10). With the observed 
benefit of THF in Condition 6 (Table 3.1), it was decided to use THF as the solvent in this 
application (Table 3.1, condition 7). Gratifyingly, a dramatic improvement in the reaction 
outcome was observed, with a yield of 45 % of the desired cyclopropane and no evidence of 
isomerisation or formation of the oxirane found by 1H NMR analysis (Figure 3.7, B). 
Thompson et al. also experienced a notable improvement in yield using THF.234 They 
suggested that the sulfoxonium enolate intermediate (, B) formed in the reversible 1,4-addition 
may be stabilised in DMSO. If this is the case, they proposed that the stabilised sulfoxonium 
enolate may cyclise less readily relative to the reverse reaction yielding starting material 1.76 




Figure 3.7. 1H NMR of region of interest of spectra of the undesired isomer 3.9 (A) and the desired product 1.78 
(B). Additional peak in spectra A at ppm 1.68 (dd, J= 6.5, 1.7 Hz, 3H)- not shown here indicative of terminal Me 
in isomer 3.9 
 
In addition to selective formation of the desired cyclopropane 1.78, Nuclear Overhauser Effect 
Spectroscopy (NOESY) confirmed the relative stereochemistry of the cyclopropyl ring (Figure 
3.8). It was observed that the cyclopropyl ring was installed endo with respect to the Diels-
Alder adduct bridgehead. NOE interaction was found between the protons of the CH2 within 
the cyclopropyl ring and the two α-protons to the right of the ketones (Figure 3.8). This shows 
that these protons are sufficiently close to each other to allow for observation of a NOE cross-
peak, indicating that they are on the same face of the molecule. Furthermore, there is no 
observable correlation between the α-protons either side of the lower ketone, suggesting that 
they are too far from each other, indicative that the two protons are on opposing faces of the 
molecule (Figure 3.8). These data suggest that the cyclopropyl ring has installed with the 
desired stereochemistry. 
 
Since a suitable condition for the installation of a cyclopropyl ring had been established a scale-
up the reaction was evaluated. Initial tests of the cyclopropylation procedure, as outlined above, 







mmol scale. Unfortunately, when a scale-up was attempted, a reduction in yield was observed. 
As such, it was decided to carry out the cyclopropylation in batches to produce sufficient 







Figure 3.8. (A) NOESY NMR spectra showing ROI for stereochemical assignment of cyclopropyl ring and (B) 
schematic of correlations. (A) Correlations between (i) cyclopropyl CH2 to allyl CH2; (ii) cyclopropyl CH2 and 
two α-protons to right of ketones; (iii) α-proton adjacent to cyclopropyl ring and cyclopropyl CH2; (iv) and the 





3.3.3 Synthetic strategy for producing the final cyclopropyl analogue 
 
Scheme 3.11. Proposed route to the final cyclopropyl analogue of a modified ambuic acid. 
  
With the successful establishment of a stereoselective cyclopropylation method, a route to the 
final cyclopropyl analogue 3.15 was required. Scheme 3.11 outlines the proposed synthetic 
route, which broadly follows the same synthetic strategy used for the total synthesis of the 
corresponding epoxide-containing analogues, outlined in Chapter 2. Thus, the cyclopropane 
1.78 will be treated in an α-hydroxymethylation procedure to install the primary alcohol to 
yield 1.79. The lower ketone will then be stereoselectivly reduced to the secondary alcohol to 
afford the diol 3.12. The primary alcohol of 3.12 will then be protected at the t-
butyldimethylsilyl ether 3.13 for subsequent transformations. Silyl ether 3.13 will then be 
treated in a retro Diels-Alder procedure to dismantle the adduct giving 3.14. The intermediate 
3.14 will be treated in an ozonolysis procedure to give the aldehyde, which will be taken into 








3.3.4 Optimisation of the synthesis of target 3.1 
 
 
Scheme 3.12. Transformation of cyclopropane 1.78 to the desired alcohol 1.79. 
  
After the cyclopropylation and production of the desired cyclopropane 1.78, the subsequent 
step was the installation of the primary alcohol α to the lower ketone (Scheme 3.12). Initially, 
a procedure previously employed by Metha et al., Jung et al. and previously in this study was 
evaluated.163-164 Initial attempts made using the same conditions (Table 3.2, condition 1) proved 
to yield alcohol 1.79 in a poor yield (4%).  
 
Modifications to this procedure included doubling the number of equivalents of aqueous 
formaldehyde and increasing the reaction time (up to 24-48 h) improved the reaction outcome 
and generated the desired alcohol 1.79 (Table 3.2, condition 2). Unfortunately, the yield of the 
product 1.79 proved variable, with yields of 12-62 % observed (Table 3.2, condition 2). 
However this was an improvement over the previous condition, sufficient for use here. 
 







With the successful production of the desired alcohol 1.79, the next step was to stereoselectivly 
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Scheme 3.13. Reduction of the lower ketone to the secondary alcohol. 
 
Initial attempts at the stereoselective reduction used the same conditions as had previously been 
successfully employed for the production of epoxide containing analogues in Chapter 2. Hence, 
0.5 eq. of DIBAL-H were added to 1.79 and stirred (Table 3.3, condition 1). No change in the 
reaction mixture was observed, therefore a further ~0.5 eq. DIBAL-H was added. 
Unfortunately this also failed to improve the reaction outcome with no formation of product 
(established by using HRMS).  
 
 
Scheme 3.14. The reduction wherein Mehta et al.suggest that the primary alcohol is required for the 
stereoselective reduction of the ketone of 3.16 giving diol 3.17.180 
 
Mehta et al. in their synthesis of yanuthones, a family of epoxy cycyclohexenones suggest that 
the carbonyl and primary alcohol are important for the stereoselective reduction of the ketone 
3.16 giving diol 3.17 through the coordination of the aluminium within DIBAL-H (Scheme 
3.14).180 In this study, isosteric replacement of the epoxide with a cyclopropyl ring has a clear 
effect on the reaction outcome, suggesting that the epoxide may play a role in the 








Table 3.3. Table of conditions for the reduction of lower ketone to the corresponding secondary alcohol 
 
In an attempt to improve the reaction outcome and due to the lack of any change in the reaction 
mixture observed with DIBAL-H, it was decided to use the stronger reducing agent LiAlH4 to 
stereoselectively reduce the ketone.  
 
Thus, 0.5 eq. LiAlH4 was added to a stirring solution of alcohol 1.79. The reaction proceeded 
slowly and required stirring for 48 h, which is unexpected for this type of reaction. However 
upon completion, it was found that a mix of products had been generated (Table 3.3, condition 
2). Upon purification, it was found that the products were a diastereoisomeric mix of both the 
secondary alcohols. Furthermore, some starting material was also observed. It was clear that 
LiAlH4 was unsuitable for this application. 
 
Other methods of reduction such as a Leusch are available, however, they are not suitable for 
this application as selectivity for the lower ketone cannot be guaranteed.  
 
 
Figure 3.9. The dione analogue 3.18 produced by Dr Leonardo Baldessarre, found to be as active against agr 
activity as 1.62. 
 
At this time, it had been found that the dione 3.18 produced by Dr Leonardo Baldassarre, 
formerly of this research group (Figure 3.9) showed anti-virulence activity comparable to that 
of the alcohol 1.62 and as such, it was decided to produce the dione version of the cyclopropyl 
analogue 1.75, negating the need for this reduction. 
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addition of 0.5) 
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Scheme 3.15. Installation of the t-butyldimethylsilyl ether 
  
Subsequently, dione 1.79, was taken into the silyl ether protection step. Initial attempts at 
protecting the primary alcohol as the silyl ether 1.80 (Scheme 3.15) proved surprisingly 
problematic for a reaction of this type with yields of 23-38 % observed. Initially, 5 equivalents 
of TBDMSCl and imidazole were used to install the silyl ether (Table 3.4, condition 1). 
Unfortunately the reaction yield proved surprisingly poor (23-38 %).  
 
An improvement of the reaction outcome proved to be facile. Simply increasing the number of 
equivalents of TBDMSCl and imidazole to 10 and increasing the reaction time allowed for a 
dramatic improvement in the reaction outcome with an observed yield of 82% (Table 3.4, 
condition 2).  
  
Table 3.4. Table of conditions for installation of TBDMS silyl ether 
 
 
With the successful production of silyl ether 1.80, the Diels-Alder adduct was to be dismantled 
in a retro Diels-Alder procedure (Scheme 3.16). 
 
Condition Reagents Equivalents 
Yield 
(%) 
1 TBDMSCl, imidazole 5 23-38 




Scheme 3.16. Retro Diels-Alder reaction to dismantle the adduct. 
 
Previously, the retro Diels-Alder reaction had given variable yields (~30-60%) in the 
production of epoxide-containing analogues based on 1.62. The reaction conditions, as 
previously discussed in chapter 2 are harsh, requiring the heating of substrate in Ph2O for 2-3 
h at 230 ºC. Poor yields were often characterised by the appearance of multiple products, as 
observed by TLC. This could be indicative of pyrolysis of the starting material and indeed the 
desired product when formed. Pyrolysis could be due to the harsh reaction conditions. 
Furthermore, oxidation of compounds may have occurred despite best efforts to maintain an 
inert atmosphere. Thus, it was decided to employ microwave-assisted chemistry in an attempt 
to improve the variable yields observed. Microwave chemistry has previously been used to 
great success in a wide array of synthetic applications.235 
 
Thus, the starting material 1.80 was dissolved in Ph2O and the microwave reaction vessel was 
flushed with argon before heating to 200 ºC for 15 min with 250 W microwave radiation (Table 
3.5, condition 1). It was found that the microwave struggled to heat the reaction mixture to a 
temperature in excess of 140-150 ºC. Nevertheless, TLC analysis indicated that the reaction 
had proceeded relatively cleanly. There was some evidence of compound degradation with the 
formation a by-product that did not migrate on TLC analysis, typical of what had been 
experienced previously using conventional heating methods. Upon purification, it was found 
that the desired product 1.81 had indeed been formed however the yield of the reaction proved 






 Table 3.5. Table of conditions for retro Diels-Alder reaction. 
 
 
A review of literature found that methodologies for retro Diels-Alder reactions with unstable 
reaction substrates utilised MeCN as the reaction solvent, albeit with conventional oven 
heating.236 It was decided to utilise MeCN as the solvent for this application.  
 
Thus, the substrate 1.80 was dissolved in MeCN and heated to 140 ºC with 200 W microwave 
radiation (Table 3.5, condition 2). TLC and HRMS analyses found that after 30 minutes of 
heating, the starting material 1.80 had been consumed and that the desired product 1.81 had 
formed. A small amount of degradation product appeared to be present on the baseline of the 
TLC. Relative to Table 3.5, condition 1, the level of degradation product appeared minimal. 
In-order to remove the degradation by-product, the reaction mixture was filtered through a 
silica plug before concentration in vacuo. Pleasingly, this gave the desired product 1.81 in 
excellent yield (80-91%). Potentially, the improved outcome may be due to the increased 
polarity of MeCN, aiding heating by the microwave. It was also pleasing to note that the 
reaction had proceeded so cleanly (determined by NMR) that the crude filtrate could be used 
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Scheme 3.17. Production of the final compound 1.75 through a 2-step procedure, ozonolysis followed by Wittig 
olefination. The aldehyde intermediate 3.19 and ylide 2.44 are shown here. 
  
After the optimisation of the retro Diels-Alder reaction, compound 1.81 was treated in an 
ozonolysis procedure with a reductive workup to generate the aldehyde 3.19 before a final 
stabilised Wittig reaction with ylide 2.44 to install the t-butyl ester moiety to generate the final 
compound 1.75 in 40 % yield (Scheme 3.17, Figure 3.10). In summary, the desired compound 



























This chapter has described the production of a novel cyclopropyl analogue 1.75 of the epoxide 
containing compound 1.62. An efficient and facile synthetic route to 1.75 has been established 
(Scheme 3.18).  
 
The production of 1.75 necessitated the development of a Corey-Chaycovsky cyclopropylation 
reaction to facilitate the stereoselective installation of the cyclopropyl ring, providing 
cyclopropane 1.78. Thorough optimisation of this key, synthetic transformation has been 
carried out utilising numerous procedures adapted from the literature. Pleasingly, the reaction 
of dione 1.76 in THF with the methylide species 3.7, produced by treatment of 
trimethylsulfoxonium iodide 1.77 with n-BuLi, gave the desired compound in a good yield of 
45 % (Scheme 3.18). Furthermore, NOESY spectroscopy confirmed that the cyclopropyl ring 
of 1.78 had installed endo with respect to the Diels-Alder adduct bridgehead. 
 
The optimisation of the subsequent synthetic steps to afford the final cyclopropane 1.75 has 
also been carried out. Modification of the hydroxymethylation and subsequent TBDMS 
protection steps (previously used in Chapter 2) proved facile, with an increase in the number 
of reagent equivalents and reaction time providing the desired products in satisfactory yields 
(Scheme 3.18). 
 
In addition, a highly efficient and reliable microwave-catalysed retro Diels-Alder reaction has 
been developed. Previous approaches, requiring harsh conditions, gave the desired product 1.81 
with poor yield. With microwave assisted heating and relatively mild conditions, 1.81 was 
provided in an excellent yield, observed to be 80-91 % (Scheme 3.18). The microwave-
catalysed reaction is a dramatic improvement upon previous conditions which have been 
utilised within this study and is makes the production of 1.75 more facile. 
 
The cyclopropyl analogue 1.75 will be taken forwards for biological assessment as an inhibitor 
of staphylococcal agr activity. Determining the biological activity of 1.75 will be of great 
interest as it may prove insightful in the determination of the mode of action of ambuic acid 
and the analogues synthesised in this thesis. If 1.75 is inactive, it shows that the epoxide is the 
key functional group required for inhibition. Conversely, if 1.75 is active against the agr 
system, it would suggest that the epoxide is not necessary for inhibition. In this instance, 
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replacement of the epoxide (which can irreversibly alkylate a range of nucleopiles) would make 
the compound an improved candidate compound in the production of a novel therapeutic agent. 
 
 
Scheme 3.18. The optimised route to the cyclopropyl analogue 1.75. (a) Pd(PPh3)4, allyltributyl stannane, THF, 
100 ºC, 150 W µW radiation, 68%; (b) 1 N H2SO4, acetone, THF, 30 min, rt., 96%; (c) Me3SOI, n-BuLi, THF, -
78 ºC 45%; (d) 37% (w/v) aqueous formaldehyde, DBU, THF, 30 min, 0 ºC, 62%; (e) TBSCl, imidazole, DMF, 
4 h, 0 ºC. 82%; (f) MeCN, 140 ºC, 200 W µM radiation, 91%; (g) O3, dimethylsulfide, MeOH, -78 ºC, 30 min 
















4.1 Chapter outline 
 
The characterisation of the anti-virulence activity of analogues of ambuic acid, which have 
been synthesised is outlined in this chapter. In addition, compounds synthesised by Dr 
Leonardo Baldassarre will also be tested herein. Furthermore, the agr-inhibitory activity of 
ambuic acid will also be fully characterised. 
 
The agr-inhibitory activity of the compounds will be assessed using a bioluminescent lux-based 
reporter strain of agr activity. Analogues which are found to be potent inhibitors of agr in the 
bioluminescence assay will be assessed for their ability to inhibit the production of α-





















The highly functionalised epoxycyclohexenone ambuic acid 1.1 has been previously assessed 
for anti-virulence properties in several studies.153, 155 Through the use of anti-virulence 
screening of fungal extracts, Nakayama et al. identify ambuic acid 1.1 as an inhibitor of quorum 
sensing-mediated gelatinase production in Enterococcus faecalis, with an inhibitory 
concentration of approximately 10 µM.153 Furthermore, no effect on bacterial growth was 
observed, even with concentrations up to 1 mM.153  
 
In order to investigate the mechanism by which ambuic acid inhibits gelatinase biosynthesis, 
Nakayama et al. investigated the effect of ambuic acid has on gelatinase biosynthesis-activating 
protein (GBAP), an AIP analogue in E. faecalis (described in more detail in the chapter 1). To 
do this, they cultured the GBAP-negative strain of E. faecalis OU510 in media containing 
GBAP (to induce gelatinase expression) in the presence and absence of ambuic acid 1.1.153 
Gelatinase expression is mediated by the fsr quorum sensing system (outlined in greater detail 
in chapter 1) and gelatinase activity can be used as a reporter of fsr activity. Nakayama et al. 
found that treatment of OU510 cells with ambuic acid had no effect on the observed level of 
gelatinase activity, thus it was suggested that ambuic acid has no effect on the ability of E. 
faecalis to sense the GBAP signal quorome molecule.153 This is indicative of ambuic acid 
inhibition of GBAP production.153 
 
In addition to investigating inhibition of GBAP signalling in E. faecalis, Nakayama et al. 
probed the effect of ambuic acid 1.1 on quorum sensing in other Gram-positive bacteria, 
namely S. aureus and Listeria innocua.153 They found that ambuic acid inhibits agr quorum 
sensing in S. aureus and the biosynthesis of cyclic peptide quoromes in L. innocua.153 
 
Todd et al. further investigated the effect of ambuic acid 1.1 on agr activity in S. aureus.155 
They found that ambuic acid functioned as an inhibitor of AIP-I biosynthesis in a strain where 
AIP-I biosynthesis is de-coupled from quorum sensing.155 Inhibition of AIP-I biosynthesis by 
ambuic acid was observed in the MRSA strain USA300 (IC50= 2.5 ± 0.1 µM) as well as the 
constitutively producing AIP-I strain, thus indicating the inhibition of AIP-I biosynthesis.155 
To further confirm this, the authors investigated inhibition of AIP-I production in the 
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constitutively producing strain with the known inhibitor of AgrC, AIP-II.155 Todd et al. found 
that AIP-II was unable to inhibit production of AIP-I in this strain.155 
 
Todd et al. further showed the promise of ambuic acid as an inhibitor by assessing its in vivo 
inhibitory activity in a mouse murine dermal infection model of MRSA.155 With a single dose 
of ambuic acid (either 5 µg or 25 µg), delivered in conjunction with MRSA challenge, a 
reduction in skin ulcer formation was observed, in a dose-dependent manner.155 Furthermore, 
when the mice were challenged with an agr-driven lux containing strain, the authors observed 
a reduction in virulence in animals treated with ambuic acid.155 
 
These data demonstrated that ambuic acid 1.1 is an anti-virulence compound of some utility. 
Thus, the anti-virulence activity of ambuic acid and the activity of numerous unique synthetic 
analogues will be discussed herein. 
 
4.3 The characterisation of the anti-virulence properties of ambuic 
acid 
 
The initial testing of ambuic acid was carried out using the methicillin-sensitive S. aureus 
SH1000 (EJM82) native agr activity assay, as outlined in chapter 5.1. The SH1000 S. aureus 
cells with an intact agr locus are modified at the attB2 ectopic locus with a re-engineered lux 
cassette from Photorhabdus luminescens, which is under the direct control of the agrP3 
promoter.237-238 This provides a real-time, luminescent reporter of transcriptional activity from 
the native agrP3 promoter (Figure 4.1).  
 
The lux cassette is under the direct transcriptional control of the agrP3 promoter and thus, an 
increase in luminescence is indicative of increased agr activity. Conversely, a decrease in the 
observed luminescent signal, relative to the solvent only control is indicative of inhibition of 
agr activity. The EJM82 strain contains an intact agr (group-I) system and the only source of 





Figure 4.1. A schematic of the EJM82 reporter strain used for assessment of anti-agr activity of the test 
compounds. 
 
Using the native AIP production assay, it was found that ambuic acid 1.1 was a potent inhibitor 
of agr activity (Figure 4.2) as a result of inhibition of AIP production. The IC50 value was 
calculated to be 0.95 ± 0.13 µM with complete shutdown of agr activity observed at 
concentrations exceeding 10 µM (Figure 4.2). The IC50 observed experimentally in this study 
corroborates with those reported by Todd et al. (2.5 ± 0.1 µM).155 
 
Figure 4.2. Ambuic acid 1.1. and the IC50 curve generated from the EJM82 native production assay assay (IC50 
0.95 ± 0.13 µM, n= 4). Integrated RLU was calculated by dividing the luminescence value by the corresponding 
OD600 value and plotting against time for the duration of the assay, the area under the curve was measured at t > 
210 mins, giving integrated RLU. 
 




















It was important to establish whether the effect caused by ambuic acid 1.1 (Figure 4.2) in the 
native AIP production assay was a real effect on agr activity, or non-specific inhibition of lux 
by ambuic acid. In order to achieve this, a Δagr strain of S. aureus RN4220 with a plasmid 
based pxyl/ tet inducible lux cassette, was utilised. Within these cells, the lux bioluminescent 
signal is de-coupled from regulation by agr activity (as in the EJM82 cells) and is instead, 
under the direct control of a tetracycline inducible promoter, wherein treatment with 
tetracycline gives a bioluminescent signal.  
 
Thus, the cells were treated with a range of concentrations of anhydrous tetracycline (1-100 
ng/ mL) and ± 20 µM ambuic acid. Increasing the concentration of anhydrous tetracycline was 
found to increase the bioluminescent signal. Importantly, upon analysis of bioluminescent 
signal, when comparing treatment with 20 µM ambuic acid to the DMSO only control, no 
significant difference is observed (Figure 4.3). This suggests that ambuic acid has minimal 
effect on the lux bio reporter, implying that the effect observed in the native AIP production 
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In addition to the observed decrease in the bio-reporter signal in the native AIP production 
assay, it was important to determine whether ambuic acid has an effect on the level of toxin 
production, with the focus here on α-haemolysin. As described in chapter 1, activation of agr 
leads to the upregulation of the production of numerous exotoxins, such as α-haemolysin. 
Investigation of the effect of ambuic acid 1.1 on α-haemolysin production thus provides a 
further, viable readout for the effect of ambuic acid on agr activity.  
 
In order to investigate the effect of ambuic acid on the production of α-haemolysin, the CA-
MRSA strain USA300_LAC was grown with shaking in the presence of increasing 
concentrations of ambuic acid, from 1-40 µM. These concentrations of ambuic acid were 
selected as full shutdown of agr activity was observed in the native AIP-I production assay 
with concentrations >10 µM (Figure 4.2). 1 µM was also chosen as it is near the experimentally 
observed IC50 (Figure 4.2).  
 
After 8 h of bacterial growth, the growth media were collected and assessed for α-haemolysin 
content by Western blotting. It was found that increasing concentrations of ambuic acid caused 
a decrease in the level of α-haemolysin in culture supernatant relative to the solvent (DMSO) 
control (Figure 4.4).  
 
     
Figure 4.4. Western blot showing inhibition of α-haemolysin by the S. aureus CA-MRSA strain USA300_LAC 
(1) 0.5 % (v/v) DMSO, (2) ambuic acid 40 µM, (3) ambuic acid 20 µM, (4) ambuic acid 10 µM, (5) ambuic acid 
1 µM, (6) AIP-95 1 µM (positive control). 
 
With the finding that ambuic acid 1.1 has promising inhibitory activity towards the agr system, 
ambuic acid 1.1 was assessed for anti-bacterial properties. As described in chapter 1, the 
disruption of bacterial growth is problematic in the development of anti-virulence compounds, 
as anti-growth activity would impart a selective pressure for the development of resistance to 
the compound. It was found that ambuic acid 1.1 has minimal effect on S. aureus growth 
(Figure 4.5) 




Figure 4.5. Growth curve of S. aureus USA300_LAC in the presence of increasing concentrations of ambuic acid. 
 
It was also important to determine whether ambuic acid 1.1 was having an effect on the sensing 
of the extracellular AIP-I signal molecule by the transmembrane cognate receptor AgrC1. 
Investigation as to whether ambuic acid has an effect on the AgrC1 receptor will aid in the 
identification of the molecular target of ambuic acid. 
 
To investigate whether ambuic acid 1.1 has an effect on the AgrC1 receptor, the S. aureus 
ROJ143 strain was utilised. This strain is a Δagr background containing agrP3 lux and 
agrP2agrC1agrA and has previously been reported by Jensen et al..121 This bacterial construct 
is incapable of synthesising AIP-I as it lacks the required cellular machinery (AgrB and AgrD) 
for AIP-I synthesis. ROJ143 is, however capable of sensing AIP-I as it contains AgrC1 and 
AgrA1. These cells are capable of producing a lux bioluminescent signal in response to 
exogenous AIP as they contain the luxABCDE cassette under the direct transcriptional control 
of the agrP3 promoter. Providing ROJ143 with exogenous AIP-I within the growth medium 
elicits a biomluminescent response. This strain is used for specifically investigating inhibitors 
of AgrC and AgrA, the proteins involved in the sensing of AIP-I. Thus, ROJ143 cells were 
treated with increasing concentrations of AIP-I (agonist) to generate an EC50 curve (Figure 
4.6). Additionally, the cells were treated with 1 µM and 10 µM ambuic acid. 10 µM ambuic 
acid was chosen as the highest concentration in this assay, as in the native AIP production assay 





















































AIP-1 + 1 M Ambuic acid
AIP-1 + 10 M Ambuic acid
 
Figure 4.6. EC50 curves of AIP generated from the ROJ143 assay in the presence of ambuic acid. EC50 AIP-I 
alone= 16.52 ± 31.06 nM. EC50 AIP-I and 1 µM ambuic acid= 15.83 ± 24.93 nM. AIP-I and 10 µM ambuic acid 
EC50= 15.99 ± 29.45 nM. (n= 3, bars denote SD). 
 
The data generated from the ROJ143 assay found that ambuic acid has minimal effect on the 
sensing of AIP-I by cognate AgrC1 (Figure 4.6). No evidence was observed of competitive 
inhibition, potentially of AgrC1 with comparable EC50 values with and without ambuic acid. 
This data suggests that ambuic acid targets the biosynthesis of the AIP molecule, which 
corroborates with data reported by both Nakayama et al. and Todd et al..153, 155 
 
These data showed that ambuic acid is a promising, potent inhibitor of virulence in S. aureus 
whilst exhibiting minimal effect on bacterial growth. This makes it a promising compound for 
study.  
 
Figure 4.7. Regions of ambuic acid 1.1 to be modified. Grey, compare the free acid against the t-butyl ester. Blue, 
production of an inert isostere of the epoxide. Green, modification of the ketone within the epoxycyclohexenone 
ring. Orange, removal of the right-hand heptenyl chain. Yellow, modification at the primary and secondary 
alcohols. 
 
Having established that ambuic acid 1.1 is a potent inhibitor of agr activity via inhibition of 
AIP production, chemical modification of the compound was undertaken to produce unique 
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analogues. The main areas of modification within this study are: (a) the carboxylic acid moiety, 
(b) the ketone within the epoxycyclohexenone ring, (c) the epoxide, (d) the right hand (E)-
heptene chain and (e) modification of the two alcohols (Figure 4.7). Analogues investigating 
how modification of the above position have been synthesised as part of this study (outlined in 
chapters 2 and 3) as well as those synthesised by Dr Leonardo Baldassarre. 
 
4.4 Evaluation of truncated ambuic acid analogues 
Racemate 1.52 (LB75) (Figure 4.8), synthesised by Dr Leonardo Baldessarre was tested in the 
EJM82 native AIP production assay. It was found to be active, though lower in potency (Figure 
4.8) and thus further analogues were synthesised. Analogues of this compound were 




With the initial promise of racemate 1.52 (LB75) as a weak inhibitor of agr-mediated virulence, 
enantio-selective syntheses of the (+) and (-) variants were carried out to yield compounds 1.74 
(LB153), 1.62 (LB151) and 1.63 (JWR28) (Figure 4.9). The compounds 1.62 (LB151) and 
1.63 (LB153) were synthesised by Dr Leonardo Baldassarre. These compounds were tested 
using the EJM82 native AIP production assay and were found to be potent inhibitors of agr 








































Figure 4.8. Racemate 2.44 (LB75) and a bar chart showing results of an EJM82 native AIP production 
assay where cells treated with a single concentration of compound (n= 3, bars denote SD, values blanked 





























































Figure 4.9. Enantiomerically pure analogues of the promising inhibitor 1.74. (A) The (+) enantiomer 1.74 
(LB153), the silyl ether analogue 1.62 (LB151) and the (-) enantiomer 1.63 (JWR28). (B) IC50 curves of the above 
compounds generated from the EJM82 native AIP production assay. The IC50 values are: LB153: 133.95 ± 33.80 





Table 4.1. IC50 values of the LB75 analogues 




1.74 (LB153) 133.95 ± 33.80 - 0.57 
1.62 (LB151) 1.84 ± 0.13 - 3.98 
1.63 (JWR28) 2.27 ± 0.25 7 3.98 
 
The diol 1.74 (LB153), the (+)- enantiomer of 1.52 (LB75) was found to inhibit agr activity 
with an IC50 of 133.95 ± 33.80 µM, which is ~140 times less potent than the parent natural 
product ambuic acid 1.1 (IC50 = 0.95 ± 0.13 µM). The silyl ether compounds 1.62 and 1.63, 
the (+)- and (-)-silyl ether precursors to 1.74, respectively were also tested in the same assay. 
Unexpectedly, both of these compounds were found to be potent inhibitors of agr mediated 
virulence with IC50 values of a similar order to that of ambuic acid 1.1 (Table 4.1). 
 
Hence, although the removal of the heptenyl moiety has a dramatic effect on the inhibitory 
potency of 1.74, it is clear that there is a trend in lipophilicity and potency. For example, 
compound 1.74 with a low cLogP value of 0.57 has a lower potency than compounds 1.62 and 
1.63, both of which have cLogP values of 3.98 (Table 4.1). The lower potency of 1.74 relative 
to these compounds could potentially be explained by poor cell penetration and/or poor 
membrane localisation for interaction with the putative target AgrB, imparted by a lower level 
of lipophilicity. Whereas the higher level of lipophilicity of 1.62 and 1.63 may enhance cell 
penetrative properties, thus allowing for increased potency due to increased compound access 
to the target. 
 
In addition to the trends observed with change in lipophilicity, these data provide additional 
information about ambuic acid. Firstly, all compounds show inhibition of the agr system and 
they all lacked the heptenyl chain, which is present in ambuic acid 1.1. Particularly focussing 
on 1.62 and 1.63 which have comparable IC50 values to ambuic acid, loss of the heptenyl chain 
has minimal effect on compound activity (1.62 IC50= 1.84 ± 0.13 µM, 1.63 IC50= 2.27 ± 0.25 
µM). This suggests that the heptenyl chain is not involved in a specific inter-molecular (drug-
target) interaction, as, if this were the case, an effect on compound activity would be expected. 
The heptenyl chain may however be beneficial in enhancing the cell-penetrative properties of 
ambuic acid through a general increase in lipophilicity. The fact that compounds 1.62 and 1.63 
have similar activities to ambuic acid and when the silyl ether is dismantled in 1.74, causing a 
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loss of potency is further evidence of this. This suggests that a level of lipophilicity is required 
for a potent inhibitor of agr activity. 
 
Secondly, stereochemistry affects the overall compound efficacy, not potency. Directly 
comparing compounds 1.62 and 1.63 (Figure 4.9,Table 4.1), both compounds have a 
comparable potency with IC50 values of a similar order. The difference in activities is in overall 
efficacy. The compound 1.62 causes complete shutdown of agr activity whereas 1.63 inhibition 
leaves ~7 % residual activity (Figure 4.9, Table 4.1). 
 
Figure 4.10. The free acid variant of 2.1, 4.1 (LB211) and the IC50 curve generated from the EJM82 native AIP 
production assay (IC50 = >200 µM, n= 2). cLogP of LB211= 2.2922 
 
Dismantling the t-butyl ester to afford the free acid 4.1 (LB211, produced by Dr Leonardo 
Baldassarre), like the removal of the silyl ether led to a large effect on compound activity when 
assessed in the EJM82 native AIP production assay (Figure 4.10). Free acid 4.1 has an IC50 of 
>200 µM, several hundred fold higher than both of the more potent corresponding analogue 
1.62 and the parent natural product ambuic acid 1.1. The loss of hydrophobicity may be 
detrimental to the cell penetrative properties of the compound, having a negative effect on 
compound potency. 
 
With the initial promise of silyl ether 1.62, and the previous utilisation of silyl ethers within 
theliterature to improve the activity of withaferin A 2.60 (described previously in chapter 2), it 
was decided to synthesise a number of unique silyl ether analogues, outlined in chapter 2. 
Unfortunately, the synthesis proved problematic and it was only possible to produce one 
analogue, compound 2.62 (JWR99), the dimethyl thexyl silyl ether (Figure 4.11). The 
incremental increase in hydrophobicity compared to the t-butyl dimethyl silyl ether 1.62 
(cLogP 2.62 = 4.41, 1.62= 3.98) leads to a small increase in potency (IC50 2.62= 0.65 ± 0.07 





















µM, IC50 1.62= 1.84 ± 0.13 µM). This is further evidence that a level of hydrophobicity is 
required for the compound to be a potent inhibitor of agr.  
 
Figure 4.11. The dimethyl thexyl silyl ether 2.62 (JWR99) and the IC50 curve generated from the EJM82 native 







































A range of ketal analogues based on the racemate 2.88 were also synthesised. The synthesis of 
the ketals is outlined in chapter 2. These compounds have the potential to yield some interesting 
SAR information about ambuic acid. Replacement of the two alcohols with cyclic ethers may 
yield interesting information about how these positions are involved in drug-target interactions.  
 
Figure 4.12. The structures and IC50 curves from the native AIP-I production assay of the ketal analogues, the 
dimethyl ketal 2.72 (JWR269), the diethyl ketal 2.73 (JWR298) and the cyclohexyl ketal 2.74 (JWR297). The 
IC50 curves of the above compounds were generated using the EJM82 native AIP-I production assay. The IC50 
































































Table 4.2. The IC50 values of the ketal analogues 
Compound IC50 (µM) cLogP 
2.72 (JWR269) 13.34 ± 0.08 2.54 
 2.73 (JWR298) 8.47 ± 6.32 3.59 
2.74 (JWR297) 5.06 ± 3.52 3.49 
 
The bioactivity of the ketal analogues (Figure 4.12) was assessed in the EJM82 native AIP 
assay (kindly carried out by Dr Ewan Murray of the Chan/Williams group due to COVID-19 
restrictions). Dimethyl ketal 2.72 was found to inhibit agr activity with an IC50 of 13.34 ± 0.08 
µM, approximately 13 fold less potent than ambuic acid and the potent synthetic analogue 2.1 
(Figure 4.12, Table 4.2). In contrast to 1.62, compound 2.72 is less lipophilic, which again 
correlates to a loss of potency (Table 4.2). Additionally, the replacement of the secondary 
alcohol within 1.62 with the dimethyl ketal in 2.72 may be a cause of this loss of potency. 
Additionally, the formation of the new six-membered ketal ring, containing the two cyclic 
ethers may have a detrimental effect on compound activity. This ring may adopt two 
conformers (chair/boat) and one/both of the conformers may be detrimental to compound 
binding, having a negative effect on the activity of 2.72. 
 
Interestingly, dimethyl ketal 2.72 was found to have an effect on the growth of the bacterial 
cells. Increasing concentrations of compound caused a delay in the onset of bacterial log phase 
growth (Figure 4.13), with the most pronounced effect being observed when the cells are 
treated with 200 µM 2.72 which resulted in a clear dose-dependent effect. Comparing 200 µM 
2.72 with untreated 0.5 % (v/v) DMSO, the delay of onset of log phase growth is ~150 minutes 
(Figure 4.13). 2.73 and 2.74 both also had a minor effect on bacterial growth (data not shown), 
































Figure 4.13. Growth curves of EJM82 cells, grown in a TECAN plate reader in the presence of increasing 
concentrations of dimethyl ketal 2.72 (JWR269) in 0.5 % (v/v) DMSO 
 
The bioactivity of both the diethyl (2.73) and cyclohexyl (2.74) ketals was assessed in the 
EJM82 native AIP-I assay (again, kindly undertaken by Dr Ewan Murray due to COVID-19 
restrictions). Both compounds 2.73 and 2.74 were found to be potent inhibitors of agr activity 
with IC50 values of 8.47 ± 6.32 µM and 5.06 ± 3.52 µM respectively (Figure 4.12, Table 4.2).  
 
Comparing the dimethyl ketal (2.72) with the diethyl ketal (2.73), the increase in alkyl chain 
length has a positive effect on compound potency (Table 4.2). The incremental increase in 
lipophilicity may be the cause of this. Interestingly, the cyclohexyl ketal 2.74 was also found 
to be a potent inhibitor, this is of particular interest as 2.74 contains a unique, tricyclic structure, 
not present in any of the other synthesised analogues. Like the diethyl ketal (2.73) the 
cyclohexyl ketal (2.74) again shows improved potency when compared to the dimethyl ketal 
(2.72), this could be attributed to its relative increase in lipophilicity (Table 4.2). 
 
Further information can be gained from the diol 4.2 (LB221) (Figure 4.14) where the alcohol 
at position 1 of the epoxycyclohexenone ring is a mixture of the (S) and (R) stereoisomers. 
Reduction of the ketone to the alcohol equates to ~13 fold loss of anti-virulence potency (Figure 
4.14). This may indicate that the ketone may be a key molecular contact between drug and 
target. Additionally, as 4.2 is a diastereoisomeric mix of (S) and (R) alcohols, one of the two 





Figure 4.14. The diol 4.2 (LB221) and the IC50 curve from the EJM82 assay. IC50 = 24.67 ± 4.84 µM (n= 4). 
  
Furthermore, in a comparison between 1.62 and diol 4.2, loss of the Michael acceptor, a 
possible site of covalent, conjugate addition of the key catalytic cysteine within the postulated 
target AgrB, leads to ~ 20 fold loss of potency. Within 1.62, the cyclic enone may facilitate 
conjugate addition of the thiol of the key catalytic Cys84 within AgrB at the β-carbon of the 
Michael system. This would lead to alkylation of the Cys84 residue leading to inhibition of 
proteolytic activity. Within the diol 4.2, the Michael system is destroyed through reduction of 
the ketone to the corresponding secondary alcohol, loss of this conjugation prevents conjugate 
addition of the thiol of Cys84 to the β-carbon. The loss of potency when comparing cyclic 
enone 1.62 and diol 4.2 could suggest that conjugate addition might be involved in inhibitory 
activity. 
 
To further investigate this, it was decided to synthesise an unreactive, cyclopropyl analogue of 
the epoxide in order to determine whether the epoxide was the key functional group, or whether 



























4.5 Bioactivity of the cyclopropyl analogue 
 
Figure 4.15. The cyclopropyl isostere 1.75 (JWR229) of the lead truncated ambuic acid analogue 1.62 and the 
IC50 curve generated from the EJM82 native AIP production assay. IC50 = 6.69 ± 0.14 µM (n= 3) 
 
The cyclopropyl analogue 1.75 (JWR229), (Figure 4.15) the total synthesis of which is outlined 
in chapter 3 may provide some interesting information about the mechanism by which the 
analogues inhibit agr mediated virulence. As outlined within the introduction and chapter 3, it 
is postulated that ambuic acid is a covalent inhibitor of the membrane bound cysteine protease 
AgrB, and with a conserved mechanism to the epoxysuccinates uses the epoxide electrophilic 
centre to irreversibly alkylate the key catalytic cysteine. It was anticipated that isosteric 
replacement of the epoxide of the lead ambuic acid analogue 2.1 with a cyclopropyl ring would 
lead to substantial attenuation of inhibitory activity. 
 
The agr-inhibitory properties of 1.75 (JWR229) were assessed as above using the EJM82 
native AIP production assay (kindly carried out by Dr Ewan Murray of the Williams/Chan 
group, due to COVID-19 restrictions). Unexpectedly, the cyclopropyl analogue 1.75 was found 
to be active against the agr system with an IC50 value of 6.69 ± 0.14 µM. This is approximately 
6-fold less than the epoxide containing equivalent. 
 
Retention of potent activity may suggest one of two things. Firstly, that the epoxide is not 
critical to inhibitory activity because the compounds function by a different mode of action. 
Replacement of the electrophilic epoxide centre with a less reactive cyclopropyl isostere caused 
only a ~6 fold reduction in compound potency when compared to LB151, suggesting a different 
mechanism of inhibition than postulated in chapter 3. Secondly, that there may be sufficient 
non-covalent interactions between 1.75 and the putative target AgrB to allow for non-covalent 
inhibition. 



















The observed bioactivities of diol 4.2 (LB221) and the cyclopropyl analogue 1.75 (JWR229) 
at present prove inconclusive in the determination of a possible covalent mode of action of the 
ambuic acid analogues. At present, further study is required to determine the mode of action of 
the compounds and whether they are covalent inhibitors.  
 
4.6 Ambuic acid analogues 
 
In addition to the truncated ambuic acid analogues tested above, analogues of full ambuic acid 
have been synthesised by Dr Leonardo Baldessarre. Firstly, analogues of ambuic acid 2.32 
(LB163) and 4.3 (LB182) were synthesised by Dr Leonardo Baldessarre and tested in the 
EJM82 native AIP production assay (Figure 4.16). The silyl ether 2.32 was found to be toxic 
to the cells, potentially due to hydrophobicity and disruption of the membrane (cLogP=  7.44) 
(Figure 4.16). However compound 4.3, shows potent inhibitory activity of the agr system with 
an IC50 of 1.53 ± 0.17 µM, comparable to that of the natural product ambuic acid (IC50 0.95 ± 
0.13 µM). Masking of the acid within ambuic acid as a t-butyl ester has minimal effect on the 
ability of the compound to act as a potent inhibitor of agr. This suggests that the acid may not 
be critical for compound activity. 
 
 
Figure 4.16. The structures and IC50 curves of ambuic acid analogues 2.32 (LB163) and 4.3 (t-butyl ester ambuic 
acid). IC50 LB182= 1.53 ± 0.17 µM (n= 4) 
   

















Toxic to cells 
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4.7 Testing compounds in the presence of exogenous AIP 
 
Having established that ambuic acid 1.1 was a potent inhibitor of agr activity in the native AIP 
production assay, it was decided to investigate how inhibition was affected when the SH1000 
EJM82 cells were treated with exogenous AIP-I. The agr system in these cells is effectively 
primed for activity with the presence of exogenous AIP. Cells were treated with100 nM AIP-
I, far above the EC50 for AgrC activation and a range of concentrations of ambuic acid and 
1.62, one of the most promising synthetic analogues to generate an IC50 curve. 
 
Ambuic acid 1.1 and LB151 1.62 were both found to still be potent inhibitors of agr activity 
even in the presence of 100 nM AIP-I as IC50 values are comparable ± exogenous AIP-I. There 
is however a notable difference in the overall efficacy of 1.62 (Figure 4.17). Complete 
shutdown of agr was observed when the cells were treated with ambuic acid 1.1, however, 
when the cells were treated with 1.62 approximately 15 % residual was observed, even when 
the cells were treated with the highest concentration of compound (Figure 4.17), indicating that 
inhibition is incomplete with 1.62.  





































Figure 4.17. IC50 curves generated from the EJM82 assay in the presence of 100 nM exogenous AIP-I. IC50 








4.8 Effect on AIP-I and toxin production 
 
Further to the use of the lux reporter as a means to determine agr inhibitory activity, it is 
important to determine how the tested compounds affect levels of AIP-I and exo-toxin 
production, both of which are physiologically relevant in S. aureus infections. The methicillin-
sensitive strain of S. aureus SH1000 was grown in the presence of several of the compounds 
tested above for 9 h in shaker culture. At 2, 4 and 9 h into bacterial growth, samples of culture 
supernatant were taken and the biomass was pelleted. The cell-free supernatant was diluted 
1:20 for analysis using the S. aureus ROJ143 assay, outlined previously within this chapter. S. 
aureus ROJ143 is a Δagr background with a chromosomal copy of agrP3::luxABCDE and 
plasmid based agrP2::agrC1agrA1.121 These cells cannot biosynthetically synthesise AIP-I. 
They are however, capable of responding to AIP-I and generate a bioluminescent signal, the 
amplitude of which is relatable to the level of AIP-I present in the growth media. 
 
The compounds tested in this assay were ambuic acid 1.1, 1.62 (LB151) and 4.3 (LB182). Both 
1.62 and 4.3 were selected as they had shown potent inhibitory activity in the native AIP 
production assay with IC50 values of 1.84 ± 0.13 µM and 1.53 ± 0.17 µM, respectively. Thus, 
SH1000 cells were treated with 100 µM of desired compound. The cells were also treated with 
1 µM AIP-95, a known inhibitor of AgrC as a positive control for inhibition. During preparation 
of the assay conditions, it was observed that LB151 and LB182 appeared to be poorly soluble 
(in 0.5 % DMSO (v/v) in LB growth media), as both formed a cloudy suspension, however the 
samples were both taken forward for the assay. 
 
Initial findings from this experiment showed that none of the test compounds exhibit any 
bacteriostatic or bactericidal effects, even at 100 µM. No difference was observed between 
treatment and DMSO control (Figure 4.18A).  
 
Samples taken from the bacterial growth culture after 2 h were taken forward into the ROJ143 
assay (Figure 4.18 B). The data shows little AIP-I present in the test medium, which is expected 
given the early stage in bacterial growth at which it was taken. Samples taken at 4 h showed an 
increase in bioluminescence, indicative of an increase in AIP-I production, which is expected 
given the samples were taken at late-log phase when the agr system is typically activated 
(Figure 4.18 C). A slight increase in luminescence is observed when ROJ143 cells are treated 
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with culture supernatant taken at 9 h into SH1000 growth, again indicative of an increase in 
AIP-I production (Figure 4.18 C). 
 
After 2 h of bacterial growth, there is a minor effect on the level of AIP-I when the cells are 
treated with test compounds, however, the overall signal is too low to interpret any inhibitory 
effects. After 4 h, both 100 µM ambuic acid and 1 µM AIP-95 shown inhibition of AIP-I 
production (Figure 4.18 C), with near full shutdown of bioluminescence observed. 100 µM 
1.62 (LB151) proves ineffective, with levels of luminescence observable comparable to DMSO 
control (Figure 4.18 C). The observed poor solubility of 1.62 could be the cause of this loss of 
inhibition. 100 µM 4.3 (LB182), which also showed a level of insolubility shows a level of 
inhibition of AIP-I production, however full arrest of AIP-I production was not observed. 
 
After 9 h (Figure 4.18 D), AIP-95 again shows near full shutdown of AIP-I, with low 
bioluminescence observed in the ROJ143 assay. Ambuic acid appears to lose activity as AIP-I 
appears to be produced due to the increase in bioluminescence (Figure 4.18 D) when compared 
to 4 h (Figure 4.18 C). This suggests that ambuic acid loses potency over time. 
 
In addition to the challenge of SH1000 with test compounds at the start of the growth curve, 
untreated SH1000 cells were treated with 100 µM ambuic acid 2 h into bacterial growth. This 
was done to determine how late addition with ambuic acid altered its inhibitory activity. As 
shown in Figure 4.18 C, at 4 h, the later addition of ambuic acid shows a loss in activity relative 
to treatment from the start. At 9 h (Figure 4.18 D), the level of inhibition between late addition 
of ambuic acid and addition at the start of the assay is comparable.9 
 
Investigation into how treatment affected the overall secretome of SH1000 was carried out by 
SDS-PAGE. Coomassie Blue stained gel (Figure 4.18 E) shows that at 4 h, for all treatments 
and DMSO control, very little secreted protein is present, due to early stage in growth. After 9 
h, ambuic acid, 4.3 and AIP-95 show a decrease in the overall level of secreted protein relative 
to the DMSO control (Figure 4.18 E). 
 
Western blot analysis was carried out to assess media content for α-haemolysin (Figure 4.18 
F). After 4 h, no toxin was observed (Figure 4.18 F). After 9 h, inhibition of α-haemolysin 
production was observed was observed in samples from SH1000 cells which had been treated 
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with ambuic acid, 4.3 and  AIP-95 (Figure 4.18 F). This correlates to the observed reduction 
of AIP-I production in Figure 4.18 C and D. 
 
These data show that ambuic acid and 4.3 (LB182) have an effect on the level of AIP-I 
produced by the cells as well as the secreted exotoxin α-haemolysin. This, taken with the data 
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Figure 4.18. (A) S. aureus SH1000 growth curve, (B) luminesence profile from S. aureus ROJ143 assay with 
samples taken at 2 h, (C) 4 h and (D) 9 h after start of growth SH1000 growth. (E) Coomassie stained 12 % 
acrylamide gel showing secretome profile, F) Western blot against α-haemolysin. For both (E) and (F) (1) NEB 
pre-stained protein standard, (2) 0.5 % DMSO 4 h, (3) 0.5 % DMSO 9 h, (4) ambuic acid 100 μM 4 h, (5) ambuic 
acid 100 μM 9 h, (6) 1.62 (LB151) 100 μM 4 h,(7) 1.62 (LB151) 100 μM 9 h, (8) 4.3 (LB182) 100 μM 4 h, (9) 
4.3 (LB182) 100 μM 9 h, (10)  AIP-95 1 μM (11) AIP-95 1 μM (12) ambuic acid 100 μM late addition 4 h, (13) 





The anti-agr activity of ambuic acid 1.1 has been assessed in this chapter. It has been found to 
be a potent inhibitor of agr activity in the native AIP-I production assay, with no adverse effect 
on bacterial growth, comparable to the IC50 value previously reported by Todd et al..
155 In 
addition, the inhibitory activity was found not to be non-specific inhibition of the lux bio-
reporter. Furthermore, ambuic acid treatment reduced the production of α-haemolysin in the 
MRSA strain USA300. The ROJ143 assay shows evidence that ambuic acid inhibits the bio- 
synthesis of the AIP-I signal molecule, with only a very minor effect on sensing. These data 
have shown that ambuic acid is a potent inhibitor of agr activity, with an observable effect on 
the production of α-haemolysin, making it a promising molecule for producing analogues as 
novel anti-virulence therapies. 
 
Analogues of ambuic acid have also been assessed using the native AIP production assay and 
several have been found to be potent inhibitors of agr activity (Table 4.3). Compounds 1.74, 
1.62 and 1.63 reveal that the right-hand (E)-heptenyl chain of ambuic acid 1.1 is not specifically 
required for compound activity as these compounds are active against agr. It is also clear that 
increasing lipophilicity has a positive effect on compound activity. Comparing 1.74 and 1.62, 
loss removal of the lipophilic t-butyldimethylsilyl ether moiety in 1.74 leads to a significant 
loss of compound potency (Table 4.3). It was also found that comparing 1.63 and 1.62, 
stereochemistry had a minimal effect on compound potency, with comparable IC50 values for 
both compounds, however there was a slight loss in the overall efficacy of the (-)- enantiomer 
JWR28 (Table 4.3). 
 
The free acid analogue 4.1 of 1.62 has also been tested in the EJM82 assay (Table 4.3). It was 
found that removal of the t-butyl ester led to a significant negative effect on compound potency, 
with the IC50 of 4.1 found to be >200 µM (Table 4.3). 
 
The novel silyl ether analogue 2.62 was also tested in the EJM82 native AIP production assay 
and found to be a potent inhibitor of agr activity, with an IC50 of 0.65 ± 0.07 µM. Comparing 
2.64 to 1.62, the slight increase in lipophilicity of 2.64 relative to 1.62 has a positive effect on 




Table 4.3. The structures of the compounds which have been tested as part of this study in the EJM82 and their 
IC50 values which have been experimentally found in the EJM82 native AIP production assay. 
Compound IC50 (µM) Compound IC50 (µM) 
 
0.65 ± 0.07 
 
6.69 ± 0.14 
 
0.95 ± 0.13 
  
8.47 ± 6.32 
 
1.53 ± 0.17 
 
13.34 ± 0.08 
 
1.84 ± 0.13 
 
24.67 ± 4.84 
 
2.27 ± 0.25 
(7 % residual activity) 
 
133.95 ± 33.80 
 





A number of ketal analogues have also been assessed for agr inhibitory activity in the EJM82 
native AIP production assay (Table 4.3). Dimethyl (2.72), diethyl (2.73) and cyclohexyl (2.74) 
ketals were all found to be potent inhibitors of agr activity. Comparing 2.72 and 2.73, the 
increase in the ketal chain length from methyl to ethyl was found to be beneficial in terms of 
compound potency. Compound 2.74, containing a unique tricyclic structure was also found to 




The cyclopropyl analogue 1.75, the synthesis of which is outlined in chapter 3 was found to be 
a potent inhibitor of agr activity (Table 4.3). Replacement of the epoxide with an inert 
cyclopropyl ring was carried out in an attempt to determine the mode by which ambuic acid 
and the synthetic analogues function. The cyclopropyl analogue 1.75 was found to be a potent 
inhibitor of agr activity (IC50 = 6.69 ± 0.14 µM). This suggests that the epoxide is not required 
for potent inhibition of agr activity. Further study of the mechanism by which the inhibitors 
function is required. 
 
Ambuic acid and the truncated analogue 1.62 (LB151) were both found to be potent inhibitors 
in the EJM82 assay when the cells were treated with exogenous AIP-I. Potency was comparable 
± AIP-I for both compounds, however a loss of overall efficacy of LB151 was found when the 
cells were also treated with AIP-I. 
 
The most potent compounds 1.62 (LB151), 4.3 (LB182) as well as ambuic acid 1.1 were tested 
to determine whether they inhibit AIP-I production. Ambuic acid and 4.3 were found to inhibit 
the production of AIP-I as well as reduced the level of production of α-haemolysin. It was also 
found that after growth for 9 h, ambuic acid loses inhibitory activity. 
 
The data above showed that the tested compounds are promising inhibitors of staphylococcal 
virulence and are promising therapeutic agents for the treatment of serious multi-drug resistant 
infection. It is proposed that 1.62 is a hit compound which would be the basis for further 
structure-activity exploration. 
 
Taken together, the data presented here represents the first study of analogues of ambuic acid 








































5.1 General conclusions 
The aims of this thesis were to discover novel anti-virulence compounds that target the 
staphylococcal agr system as a modality to treat serious, multi-drug resistant S. aureus 
infections. To achieve this, three key aims have been investigated. Firstly, the synthesis of a 
focused range of analogues of the natural fungal product ambuic acid 1.1. Second, the synthesis 
of a cyclopropyl isostere of the epoxide within an ambuic acid analogue to investigate how it 
alters activity. Thirdly, the in vitro biological characterisation of the synthesised analogues. 
 
 
Figure 5.1. The truncated ambuic acid analogue 1.62 and the corresponding (-)-enantiomer 1.63. 
 
The synthesis of a range of analogues of the truncated ambuic acid analogue 1.62 has been 
carried out (Figure 5.1). A synthetic route, adapted from the Jung et al. total synthesis of ambuic 
acid by Dr Leonardo Baldassarre, formerly of the Williams/Chan group has been utilised as 
the main synthetic route.163 Modification of this route has been carried out to afford a number 
of unique analogues.  
 
Scheme 5.1. The key Diels-Alder reaction to produce the (-)-adduct 1.67 which confers stereoselectivity on 
subsequent steps through steric occlusion of formation of the undesired enantiomer. 
 
Firstly, a route to the (-)-enantiomer of 1.63 (Figure 5.1) has been established through the 
modification of a key Diels-Alder reaction, by forming a, chiral Diels-Alder adduct 
intermediate 1.67 which can confer stereoselectivity on subsequent chemical transformations 
through steric occlusion of the undesired enantiomer (Scheme 5.1). Diels-Alder adduct 1.67 
was produced with good enantioselectivity, [α]D
24= +81.4 and reasonable yield (56 %). The 
opposing enantiomer, the (+)-adduct has a value of [α]D
24= -70.3, which is comparable to the 
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known value in the literature.163 With the successful production of adduct 1.67, subsequent 
synthetic transformations yielded the final compound 1.63. These included the DIBAL-H 
mediated enantioselective reduction of the ketone moiety within 1.71, a procedure pioneered 
by Mehta et al. and Jung et al. utilising DIBAL-H to afford diol 1.72 with good 
enantioselectivity (Scheme 5.2), [α]D
24= +43.9. The corresponding (+)-enantiomer has a value 
of [α]D
24= -44.4, which is comparable to the literature.163 Final compound 1.63 was 
successfully produced and taken into biological assessment. 
 
Scheme 5.2. The enantioselective reduction of the ketone of 1.71 to the corresponding secondary alcohol 1.72. 
 
Attempts were also made to produce ether analogues through modification of the primary 
alcohol in enantiomerically pure 1.62. Unfortunately, exhaustive testing of ether formation 
conditions failed to yield the desired asymmetric ethers. 
 
The synthesis of numerous silyl ether analogues was also attempted. These compounds were 
synthesised by dismantling of silyl ether 1.62 to afford the key diol intermediate 1.74 (Figure 
5.2), followed by subsequent reaction with a silyl chloride to give the corresponding silyl ether 
analogues. Unfortunately, it was only possible to produce dimethylthexyl silyl ether 2.62 
(Figure 5.2). The failed condensation reactions are likely due to steric hindrance of 
commercially available silyl chlorides (such as TBDPSCl) and the starting material. 
 
 




The synthesis of several ketal analogues of 1.62 has also been carried out. Dimethyl (2.72), 
diethyl (2.73) and cyclohexyl (2.74) ketals have been successfully synthesised utilising the key 
diol intermediate 1.74/2.77 (Figure 5.3). Reaction of diol 1.74/2.77 with symmetric ketone 
afforded the desired ketal. Moreover, an efficient trans-acetalation/ketalation procedure was 
established, which utilised the O,O-dimethoxy variant of the ketone to afford even sterically 
encumbered ketals, such as the cyclohexyl ketal 2.74 with reasonable yield (31%).  
 
Figure 5.3. The ketal analogues. Dimethyl ketal 2.72, diethyl ketal 2.73 and cyclohexyl ketal 2.74. 
 
The second aim was to produce a novel cyclopropyl isostere 1.75 of a truncated ambuic acid 
analogue 2.1 (Figure 5.4). This was carried out to determine whether the epoxide electrophilic 
warhead is required for potent inhibition of the putative cysteine protease AgrB. It was 
predicted that no inhibition would be observed with replacement of the reactive epoxide. 
 
Figure 5.4. The cyclopropyl isostere 1.75. 
 
The production of the cyclopropyl isostere 1.75 was achieved through the optimisation of a key 
Corey-Chaycovsky cyclopropylation reaction using trimethylsulfoxonium iodide in the 
presence of n-BuLi for the enantioselective installation of the cyclopropyl ring to afford 1.78 
(Scheme 5.3). Enantioselective insertion of the cyclopropyl ring was confirmed through 
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NOESY NMR. With the successful installation of the cyclopropyl ring, the optimisation of 
subsequent synthetic steps has been carried out to afford the final compound. Notably, 
advancements have been made through the development of a highly efficient microwave-
assisted retro Diels-Alder reaction to dismantle the adduct 1.80 in order to yield 1.81, typically 
with a yield of 80-91 % with the requirement of relatively mild conditions (Scheme 5.4). 
 
Scheme 5.3. The Corey-Chaycovsky cyclopropylation reaction used here to install the cyclopropyl ring giving 
key intermediate 1.78. 
 
Third, the successfully synthesised analogues were also assessed for their in vitro anti-agr 
activity. As outlined in chapter 4, a bioluminescence reporter has been utilised to determine the 
anti-virulence properties of numerous analogues.  
 
Scheme 5.4. The optimised conditions for the retro-Diels-Alder reaction giving the key intermediate 3.23. 
 
Initially, selected anti-agr properties of ambuic acid (1.1) were characterised. It was found to 
be a potent inhibitor of agr mediated virulence in the native AIP production bioluminescent 
reporter assay with an IC50 of 0.95 ± 0.13 µM (Table 5.1), which agrees with the literature (2.5 
± 0.1 µM).155 Furthermore, ambuic acid was found to cause an observable reduction in the level 
of the secreted exotoxin, α-haemolysin. These data show that ambuic acid is a potent inhibitor 
of an agr-regulated virulence factor. In addition, the ROJ143 AIP-I sensing assay indicates that 





Synthetic analogues of ambuic acid have also been assessed using the native AIP-I production 
assay. Several analogues have been found to be potent inhibitors of agr activity including 2.62 
(JWR99), 1.62 (LB151) and 1.63 (JWR28) (Figure 5.5 and Table 5.1). The opposing 
enantiomers (1.62 and 1.63) of a truncated ambuic acid analogue (Figure 5.1, Table 5.1) were 
both found to be potent inhibitors of agr activity. Stereochemistry was found to effect the 
overall efficacy of the compounds, with minimal effect on the potency.  
 
Significantly, the dimethylthexyl silyl ether 2.62 (JWR99) was found to have improved activity 
when compared to ambuic acid 1.1 (IC50 of JWR99= 0.65 ± 0.07 µM; ambuic acid= 0.95 ± 
0.13 µM). 
 
Table 5.1. The structures and IC50 values of the synthetic analogues of ambuic acid. The IC50 values were 
calculated in the EJM82 native AIP production assay. 
Compound IC50 (µM) Compound IC50 (µM) 
 
0.95 ± 0.13 
 
5.06 ± 3.52 
 
1.84 ± 0.13 
 
6.69 ± 0.14 
 
2.27 ± 0.25 
(7 % residual activity) 
 
1.53 ± 0.17 
 
0.65 ± 0.07   
 
13.34 ± 0.08   
  
8.47 ± 6.32   
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Ambuic acid (1.1) and the potent truncated analogue 1.62 (LB151) have also both been found 
to be potent inhibitors of agr activity even when the agr system within the reporter strain was 
primed with exogenous AIP-I. 
 
 
Figure 5.5. The structures of 1.62 (LB151), 1.63 (JWR28) and the silyl ether analogue 2.62 (JWR99). 
 
The ketal analogues 2.72, 2.73 and 2.74 were also assessed for anti-agr activity using the native 
AIP-I production assay (Figure 5.6). All three ketal analogues were found to have inhibitory 
activity against the staphylococcal agr system (Table 5.1). Of these analogues, the cyclohexyl 






Figure 5.6. The structures of the ketal analogues, 2.72 (JWR269), 2.73 (JWR298) and 2.74 (JWR297). 
 
The cyclopropyl analogue JWR229 1.75 (Figure 5.7) was assessed for anti-virulence activity 
in the native AIP-I production assay. Unexpectedly, the cyclopropyl analogue 1.75 was found 
to be a potent inhibitor of agr mediated virulence with an IC50 =6.69 ± 0.14 µM. This suggests 
that the electrophilic epoxide centre is not required for potent inhibitory activity. At present, 




Figure 5.7. The cyclopropyl isostere 1.75 (JWR229). 
 
A number of the most potent compounds, 1.62 (LB151), 4.3 (LB182, Figure 5.8) and ambuic 
acid (1.1) were also tested to determine whether they inhibit the production of AIP-I and the 
secreted α-haemolysin. Both ambuic acid and 4.3 were both found to inhibit AIP-I production. 
In addition, they were both able to inhibit production of α-haemolysin. It is also important to 




Figure 5.8. LB182 4.3 (LB182), t-butyl ester analogue of ambuic acid 
 
In summary, the biological characterisation of ambuic acid and the synthetic analogues has 
shown that they are inhibitors of some promise as future therapies for the treatment of serious, 
multi-drug resistant S. aureus infections. This work represents the first study of analogues of 
























5.2 Future work 
5.2.1 Ambuic acid analogues 
The work outlined in this thesis has described the synthesis and biological characterisation of 
the anti-virulence properties of numerous truncated analogues of the natural product ambuic 
acid. The synthesis of analogues has been focused on the production of analogues of 2.1. 
Herein, possible future directions for work focusing on development of ambuic acid analogues 
will be discussed. 
 
The right hand (E)-heptene moiety of ambuic acid 1.1 could be replaced with a range of 
lipophilic groups to afford a range of unique analogues. The installation of such lipophilic 
groups could provide some useful data on the inhibitory activity of ambuic acid. To this end, a 
number of target structures are shown in Figure 5.9.  
 
 
Figure 5.9. Ambuic acid 1.1 and the target right hand chain analogues. Both the free acid and t-butyl ester 
analogues could be synthesised. 
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The proposed structures incorporate an array of chemical functionalities, including the cis-
isomer of the heptene chain 5.1 (trans in natural ambuic acid 1.1), a cyclohexyl ring 5.2, 
alkynyl 5.3 (imparting rigidity), benzyl 5.4 and short alkene chains 5.5 (Figure 5.9).   
 
The proposed route to the above series of analogues would initially follow the synthesis of 
truncated ambuic acid analogue 1.62. Modification is required for the installation of the right 
hand chain. Thus, the silyl ether 2.27 will be treated in an α-bromination reaction previously 
utilised by Jung et al. to yield the bromo compound 2.28 (Scheme 5.5).163 The Diels-Alder 
adduct of 2.28 will subsequently be dismantled giving bromo-quinolone derivative 2.29, which 
will then be taken into an ozonolysis and Wittig procedure to afford the key intermediate 2.31 
(Scheme 5.5). The intermediate 2.31 will then be taken into a Stille cross-coupling with the 
appropriate stannane to furnish the compound with the desired right-hand chain 5.6 (Scheme 
5.5). This will be followed by sequential de-protection of the silyl ether (giving t-butyl ester 
compounds 5.7) and final dismantling of the t-butyl ester giving final free acid 5.8 (Scheme 
5.5). Progress towards the production of these compounds has been made, however it was 




















Scheme 5.5. The proposed route to the right-hand analogues. (a) DBU, 1,2-dibromotetrachloroethane; (b) Ph2O, 
heat; (c) O3, dimethylsulphide then Ph3P=C(Me)CO2t-Bu; (d) SnBuR3, Pd(PPh3)4, µW radiation; (e) acetic acid, 






Steps towards the production of these analogues have been undertaken. Thus, the t-butyl 
dimethyl silyl ether 2.27, was treated in an α-bromination procedure, adapted from Jung et al. 
in their total synthesis of ambuic acid.163 Silyl ether 2.27 was stirred with DBU (20 mol %) to 
remove the α-proton and before subsequent reaction with 1,2-dibromotetrachloroethane. This 
produced the desired bromide 2.28 in excellent yield (85 %, Scheme 5.6). The α-bromination 
procedure affords a key bromide intermediate that enables facile access to a range of analogues 
via Stille cross-coupling. However, when the bromide 2.28 was treated in the retro Diels-Alder 
reaction to dismantle the adduct, the quinolone derivative 2.29 was obtained in poor yield 
(Scheme 5.7). Nevertheless, with the successful production of 2.29, the subsequent step was 
the ozonolysis and Wittig procedure, previously described in this chapter to produce t-butyl 
ester 2.31. This unfortunately yielded 2.31 in poor yield (10%, Scheme 5.8). 
 
 
Scheme 5.6. The α-bromination procedure adapted from Jung et al. allowing successful production of bromide 
2.28.163 
 
t-butyl ester 2.31 was taken forward for Stille cross-coupling to install the desired right hand 
chain. The installation of he (Z)-hept-1-enyl and (E)-cyclohexyl vinylic right-hand chains, to 
afford 5.9 and 5.10 proceeded smoothly (Figure 5.10). However, installation of the benzylic, 











Scheme 5.8. The ozonolysis and Wittig procedure installing the t-butyl ester moiety providing 2.31 in poor yield, 
10%. 
 
With the installation of the desired right-hand chain giving both 5.9 and 5.10, subsequent 
sequential deprotection gave the desired final compounds. Unfortunately, the amount of 
compound was insufficient to allow for full characterisation and biological testing. However, 
the route pioneered here is a promising starting point for the production of further analogues 
of ambuic acid and future optimisation 
 
 
Figure 5.10. The (Z)-hept-1-ene 5.9 and (E)-cyclohexyl vinyl 5.10 products produced by the Stille reaction. 
 
5.2.2 Cyclopropyl analogues 
As outlined in chapter 3, the synthesis of a novel cyclopropyl isostere of the epoxide within a 
truncated ambuic acid analogue has been achieved. The cyclopropyl isostere was synthesised 
to determine whether loss of the epoxide electrophilic centre has a negative effect on the anti-
virulence activity of the compound. 
 
The next logical step in the production of cyclopropyl analogues would be to take steps towards 
the production of cyclopropyl ambuic acid 5.11, through adaptation of the synthesis of 





Scheme 5.9. The proposed route to the ambuic acid analogue 5.11 through adaptation of the route to cyclopropy 
isosotere 1.75. (a) 1,2-dibromotetrachloroethane, DBU; (b) Ph2O, heat; (c) O3, dimethylsulphide then 
Ph3P=C(Me)CO2t-Bu; (d) tributyl (E)-hept1-enyl stannane, Pd(PPh3)4; (e) acetic acid : Et2O : dH2O 1:2:1; (f) 
trifluoroacetic acid.  
 
The proposed route (Scheme 5.9) to cyclopropyl ambuic acid 5.11 requires modification of the 
route to the cyclopropyl analogue 1.75 outlined in chapter 3. It would be necessary to produce 
the dione variant as reduction of lower ketone to the corresponding secondary alcohol was not 
successful in Chapter 3, even after testing several conditions. 
 
Silyl ether 1.80 will be treated using an α-bromination procedure adapted from Jung et al. to 
provide the bromo compound 5.12 (Scheme 5.9).163 Dismantling of the Diels-Alder adduct will 
subsequently be carried out using procedures previously utilised in this study giving 5.13 which 
in turn will be treated in an ozonolysis and Wittig olefination procedure to yield the t-butyl 
ester 5.14. Subsequently, a Stille cross-couping will enable the installation of the (E)-hept-1-
ene chain, giving 5.15 (Scheme 5.9). Sequential de-protection of the silyl ether and t-butyl ester 
would yield the final compound 5.11.  
 
The cyclopropyl analogue 1.75 was synthesised as an attempt to elucidate the mechanism by 
which the inhibitors studied in this thesis function. It was postulated that replacement of the 
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electrophilic warhead with an inert cyclopropyl ring would lead to loss of inhibitory activity. 
However, upon biological testing outlined in chapter 4, 1.75 was unexpectedly found to be a 
potent inhibitor of agr activity. This suggested that the epoxide is not required for potent 
inhibitory activity. Thus, further study is required to elucidate the mechanism-of-action of these 
compounds. 
 
One potential method could be the fluorescent labelling of ambuic acid through the 
modification of the free carboxylic acid. Fluorescent ambuic acid could then be incubated with 
S. aureus culture expressing AgrB, which could then be purified for analysis. If ambuic acid is 
a covalent inhibitor of AgrB, it would be expected that fluorescently labelled ambuic acid 
would co-purify with AgrB. 
 
Du et al. developed a 6-oxo-(acetyl piperazine) fluorescein 5.16 (Figure 5.11) label for the 
selective labelling of free-fatty acids within human sera.239 In their study, they utilise this 
fluorescein label to determine the level of seven free-fatty acids through HPLC in a highly 
sensitive manner.239 Du et al. find that they could detect levels as low as 0.1-6.4 nM.239 
 
They found that the piperazine moiety within 5.16 reacts with free carboxylic acids under mild 
conditions in the presence of EDC to give fluorescently labelled carboxylic acid.239 The free 
acid of ambuic acid 1.1 could be labelled this way, giving 5.17 and indeed, the t-butyl ester of 
cyclopropyl analogue 1.75 could be dismantled and the resultant free acid could be reacted 
with 5.16 to give the corresponding fluorescently labelled cyclopropyl analogue 5.18 (Figure 
5.11).  
 
As the epoxide containing analogues are thought to irreversibly alkylate the key catalytic 
cysteine within the active site of AgrB, reaction with fluorescently labelled ambuic acid should 
yield fluorescently labelled drug-target covalent complex. In contrast, if the cyclopropyl 
analogue does not covalently modify AgrB, no signal should be observed. 
 
Like the Du study, fluorescence could be monitored though the use of HPLC.239 Reversed-
phase HPLC (RP-HPLC) can be used to give high-resolution separation of membrane 
proteins.240 An issue is that the solvents and the resins used can denature peptides.240 Thus, RP-
HPLC is typically used for analytical purification of membrane proteins.240 If the fluorescent 
labelled compound is covalently bound to the target protein, the protein would effectively be 
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fluorescently labelled. Monitoring of the eluent of the RP-HPLC column for fluorescein 
fluorescence (494/512 nm excitation/emission) could provide a readout for this potential assay. 
 
 
Figure 5.11. The fluorescein derivative 5.16 produced by Du et al. and the proposed fluorescein labelled ambuic 











5.2.3 Biological assessment of the compounds 
As outlined within chapter 4, a number of synthetic analogues of ambuic acid have been tested 
as inhibitors of agr in S. aureus. At present, compounds have only been tested in agr group-I 
and there is a need to determine whether the compounds are able to inhibit different agr groups. 
 
To determine the activity of the synthesised analogues in different agr groups, a method from 
the Nakayama study of ambuic acid inhibition could be adapted.153 Nakayama et al. utilise 
LC/MS to monitor the biosynthesis of a variety of quorum sensing signal molecules ± treatment 
with ambuic acid.153 Nakayama et al. use this method to assess the ability of ambuic acid to 
inhibit the production of the signal molecule in a number of bacterial species, including L. 
innocua and S. aureus.153  
 
The desired organism would be grown ± ambuic acid and a sample could be taken, filtered and 
analysed using LC/MS, with monitoring of the liquid-chromatography eluent of the desired 
m/z of the molecular ion of the relevant signal molecule/ This could be achieved through 
adapting methods utilised by Nakayama et al..153 Treatment could be compared against un-
treated control to determine the effect of ambuic acid on the ability of the bacterium to produce 
their corresponding signal molecule. This would allow for the screening of numerous 
organisms in a relatively facile manner. Test organisms could include Enterococcus faecalis, 
Clostridium difficile, Listeria innocua and further species of staphylococci, such as 
Staphylcoccus pseudointermedius. These experiments have the potential to further show the 
utility of ambuic acid 1.1, and indeed the synthetic analogues produced as part of this study as 














































6.1 Table of strains 
 
Table 6.1. Table of strains. 


































Wild-type - Bei Resources 
 S. aureus 
USA300_LAC 




6.2 Measurement of agrP3 promoter by bioluminescence (EJM82 
native AIP production assay)  
S. aureus EJM82 and S. aureus EJM83 (Table 6.1) were grown overnight in Luria-Bertani (LB) 
broth containing 100 µg/ mL kanamycin in shaker culture (37 ºC, 200 rpm). Cells were pelleted 
(12,000 × G) and washed 3 times with LB broth. After final wash and suspension, the culture 
was diluted to OD600 0.05 with LB broth containing 100 µg/ mL kanamycin and grown for 4 h 
at 37oC, 200 rpm. After growth, the culture was washed as above and diluted 1 : 20 in LB broth 
for inoculation of a 96-well Greiner microtiter plate which had been treated with a range of 
concentrations of test compounds (0-200 µM) in DMSO, such that final DMSO assay 
concentration didn’t exceed 0.5 % (v/v). EJM83 (Δagr) was also plated with 0.5 % (v/v) DMSO 
as a negative control for bioluminescence. 
 
6.3 S. aureus ROJ143 AgrC inhibition bioreporter assay  
The AIP-I bioreporter strain S. aureus ROJ143 (Table 6.1) was grown overnight in shaker 
culture (37 ºC, 200 rpm) in LB broth containing 10 μg/mL chloramphenicol. The overnight 
culture was diluted to an OD600 of 0.05 in LB broth containing 10 μg/mL chloramphenicol and 
grown for 4 hours. After growth, the culture was diluted 1:20 for inoculation of a 96-well 
Greiner microtiter plate, which had been treated with a range of concentrations of AIP-I to 
generate an EC50 curve ± ambuic acid. 
 
6.4 S. aureus RN4220 non-specific lux inhibition assay 
 
The tetracycline inducible lux reporter strain of RN4220 (Table 6.1) was grown in BHI medium 
for 4 h (37 ºC, 200 rpm) and diluted 1:500 in BHI before inoculation of a Greiner microtiter 
plate. The plate had previously been treated with a range of concentrations of 
anhydrotetracycline (100-1 ng/ mL in H2O) to induce bioluminescence and either ambuic acid 
(20 µM in 0.5 % (v/v) DMSO) or vehicle (0.5 % (v/v) DMSO). The level of bioluminescence 







6.5 The measurement of lux bioluminescence 
 
S. aureus EJM82 is able to produce AIP-I and can produce a luminescent signal, the amplitude 
of which is dependent on the level of agr activity. S. aureus ROJ143 cannot produce AIP-I but 
it can respond to exogenous AIP-I and as such, when grown in the presence of AIP-I, a 
luminescent signal is observed. 
 
Bioluminescence production from the S. aureus EJM82, S. aureus ROJ143 and RN4220 non-
specific lux inhibition assays were measured using a Tecan Infinite F200 plate reader. Cells 
were grown under static conditions. Cellular growth was monitored at OD600 every 15 min for 
15 h. Bioluminescence of EJM82 cells was measured with an integration time of 4,000 ms 
every 15 min for 15 h. ROJ143 and RN4220 bioluminescence was measured with an integration 
time of 1000 ms every 15 minutes for 15 h. 
 
Bioluminescence was determined by dividing each luminescence value by the corresponding 
OD600 value. Integrated luminescence was calculated by measuring the area under the 
luminescence curve from time > 210 min. For S. aureus EJM82 assays, integrated 
luminescence was blanked by subtracting the value from the Δagr strain S. aureus EJM83 
(background) from each test value.  
 
6.6 S. aureus USA300_LAC and SH1000 growth curves 
The MRSA strain of S. aureus USA300_LAC or the MSSA strain SH1000 (Table 6.1) were 
grown overnight in LB broth in shaker culture (37 ºC, 200 rpm). Overnight culture was washed 
3 times in LB (12,000 × G) and diluted to OD600 0.05 in LB ± treatment with compound in a 
final assay concentration of DMSO of 0.5 % (v/v). The cells were grown for 9 h in shaker 
culture (37 ºC, 200 rpm). OD600 measured every hour (from 2 h). 
 
6.7 Preparation of samples from S. aureus SH1000 growth culture 
for S. aureus ROJ143 assay 
At 2, 4 and 9 h into the S. aureus SH1000 growth curve, 200 μL of culture suspension was 
taken and the bio mass was pelleted (20,000× G). The supernatant was taken and stored at -20 
ºC until required 
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6.8 Preparation of secreted protein Samples from S. aureus 
USA300_LAC Growth Culture 
At 4 h and 9 h into the S. aureus USA300_LAC growth curve, samples of culture were taken 
and the cells were pelleted at 20,000 × G. The supernatant removed and stored at –20 ºC until 
required. 
 
Samples of supernatant were thawed and protein was precipitated in 20 % (v/v) trichloroacetic 
acid for 15 min at 0 ºC. Protein was pelleted at 20,000 ×G and protein pellets were washed 3 
times with acetone (20,000 × G). Acetone was evaporated after the final wash and the pellets 
were suspended in 2 × SDS loading buffer (100 mM Tris-Cl, 2.5 M glycerol, 4 % (v/v) SDS, 
0.005 % (w/v) bromophenol blue and 200 mM β-mercaptoethanol). Volume of loading buffer 
was varied to normalize samples to the lowest OD600 from the growth curves. Samples were 
heated to 95 ºC for 10 minutes and the debris was pelleted (20,000 × G). Samples were stored 
at -20 ºC until required.  
 
6.9 S. aureus ROJ143 AIP-I production bioreporter assays 
 
The AIP-I bioreporter strain S. aureus ROJ143 (Table 6.1) was grown overnight in shaker 
culture (37 ºC, 200 rpm) in LB broth containing 10 μg/mL chloramphenicol. The overnight 
culture was diluted to an OD600 of 0.05 in LB broth containing 10 μg/mL chloramphenicol and 
grown for 4 h. After growth, the culture was diluted 1:20 for inoculation of a 96-well Greiner 
microtiter plate, treated with 10 μL of test supernatants obtained from the S. aureus SH1000 
growth curve. Final dilution of supernatants 1:20. Bioluminescence was measure as described 
in section 6.5. 
 
6.10 SDS-PAGE, Coomassie staining and Western blotting of S. 
aureus α-haemolysin 
SDS-PAGE on protein samples was carried out using 12 % acrylamide SDS-PAGE gels. 
Resolving gel (12 % (v/v) acrylamide, 380 mM Tris-base pH 8.8, 0.1 % (w/v) SDS, 0.1 % 
(w/v) ammonium persulphate and 0.14 mM tetramethylethylenediamine in dH2O) were poured 
and isopropanol was used to level. When the gel had set, isopropanol was removed and stacking 
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gel (6 % (v/v) acrylamide, 78 mM Tris-base pH 6.8, 0.12 % (w/v) SDS, 0.12 % (w/v) 
ammonium persulphate and 0.12 mM tetramethylethylenediamine in dH2O) was poured. 
 
Samples and NEB protein standard molecular weiht markers (NEB prestained protein ladder, 
broad molecular weight) loaded and gel run at 50 mA in 1 × SDS-PAGE running buffer (0.19 
mM glycine, 0.027 mM Tris-base, 0.1 % (w/v) SDS in dH2O) until the loading buffer front had 
reached the bottom of the gel. Proteins were visualized with Coomassie Blue (GelCodeTM) and 
destained with H2O. Imaged using GelDoc
TM (Biorad). 
 
S. aureus α-haemolysin was detected using Western blotting. Protein transferred from gel to 
0.4 µm nitrocellulose membrane in transfer buffer (20 % (v/v) methanol, 0.25 mM Tris-base, 
0.2 mM glycine) at 200 V for 1 h. 
 
Blocking carried out either overnight at 4 ºC or for 2 h at ambient temperature in 5 % (w/v) 
skimmed milk in TBS-Tween20 (26 mM Tris-base, 72 mM NaCl and 0.1 % (v/v) Tween20, 
pH 7.6 in dH2O). Primary anti α-haemolysin monoclonal antibody (kind gift from Prof. Lindy 
Durrant, School of Medicine, University of Nottingham) was diluted 1 : 5,000 in 0.5 % (w/v) 
skimmed milk in TBS-Tween20 and incubated for 1 h at ambient temperature. Membrane 
washed with TBS-Tween20. Secondary antibody- S. aureus protein-A conjugated to 
horseradish peroxidase (Sigma) diluted 1 : 5,000 in 5 % (w/v) skimmed milk in TBS-Tween20 
and incubated with membrane for 45 min at ambient temperature. Membrane washed with 
TBS-Tween20. 
 
S. aureus α-haemolysin visualized with ECLTM or ECLTM prime detection reagents (Amersham 









































7.1 General synthetic chemistry procedures 
All reagents, unless otherwise stated were purchased from Sigma Aldrich, Merck, VWR, 
Thermo Scientific and Acros Organics.  
 
Reactions carried out at r.t., 0 ºC, -40 ºC and -78 ºC.. 0 ºC achieved with ice, -40 ºC with 
acetonitrile and dry ice and -78 ºC with acetone and dry ice. For reactions requiring heating, a 
hotplate was used. Where microwave radiation was required, a CEM Discover-S microwave 
digestion system was utilised. 
 
Moisture sensitive reactions were carried out in flame-dried or oven dried glassware under inert 
nitrogen atmosphere. 
 
All reactions monitored by analytical thin-layer chromatography (Merck 60 F254, pre-coated, 
aluminium backed plates), high-resolution mass spectrometry (BruckerTM microTOF mass 
spectrometer by positive electrospray ionization), compounds dissolved in methanol and 
liquid-chromatography/ mass-spectrometry. Thin-layer chromatography visualized with short 
wavelength (254 nm) UV light and stained with potassium permanganate stain. 
 
Silica gel chromatography was performed using Sigma Aldrich technical grade silica gel, 60 
Å, 230-400 nm mesh, 40-63 µm. 
 
Preparative TLC (pTLC) carried out on commercially available Merck PLC silica gel 60, 0.5 
mm glass-backed plates. 
 
Chemical structures verified by 1H and 13C NMR. Compound purity (>95 %) verified by NMR 
spectrometry. 1H and 13C spectra samples dissolved in chloroform-d and recorded using Brüker 
Avance-400 operating at 400 MHz for 1H and 100 MHz for 13C spectra. NOESY spectra 
recorded on Brüker AV(III) 500 MHz spectrometer. Chemical shifts reported in ppm and 
referenced to internal solvent standard (chloroform-d 1H- 7.26 ppm, 13C 77.16 ppm). Coupling 
constants reported in Hz. COSY and HSQC 2D spectra used for assignment. 
 
Optical rotation was measured using a Bellingham & Stanley ADP-220 polarimeter in a 0.25 
dm cuvette. Concentration (c) of the compound was given in g/100 mL.  
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Semi-preparative RP-HPLC was carried out using a Waters HPLC system equipped with 
binary pump modules and a dual wavelength UV detector (detection at 214 nm and 254 nm). 
The mobile phase  consisted of solvent A (Milli-Q ± 0.06% TFA) and solvent B (MeCN/Milli-
Q 9:1 ± 0.06% TFA). Semi-preparative RP-HPLC carried out using a Hichrom Kromasil 100 
5-C8 (150 × 10 mm, 5 µm) column at 4 mL/min. 
 
Melting points recorded using a Gallenkamp melting point apparatus, values given in degrees 





7.2 Full synthetic procedures 
 
7.2.1. (1'S,4'R,4a'S,8a'R)-7'-iodo-1',4',4a',8a'-tetrahydro-8'H-spiro[[1,3]dioxolane-2,5'-




Triflic acid (8.77 mL, 0.2 M) in dry DCM was added dropwise to a solution of (R)-(+)-o-tolyl-
CBS oxazaborolidene in toluene (4.2 mL, 0.5 M) at -78 ºC and stirred for 15 minutes. A 
solution of  1.54 (3.16 g, 11.3 mmol) in dry DCM (12 mL) and freshly distilled cyclopentadiene 
(1.12 mL) were added dropwise to the stirring solution. Reaction monitored by TLC 
(hexane/EtOAc 3:1). Upon completion, reaction quenched with TEA (1 mL). Crude mixture 
was concentrated under reduced pressure. Product purified by silica gel chromatography (PET 
ether/ EtOAc 3:1) yielding the title compound as a yellow/ brown oil (3.44 g/ 88 %). Rf = 0.5 
(hexane/EtOAc 3:1). [α]D
25 = -70.3 (c 1, CHCl3).  MS: m/z (+ESI) exact mass calc’d for 
C13H13IO3 [M + Na]+ 366.9807 found 366.9802. 
1H NMR (400 MHz, Chloroform-d) δ 7.04 
(d, J = 1.3 Hz, 1H, C2-H), 6.06 (dd, J = 5.7, 2.9 Hz, 1H, C14-H), 5.82 (dd, J = 5.6, 2.8 Hz, 1H, 
C15-H), 4.10 (ddd, J = 6.4, 5.6, 3.7 Hz, 1H, OCH2CH2O), 4.07 – 3.89 (m, 3H, OCH2CH2O), 
3.29 (dq, J = 4.2, 1.4 Hz, 1H, C5-H), 3.26 (dd, J = 8.4, 4.2 Hz, 1H, C16-H), 3.19 (dp, J = 3.5, 
1.7 Hz, 1H, C13-H), 2.81 (ddd, J = 8.4, 3.6, 1.3 Hz, 1H, C4-H), 1.38 (dt, J = 8.6, 1.8 Hz, 1H, 
C19-H), 1.34 – 1.27 (m, 1H, C19-H). 13C NMR (101 MHz, Chloroform-d) δ 193.53, 153.87, 









Anhydrous DME (44.8 mL) was added dropwise to compound 2.34 at -78 ºC. BF3Et2O (1.86 
mL, 15 mmol) and ethylene glycol (4.2 mL, 75 mmol) were added and the reaction was stirred 
for 2 h, with gradual raising to ambient temperature. The reaction was monitored by TLC 
(hexane/EtOAc 3:1). When completed, reaction was quenched with sat. NH4Cl (aq.). The 
organic layer was extracted with DCM (3 × 20 mL) and dried over anhydrous MgSO4. Mixture 
was filtered and the crude mixture was concentrated under reduced pressure. Product purified 
by silica gel chromatography (PET ether/ EtOAc 3:1) yielding the title compound as a yellow 
powder (3.33 g, 81 %). Rf = 0.35 (hexane/EtOAc 3:1). m.p. 94-96 ºC. MS: m/z (+ESI) exact 
mass calc’d for C8H7IO3 [M + Na]+ 300.9332 found 300.9345.
1H NMR (400 MHz, 
Chloroform-d) δ 7.38 (d, J = 2.8 Hz, 1H, C6-H), 6.65 (dd, J = 10.0, 2.9 Hz, 1H, C9-H), 6.31 
(d, J = 10.0 Hz, 1H, C10-H), 4.13 (s, 4H, C2/3-H).13C NMR (101 MHz, Chloroform-d) δ 











7.2.3. (Iodine route) (1'S,4'R,4a'S,8a'R)-7'-allyl-1',4',4a',8a'-tetrahydro-8'H-




Pd(PPh3)4 (863 mg, 7.5 mol%) and allyltributyl tin (6.2 mL, 20 mmol) were added to a solution 
of 1.53 in degassed THF (10 mL) under nitrogen. The reaction mixture was heated to 110 ºC 
with microwave radiation (150 W) and stirred for 10 min. The reaction monitored by TLC 
(hex/EtOAc 3:1). Upon completion, the reaction was cooled to ambient temperature and 
quenched with sat. NH4Cl (aq.). Organic layer extracted with EtOAc (3 × 10 mL). Crude mix 
concentrated under reduced pressure. Product was purified by silica gel chromatography (PET 
ether/EtOAc 9:1) yielding the title compound as a brown oil (1.78 g, 68 %). Rf = 0.5 
(hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass calc’d for C16H18O3 [M + Na]+ 281.1154 
found 281.1157. 1H NMR (400 MHz, Chloroform-d) δ 6.08 – 6.00 (m, 2H, CH=CH), 5.80 (dd, 
J = 5.6, 2.9 Hz, 1H, C2-H), 5.78 – 5.64 (zm, 1H, C20-H), 5.11 – 5.01 (m, 2H, C21-H), 4.16 – 
4.05 (m, 1H, OCH2CH2O), 4.05 – 3.91 (m, 3H, OCH2CH2O), 3.31 (dhept, J = 4.2, 1.4 Hz, 1H, 
C13-H), 3.17 (dh, J = 3.5, 1.7 Hz, 1H, C16-H), 3.06 (dd, J = 8.8, 4.3 Hz, 1H, C4-H), 2.87 (dq, 
J = 6.9, 1.3 Hz, 2H, C12H), 2.82 (ddd, J = 8.8, 3.6, 1.4 Hz, 1H, C5-H), 1.41 (dt, J = 8.5, 1.8 
Hz, 1H, C19-H), 1.35 – 1.28 (m, 1H, C19-H). 13C NMR (101 MHz, Chloroform-d) δ 199.63, 
141.86, 140.74, 135.58, 134.53, 133.48, 117.36, 104.57, 65.49, 64.19, 50.41, 48.91, 47.88, 









10 % (w/v) Na2CO3 (aq.) (3.81 mL) and H2O2 (7.83 mL, non-stabilised, 30 % v/v) were added 
to a solution of 1.57 (1.38 g, 6.4 mmol) in acetone at 0 ºC and stirred for 30 min. Reaction 
monitored by TLC (hexane/EtOAc 3:1). Upon completion, reaction was quenched with 
saturated NH4Cl (aq.) and the organic layer was extracted with DCM (3 × 10 mL). Organic 
fractions combined and dried over anhydrous MgSO4. The mixture was filtered and the crude 
was concentrated under reduced pressure. Product purified by flash chromatography (PET 
ether/EtOAc 9:1) yielding title compound as a brown/ red oil (1.24 g, 83 % yield). Rf = 0.74 
(hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass calc’d for C14H14O3 253.25282 found 
253.0833. 1H NMR (400 MHz, Chloroform-d) δ 6.05 (t, J = 1.8 Hz, 2H, C10-H/C11-H), 5.70 
– 5.55 (m, 1H, C16-H), 5.16 – 5.04 (m, 2H, C17-H), 3.57 – 3.42 (m, 2H, C9-H/C12-H), 3.39 
(s, 1H, C2-H), 3.29 (ddh, J = 4.9, 3.3, 1.5 Hz, 2H, C4-H/C5-H), 2.71 (ddt, J = 15.1, 6.4, 1.4 
Hz, 1H, C8-H), 2.56 (ddt, J = 15.3, 7.5, 1.2 Hz, 1H, C8-H), 1.48 (dt, J = 8.8, 2.0 Hz, 1H, C15-
H), 1.30 (dt, J = 8.6, 1.5 Hz, 1H, C15-H). 13C NMR (101 MHz, Chloroform-d) δ 204.91, 









DBU (165 µL, 20 mol %) and aqueous formaldehyde (2.06 mL, 37 % (w/v)) were added to a 
solution of 1.58 (1.24 g, 5.3 mmol) in anhydrous THF at 0 ºC. Reaction was allowed to proceed 
for 30 min and was monitored by TLC (hexane/EtOAc 3:1). When complete, reaction was 
quenched with saturated NH4Cl (aq.) and organic layer extracted in EtOAc (3 × 10 mL). 
Organic layers were combined, dried over anhydrous MgSO4, filtered and concentrated under 
reduced pressure. Product was purified by silica gel chromatography (PET ether/EtOAc 5:1) 
yielding title compound as a clear oil (1.09 g, 79 %). . Rf = 0.2 (hexane/EtOAc 3:1). MS: m/z 
(+ESI) exact mass calc’d for C15H16O4  [M + Na]
+ 283.0946 found 283.0949. 1H NMR (400 
MHz, Chloroform-d) δ 6.07 (t, J = 1.9 Hz, 2H, CH=CH), 5.71 – 5.55 (m, 1H, C16-H), 5.18 – 
5.04 (m, 2H. C17-H), 4.35 (dd, J = 11.7, 4.5 Hz, 1H, C13-H), 3.81 (dd, J = 11.5, 4.2 Hz, 1H, 
C13-H), 3.46 (s, 1H, C2-H), 3.32 (ddq, J = 13.5, 3.7, 1.8 Hz, 2H, C9-H/C12-H), 2.87 (d, J = 
3.7 Hz, 1H, C5-H), 2.76 – 2.55 (m, 2H, C8-H), 2.06 – 1.91 (m, 1H, CH2OH), 1.53 (dt, J = 9.5, 
1.6 Hz, 1H, C15-H), 1.46 (dt, J = 9.5, 1.8 Hz, 1H, C15-H). 13C NMR (101 MHz, Chloroform-
d) δ 205.24, 204.09, 138.11, 137.97, 129.95, 120.14, 68.27, 67.15, 61.92, 61.62, 53.80, 45.98, 










DIBAL-H (8.08 mL, 9.6 mmol, 1.2 M in toluene) was added dropwise to a solution of 1.59 
(1.09 g, 4.2 mmol) in anhydrous THF at -78 ºC. Reaction stirred for 30 min, after which, 
additional DIBAL-H (2 mL, 2.3 mmol) added. Reaction monitored by TLC (hexane/EtOAc 
2:1). Upon completion, reaction quenched with MeOH (3 mL) and HCl (21.7 mL, 1 M). 
Organic layers extracted with EtOAc (3 × 10 mL), dried over anhyd. MgSO4, filtered and 
concentrated in vacuo. Product purified by flash chromatography (PET ether/ EtOAc 2:1) 
yielding the title compound as a clear solid (470 mg, 43 %). Rf = 0.17 (hexane/EtOAc 2:1). 
[α]D
25 = -44.4 (c 1, CHCl3). MS: m/z (+ESI) exact mass calc’d for C15H18O4 [M + Na]
+ 
285.1103 found 285.1101. 1H NMR (400 MHz, Chloroform-d) δ 6.29 (dd, J = 5.7, 3.0 Hz, 1H, 
C10-H), 6.11 (dd, J = 5.7, 3.2 Hz, 1H, C11-H), 5.71 – 5.56 (m, 1H, C16-H), 5.12 – 5.03 (m, 
2H, C17-H), 4.68 (d, J = 11.5 Hz, 1H, C13-H), 3.97 (s, 1H, C3-H), 3.79 (dd, J = 11.5, 1.1 Hz, 
1H, C13-H), 3.46 (s, 1H, C2-H), 3.31 (dt, J = 2.8, 1.4 Hz, 1H, C9-H), 3.25 – 3.18 (m, 1H, C12-
H), 2.64 (ddt, J = 15.2, 6.6, 1.4 Hz, 1H, C8-H), 2.52 – 2.42 (m, 2H, C5-H/C8-H), 1.58 (dt, J = 
9.3, 1.6 Hz, 1H, C15-H), 1.46 (dt, J = 9.3, 1.8 Hz, 1H, C15-H). 13C NMR (101 MHz, 
Chloroform-d) δ 207.62, 140.20, 136.09, 131.11, 119.18, 73.07, 69.72, 66.41, 63.45, 55.09, 









A solution of 2.27 (571 mg, 1.5 mmol) in diphenyl ether (10 mL) was heated for 4 h at 230 ºC. 
Reaction monitored by TLC (hexane/EtOAc 3:1). Upon completion, the reaction mixture was 
cooled to ambient temperature and product purified by flash chromatography, initially with 
PET ether, followed by PET ether:EtOAc 10:1 yielding the title compound as an off-white 
solid (333 mg, 73 %). Rf = 0.25 (hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass calc’d for 
C16H26O4Si [M + Na]
+ 333.1498 found 333.1493. 1H NMR (400 MHz, Chloroform-d) δ 6.00 
(q, J = 1.7 Hz, 1H, C15-H), 5.73 (dddd, J = 16.9, 10.6, 7.5, 6.5 Hz, 1H, C9-H), 5.19 – 5.09 (m, 
2H, C10-H), 4.65 (ddd, J = 9.1, 3.0, 1.3 Hz, 1H, C3-H), 4.49 – 4.34 (m, 2H, C13-H), 3.74 (d, 
J = 3.0 Hz, 1H, C2-H), 2.84 (ddt, J = 15.1, 7.6, 1.2 Hz, 1H, C8-H), 2.62 – 2.49 (m, 2H, C8-
H/C11-H), 1.61, 0.91 (s, 9H, tBu-H), 0.09 (d, J = 1.5 Hz, 6H, C17-H/C18-H). 13C NMR (101 
MHz, Chloroform-d) δ 193.19, 157.19, 131.32, 120.25, 119.25, 65.98, 63.12, 60.76, 59.17, 









A solution of 1.61 (333 mg, 1.5 mmol) in MeOH (10 mL) was cooled to -78 ºC and ozonloysed 
for 3 min. Dimethylsulphide (2.64 mL) was added and the reaction was allowed to proceed for 
30 min with stirring and gradual warming to ambient temperature. Monitored by TLC 
(hexane/EtOAc 3:1). Upon completion, reaction mixture quenched with H2O and organic phase 
extracted with DCM (3 × 10 mL) and organic layers concentrated under reduced pressure. To 
a solution of the crude aldehyde (280 mg, 0.89 mmol) in DCM (5 mL), a solution of 
Ph3P=C(CH3)CO2t-Bu (567 mg, 1.45 mmol) in DCM (5 mL) was added dropwise at -40 ºC 
with stirring. Reaction allowed to warm to -10 ºC and stirred for 2 h. Monitored by TLC 
(hexane/EtOAc 10:1). When completed, product purified by silica gel chromatography (PET 
ether/EtOAc 10:1) yielding the title compound as a yellow/ brown oil (157 mg, 25 %). Rf = 
0.26 (hexane/EtOAc 10:1); MS: m/z (+ESI) exact mass calc’d for C22H36O6Si [M + Na]
+ 
447.5988 found 447.2182. 1H NMR (400 MHz, Chloroform-d) δ  H-9 6.50 (ddd, J = 8.3, 6.9, 
1.5 Hz, 1H, C9-H), 6.01 (q, J = 1.7 Hz, 1H, C18-H), 4.67 (s, 1H, C3-H), 4.49 – 4.35 (m, 2H, 
C19-H), 3.73 (d, J = 3.0 Hz, 1H, C2-H), 2.95 (dd, J = 15.8, 8.0 Hz, 1H, C8-H),  2.66 (dd, J = 
15.9, 7.0 Hz, 1H, C8-H), 1.84 (d, J = 1.4 Hz, 3H, C14-H), 1.48 (s, 9H, tBu17-H), 0.92 (s, 9H, 
tBu26-H), 0.10 (d, J = 1.4 Hz, 6H, C22-H/C27-H). 13C NMR (101 MHz, Chloroform-d) δ 
192.87, 166.89, 157.30, 132.95, 132.42, 120.15, 80.48, 65.96, 63.17, 60.51, 59.25, 28.10, 









A solution of 1.73 (101 mg, 0.33 mmol) in MeOH (6.6 mL) was ozonolysed at -78 ºC for 3 
min. Dimethylsulphide (0.53 mL) was added and the reaction was allowed to proceed for 30 
min whilst warming to ambient temperature. Monitored by TLC (hexane/EtOAc 3:1). When 
complete, the reaction was quenched with Milli-Q, the organic phase extracted into DCM (3 × 
10 mL) and the crude was concentrated under reduced pressure.  
 
A solution of Ph3P=C(CH3)CO2t-Bu (156 mg, 0.38 mmol) in DCM (1.3 mL) was cooled to -
40 ºC and a solution of the crude aldehyde (77 mg, 0.22 mmol) in DCM (2.3 mL) was added 
dropwise. The reaction was warmed to -10 ºC and allowed to proceed for 2 h with stirring. 
Monitored by TLC (hexane/EtOAc 10:1). When complete, the product was purified by flash 
chromatography (PET ether/EtOAc 10:1) yielding the title compound as a clear oil (53 mg, 36 
%). Rf = 0.3 (hexane/EtOAc 10:1). [α]D
25 = -23.9 (c 0.62, CHCl3). MS: m/z (+ESI) exact mass 
calc’d for C22H36O6Si [M + Na]+ 447.2179 found 447.2173. 
1H NMR (400 MHz, Chloroform-
d) δ 6.53 (ddd, J = 8.3, 7.0, 1.6 Hz, 1H, C9-H), 6.04 (q, J = 1.7 Hz, 1H, C5-H), 4.73 – 4.66 (m, 
1H, C3-H), 4.52 – 4.38 (m, 2H, C19-H), 3.75 (d, J = 3.0 Hz, 1H, C2-H), 2.97 (dd, J = 15.8, 8.0 
Hz, 1H, C8-H), 2.68 (ddd, J = 15.9, 6.9, 1.3 Hz, 1H, C8-H), 2.58 (d, J = 8.9 Hz, 1H, C11-H), 
1.86 (d, J = 1.5 Hz, 3H, C14-H), 1.50 (s, 9H, tBu17-H), 0.94 (s, 9H, tBu24-H), 0.12 (d, J = 1.3 
Hz, 6H, C22-H/C23-H). 13C NMR (101 MHz, Chloroform-d) δ 192.88, 157.32, 132.95, 132.43, 








Triflic acid (9 mL, 0.2 M in dry DCM) was added dropwise over 30 sec to a solution of of (S)-
(-)-o-Tolyl-CBS oxazoborolidine in toluene (4.3 mL, 0.5 M) at -78 ºC. After 15 min, a solution 
of 1.54 (3.26 g, 11.7 mmol) in dry DCM (12 mL) and freshly distilled cyclopentadiene (1.15 
mL) were added. Monitored by TLC (hexane/EtOAc 3:1). Upon completion, reaction quenched 
with 1 mL TEA and warmed to ambient temperature. Crude concentrated in vacuo and product 
purified by silica gel chromatography (PET ether/EtOAc 3:1) yielding the title compound as a 
yellow/ brown oil (2.27 g, 56 %). Rf = 0.5 (hexane/EtOAc 3:1). [α]D
25 = +81.4 (c 1, CHCl3). 
MS: m/z (+ESI) exact mass calc’d for C13H13IO3 [M + Na]
+ 366.9807 found 366.9807. 1H 
NMR (400 MHz, Chloroform-d) δ 7.05 (d, J = 1.2 Hz, 1H, C2-H), 6.08 (dd, J = 5.7, 2.9 Hz, 
1H, C14-H), 5.84 (dd, J = 5.7, 2.8 Hz, 1H, C15-H), 4.16 – 4.07 (m, 1H, OCH2CH2O), 4.07 – 
3.90 (m, 3H, OCH2CH2O), 3.31 (ddd, J = 4.6, 3.0, 1.5 Hz, 1H, C13-H), 3.27 (dd, J = 8.4, 4.2 
Hz, 1H, C4-H), 3.21 (dq, J = 3.5, 1.9 Hz, 1H, C16-H), 2.87 – 2.79 (m, 1H, C5-H), 1.39 (dt, J 
= 8.7, 1.9 Hz, 1H, C19-H), 1.33 (d, J = 8.6 Hz, 1H, C19-H).13C NMR (101 MHz, Chloroform-










Pd(PPh3)4 (564 mg, 7.5 mol%) and allyltributyl tin (4 mL, 13.1 mmol) were added to a solution 
of 1.67 (2.23 g, 6.6 mmol) in degassed THF (10 mL) under nitrogen. The mixture was heated 
to 110 ºC with 150 W microwave radiation for 10 min with stirring. Monitored by TLC 
(hexane/EtOAc 3:1) and upon completion, the reaction mix was cooled to ambient temperature 
and quenched with saturated NH4Cl (aq.). Organic phase extracted with EtOAc (3 × 10 mL). 
Crude concentrated under reduced pressure and product purified by silica gel chromatography 
(PET ether/EtOAc 9:1) yielding the title compound as a brown oil (1.18 g, 69 %). Rf = 0.5 
(hexane/EtOAc 3:1); MS: m/z (+ESI) exact mass calc’d for C16H18O3 [M + Na]
+ 281.1154 
found 281.1156. 1H NMR (400 MHz, Chloroform-d) δ 6.08 – 6.00 (m, 2H, CH=CH), 5.80 (dd, 
J = 5.6, 2.8 Hz, 1H, C2-H), 5.78 – 5.64 (m, 1H, C20-H), 5.06 (ddq, J = 15.4, 3.5, 1.8 Hz, 2H, 
C21-H), 4.16 – 4.04 (m, 1H, OCH2CH2O), 4.04 – 3.91 (m, 3H, OCH2CH2O), 3.31 (dhept, J = 
4.3, 1.4 Hz, 1H, C13-H), 3.17 (dh, J = 3.5, 1.7 Hz, 1H, C16-H), 3.06 (dd, J = 8.8, 4.3 Hz, 1H, 
C5-H), 2.91 – 2.86 (m, 2H, C12-H), 2.86 – 2.78 (m, 1H, C4-H), 1.41 (dt, J = 8.5, 1.8 Hz, 1H, 
C19-H), 1.35 – 1.28 (m, 1H, C19-H). 13C NMR (101 MHz, Chloroform-d) δ 199.63, 141.86, 










10 % Na2CO3 (2.57 mL, aq.) was added to a solution of 2.45 (918 mg, 4.2 mmol) and the 
mixture was stirred at 0 ºC. H2O2 (5.22 mL, non-stab., 30 % (v/v)) was then added dropwise 
and the reaction was allowed to proceed for 30 min at 0 ºC. Monitored by TLC (hexane/EtOAc 
3:1). When complete, reaction quenched with sat. NH4Cl (aq.) and the organic layer extracted 
into DCM (3 × 10 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure. Product purified by silica gel chromatography (PET ether/EtOAc 9:1) yielding the 
title compound as a red/brown oil which (759 mg, 76 %). Rf = 0.50 (hexane/EtOAc 3:1). MS: 
m/z (+ESI) exact mass calc’d for C14H14O3 [M + Na]+ 253.2528 found 253.0828. 
1H NMR 
(400 MHz, Chloroform-d) δ 6.04 (t, J = 1.8 Hz, 2H, CH=CH), 5.62 (dddd, J = 16.5, 10.9, 7.5, 
6.4 Hz, 1H, C16-H), 5.16 – 5.06 (m, 2H, C17-H), 3.51 – 3.40 (m, 2H, C9-H/C12-H), 3.38 (s, 
1H, C2-H), 3.28 (ddp, J = 4.9, 3.3, 1.7 Hz, 2H, C4-H/C5-H), 2.70 (ddt, J = 15.2, 6.5, 1.4 Hz, 
1H, C8-H), 2.55 (ddt, J = 15.3, 7.6, 1.2 Hz, 1H, C8-H), 1.48 (dt, J = 8.8, 1.9 Hz, 1H, C15-H), 
1.29 (dt, J = 8.6, 1.5 Hz, 1H, C15-H). 13C NMR (101 MHz, Chloroform-d) δ 204.90, 204.89, 









DBU (45 µL, 20 mol %) and aqueous formaldehyde (573 µL, 7.44 mmol, 37 % (w/v)) were 
added to a solution of 1.70 (759 mg, 3.2 mmol) in THF (10 mL) at 0 ºC. The mixture was 
stirred for 30 min, after which additional formaldehyde (500 µL, 6.48 mmol, 37 % (w/v)) was 
added. The mixture was stirred for a further 30 min. Monitored by TLC (hexane/EtOAc 3:1). 
When complete, reaction quenched with sat. NH4Cl (aq.), aqueous phase extracted with EtOAc 
(3 × 10 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced pressure. 
Product purified by silica gel chromatography (PET ether/EtOAc 5:1) yielding title compound 
as a white solid (730 mg, 87 %). Rf = 0.2 (hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass 
calc’d for C15H16O4 [M + Na]+ 283.0946 found 283.0947. 
1H NMR (400 MHz, Chloroform-
d) δ 6.07 (t, J = 1.8 Hz, 2H, CH=CH), 5.62 (dddd, J = 16.9, 10.4, 7.4, 6.5 Hz, 1H, C16-H), 5.14 
(dp, J = 5.2, 1.7 Hz, 1H, C17-H), H-17 5.12 – 5.04 (m, 1H, C17-H), 4.39 – 4.28 (m, 1H, C13-
H), 3.82 (dd, J = 11.5, 4.6 Hz, 1H, C13-H), 3.45 (d, J = 5.3 Hz, 1H, C2-H), 3.31 (ddq, J = 11.9, 
3.6, 1.8 Hz, 2H, C9-H/C12-H), 2.87 (d, J = 3.7 Hz, 1H, C5-H), 2.74 – 2.55 (m, 2H, C8-H), 
1.52 (dt, J = 9.4, 1.6 Hz, 1H, C15-H), 1.45 (dt, J = 9.5, 1.8 Hz, 1H, C15-H). 13C NMR (101 
MHz, Chloroform-d) δ 205.25, 204.12, 138.10, 137.98, 129.95, 120.13, 68.25, 67.16, 61.92, 










DIBAL-H (5.38 mL, 6.4 mmol, 1.2 M in toluene) was added dropwise to a solution of 1.71 
(730 mg, 2.8 mmol) in dry THF at -78 ºC. Reaction was stirred for 30 min at -78 ºC. After 30 
min, additional DIBAL-H (2 mL, 2.3 mmol) was added. Monitored by TLC (hexane/EtOAc 
2:1). When complete, quenched with MeOH (3 mL) and HCl (14.45 mL, 1 M), organic phase 
extracted with EtOAc (3 × 10 mL), dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure. Product purified by silica gel chromatography (PET ether/ EtOAc 2:1) 
yielding the title compound as a clear solid (429 mg, 57 %). = 0.2 (hexane/EtOAc 2:1). [α]D
25 
= 43.9 (c 59, CHCl3). MS: m/z (+ESI) exact mass calc’d for C15H18O4 [M + Na]+ 285.1103 
found 285.1104. 1H NMR (400 MHz, Chloroform-d) δ 6.30 (dd, J = 5.8, 2.9 Hz, 1H, C11-H), 
6.12 (dd, J = 5.7, 3.2 Hz, 1H, C10-H), 5.65 (ddt, J = 18.0, 9.3, 7.0 Hz, 1H, C16-H), 5.13 – 5.04 
(m, 2H, C17-H), 4.65 (d, J = 11.5 Hz, 1H, C13-H), 4.06 (s, 1H, 20 OH), 3.97 (s, 1H, C3-H), 
3.83 (d, J = 11.5 Hz, 1H, C13-H), 3.47 (s, 1H, C2-H), 3.30 (s, 1H, C9-H), 3.24 (d, J = 4.5 Hz, 
1H. C12-H), 2.93 (s, 1H, C13-H), 2.65 (dd, J = 15.1, 6.5 Hz, 1H, C8H), 2.55 – 2.43 (m, 2H, 
C8-H/C5-H), 1.58 (d, J = 9.2 Hz, 1H, C15-H), 1.47 (dt, J = 9.2, 1.9 Hz, 1H, C15-H). 13C NMR 
(101 MHz, Chloroform-d) δ 207.41, 140.25, 136.10, 131.12, 119.18, 73.12, 70.00, 66.47, 









A solution of 2.46 (591 mg, 1.56 mmol) in diphenyl ether (10 mL) was heated for 4 h at 230 
ºC with stirring. Monitored by TLC (hexane/EtOAc 3:1). When complete, reaction allowed to 
cool and product purified by silica gel chromatography- initially with PET ether followed by 
PET ether:EtOAc 10:1 yielding the title compound as an off-white solid (206 mg, 38 %). Rf = 
0.2 (hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass calc'd for C16H26O4Si [M + Na]+ 333.1498 
found 333.1493. 1H NMR (400 MHz, Chloroform-d) δ 6.00 (q, J = 1.7 Hz, 1H, C5-H), 5.73 
(dddd, J = 17.0, 10.6, 7.6, 6.5 Hz, 1H, C9-H), 5.19 – 5.09 (m, 2H, C10-H), 4.65 (ddd, J = 9.0, 
3.0, 1.4 Hz, 1H, C3-H), 4.49 – 4.42 (m, 1H, C13-H), 4.42 – 4.35 (m, 1H, C13-H), 3.74 (d, J = 
3.1 Hz, 1H, C2-H), 2.84 (ddt, J = 15.0, 7.6, 1.2 Hz, 1H, C8-H), 2.60 – 2.47 (m, 2H. C8-H/C11-
H), 0.91 (s, 9H, C-tBu-H), 0.09 (d, J = 1.5 Hz, 6H, C17-H/C18-H). 13C NMR (101 MHz, 
Chloroform-d) δ 192.99, 156.96, 131.14, 120.10, 119.07, 65.81, 62.96, 60.58, 58.98, 31.90, 




7.2.16. (TBAF route) tert-butyl (E)-4-((1R,5R,6R)-5-hydroxy-4-(hydroxymethyl)-2-oxo-
7-oxabicyclo[4.1.0]hept-3-en-1-yl)-2-methylbut-2-enoate (Compound 1.74) 
 
  
TBAF (800 µL, 0.8 mmol, 1 M in THF) was added to a solution of 1.62 (157 mg, 0.37 mmol) 
in dry THF (5 mL) at 0 ºC and the mixture stirred for 4 h. Monitored by TLC (hexane/EtOAc 
1:1). Upon completion, the mixture was quenched with saturated NH4Cl (aq.), organic layer 
extracted with EtOAc (3 × 10 mL), dried over MgSO4, filtered and concentrated in vacuo. 
Product purified by silica gel chromatography (PET ether/ EtOAc 1:1) yielding the tile 
compound as a brown oil (41 mg, 40 %). Rf = 0.15 (hexane/EtOAc 1:1). MS: m/z (+ESI) exact 
mass calc’d for C16H22O6 [M + Na]
+ 333.1314 found 333.1316. 1H NMR (400 MHz, 
Chloroform-d) δ 6.49 (tt, J = 6.9, 1.5 Hz, 1H, C9-H), 5.99 (q, J = 1.5 Hz, 1H, C5-H), 4.73 (d, 
J = 5.3 Hz, 1H, C3-H), 4.42 (s, 2H, C19-H), 3.74 (d, J = 2.9 Hz, 1H, C2-H), 3.10 (s, 1H, C11-
H), 2.98 – 2.86 (m, 1H, C8-H), 2.67 (ddd, J = 16.0, 7.0, 1.3 Hz, 1H, C8-H), 2.54 (s, 1H, C20-
H), 1.83 (d, J = 1.5 Hz, 3H, C14-H), 1.47 (s, 9H, tBu17-H). 13C NMR (101 MHz, Chloroform-





7.2.17. (AcOH route) tert-butyl (E)-4-((1R,5R,6R)-5-hydroxy-4-(hydroxymethyl)-2-oxo-




1.62 (393 mg/ 0.92 mmol) was dissolved in diethyl ether (2 mL) and cooled to 0 ºC. Once 
cooled, 4mL of acetic acid and 2 mL of Milli-Q were added and the reaction was stirred 
overnight with gradual warming to ambient temperature. The reaction was monitored by TLC 
(hexane/EtOAc 1:1). Upon completion, the reaction mixture was concentrated under reduced 
pressure yielding the title compound as a yellow oil (157 mg/ 54 %). Rf = 0.16 (hexane/ EtOAc 
1:1). MS: m/z (+ESI) exact mass calc’d for C16H22O6 [M + Na]
+ 333.1309 found 333.1312. 1H 
NMR (400 MHz, Chloroform-d) δ 6.47 (ddd, J = 8.1, 6.8, 1.6 Hz, 1H, C9-H), 5.97 (d, J = 1.6 
Hz, 1H, C5-H), 4.71 (s, 1H, C3-H), 4.38 (s, 2H, C19-H), 3.73 (d, J = 2.8 Hz, 1H, C2-H), 2.87 
(dd, J = 15.9, 7.9 Hz, 1H, C8-H), 2.71 – 2.60 (m, 1H, C8-H), 1.81 (d, J = 1.4 Hz, 3H, C14-), 
1.46 (s, 9H, t-butyl H). 13C NMR (101 MHz, Chloroform-d) δ 193.36, 167.37, 157.98, 132.83, 





dioxobicyclo[4.1.0]hept-3-en-1-yl)-2-methylbut-2-enoate (Compound 1.75) 
 
 
   
A solution of 1.81 (29 mg, 0.22 mmol) in MeOH (5 mL) was ozonolysed for 4 min at – 78 ºC 
with stirring. Dimethyl sulphide (414 µL) was added and the reaction was allowed to proceed 
for 30 min at r.t.. Monitored by TLC (hexane/EtOAc 3:1). When complete, reaction was 
quenched with Milli-Q and the organic layer was extracted with DCM (3 × 5 mL), dried over 
anhyd. MgSO4, filtered and concentrated in vacuo. 
 
A solution of Ph3P=C(CH3)CO2t-Bu (9 mg) in dry DCM (5 mL) was cooled to -40 ºC and a 
solution of the crude aldehyde in dry DCM (5 mL) was added dropwise with stirring. The 
reaction was allowed to proceed for 2 h with gradual warming to -10 ºC. Monitored by TLC 
(hexane/EtOAc 10:1). Purified by preparatory TLC (hexane/EtOAc 3:1) yielding the title 
compound as a clear oil (37 mg, 0.088 mmol, 40 %). Rf = 0.52 (hexane/EtOAc 3:1). MS: m/z 
(+ESI) exact mass calc’d for C23H36O5Si [M + Na]
+ 443.2224, found 443.2233. 1H NMR (400 
MHz, Chloroform-d) δ 6.59 – 6.47 (m, 2H, C5-H, C13-H), 4.54 (dd, J = 18.5, 2.5 Hz, 1H, C10-
H), 4.30 (dd, J = 18.5, 2.1 Hz, 1H, C10-H), 2.97 – 2.82 (m, 1H, C12-H), 2.47 – 2.31 (m, 2H 
C12-H/ C9-), 1.83 (d, J = 1.4 Hz, 3H C16-H), 1.76 (t, J = 5.0 Hz, 1H C2-H), 1.55 (dd, J = 8.9, 
4.9 Hz, 1H C9-H), 1.47 (s, 9H COOt-Bu H), 0.91 (s, 9H t-Bu), 0.11 – 0.06 (m, 6H C24-H/ 
C25-H). 13C NMR (101 MHz, Chloroform-d) δ 195.46, 195.32, 148.31, 134.90, 132.15, 









H2SO4 (8.08 mL, 1 N) and acetone (8.08 mL) were added to a solution of 1.57 (1.78 g, 6.8 
mmol) in dry THF (5 mL) and the mixture was stirred for 30 min at ambient temperature. 
Reaction monitored by TLC (hexane/EtOAc 3:1). When complete, the organic phase was 
extracted with DCM (3 × 10 mL) and dried over anhydrous MgSO4, filtered and concentrated 
under reduced pressure yielding title compound as a brown/ red waxy solid (1.38 g, 96%) which 
was used in the next step without further purification. Rf = 0.5 (hexane/EtOAc 3:1). MS: m/z 
(+ESI) exact mass calc’d for C14H14O3 237.0891 found 237.0881. 
1H NMR (400 MHz, 
Chloroform-d) δ 6.45 (t, J = 1.5 Hz, 1H, C2-H), 6.05 (ddd, J = 18.0, 5.7, 2.8 Hz, 2H, CH=CH), 
5.74 (ddt, J = 17.0, 10.1, 6.8 Hz, 1H, C16-H), 5.26 – 4.97 (m, 2H, C17-H), 3.54 (dh, J = 4.5, 
1.4 Hz, 2H, C9-H/C12-H), 3.23 (t, J = 2.6 Hz, 2H, C8-H), 3.06 (dq, J = 6.9, 1.4 Hz, 2H, C4-
H/C5-H), 1.49 (ddt, J = 40.3, 8.7, 1.7 Hz, 2H, C15-H). 13C NMR (101 MHz, Chloroform-d) δ 










n-BuLi (520 µL, 1.3 mmol) was added dropwise to a stirring suspension of 
trimethylsulphoxonium iodide (568 mg, 2.6 mmol) in dry THF (10 mL) at – 76 ºC and stirred 
for 1 h. After 1 h, a solution of 1.76 (271 mg, 1.3 mmol) in dry THF (10 mL) was added and 
the reaction was stirred for 1 h whilst warming to ambient temperature. Monitored by TLC 
(hexane/EtOAc 3:1). Upon completion, reaction quenched with Milli-Q, organic phase 
extracted with DCM (3 × 20 mL), dried over anhyd. MgSO4, filtered and concentrated under 
reduced pressure. Product purified by silica gel chromatography (PET ether/EtOAc 3:1) 
yielding the title compound as a brown oil (133mg, 45 %). Rf = 0.3 (hexane/EtOAc 3:1). ). MS: 
m/z (+ESI) calc’d for C15H16O2 [M + Na]
+ 251.1043  found 251.1039. 1H NMR (500 MHz, 
Chloroform-d) δ 6.07 (qd, J = 5.6, 2.7 Hz, 2H, C8-H/ C9-H), 5.64 (ddt, J = 17.1, 10.2, 6.8 Hz, 
1H, C14-H), 5.05 – 4.94 (m, 2H, C15-H), 3.42 – 3.32 (m, 2H, C7-H/ C10-H), 3.23 – 3.12 (m, 
2H, C4H/ C5-H), 2.33 (qdt, J = 14.9, 6.8, 1.3 Hz, 2H, C13-H), 2.07 (dd, J = 8.4, 5.6 Hz, 1H, 
C17-H), 2.01 (t, J = 5.6 Hz, 1H, C17-H), 1.57 (dd, J = 8.4, 5.6 Hz, 1H, C2-H), 1.43 (dt, J = 
8.8, 1.9 Hz, 1H, C11-H), 1.24 (dt, J = 8.8, 1.5 Hz, 1H, C11-H).13C NMR (126 MHz, 
Chloroform-d) δ 205.91, 205.77, 136.87, 136.74, 133.37, 117.99, 49.59, 49.08, 46.64, 44.88, 










DBU (15 µL, 20 mol%) and aqueous formaldehyde (190 µL, 2.5 mmol, 37 % (w/v)) were 
added to a solution of 1.78 (122 mg, 0.5 mmol) in dry THF (5 mL) at 0 ºC. The reaction was 
stirred for 2 h with gradual warming to ambient temperature. After 2 h, additional 
formaldehyde (190 µL, 2.5 mmol) was added and the reaction was stirred for a further 14 h at 
ambient temperature. Monitored by TLC (hexane/EtOAc 1:1). When complete, reaction 
quenched with sat. NH4Cl (aq.), aqueous phase extracted with EtOAc (3 × 10 mL), organic 
layers combined, dried over anhyd. MgSO4, filtered and concentrated under reduced pressure. 
Product purified by silica gel chromatography (PET ether/EtOAc 1:1) yielding the title 
compound as a light yellow oil (82 mg, 62 %). Rf = 0.17 (hexane/EtOAc 1:1). MS: m/z (+ESI) 
exact mass calc’d for C16H18O3 [M + Na]
+ 281.1148 found 281.1147. 1H NMR (400 MHz, 
Chloroform-d) δ 6.19 – 6.10 (m, 1H, C8-H), 6.08 (dd, J = 5.7, 2.8 Hz, 1H, C9-H), 5.61 (ddt, J 
= 17.2, 10.6, 6.9 Hz, 1H, C14-H), 5.11 – 4.95 (m, 2H, C15-H), 3.98 – 3.85 (m, 1H, C18-H), 
3.74 (d, J = 10.8 Hz, 1H, C18-H), 3.50 (p, J = 2.1 Hz, 1H, C10-H), 3.26 (s, 1H, C7-H), 2.79 – 
2.67 (m, 2H, C5-H, C13-H), 2.27 (q, J = 5.6 Hz, 1H, C17-H), 2.13 – 2.03 (m, 1H, C17-H), 1.93 
(dd, J = 14.7, 6.9 Hz, 1H, C13-H), 1.51 – 1.28 (m, 3H, C2-H/ C11-H). 13C NMR (101 MHz, 
Chloroform-d) δ 209.41, 206.14, 138.57, 136.98, 133.61, 118.09, 70.19, 59.59, 52.17, 50.88, 










Imidazole (51 mg, 0.75 mmol) was added to a solution of 1.79 (30 mg, 0.16 mmol) in dry DMF 
(5 mL). Mixture was stirred at r.t. for 30 min, before cooling to 0 ºC and addition of TBSCl 
(60 mg, 0.34 mmol). Stirred overnight with gradual warming to r.t.. Additional TBSCl (60 mg, 
0.34 mmol) was added. Reaction progress monitored by TLC (hexane/EtOAc 9:1). Upon 
completion, reaction quenched with Milli-Q and organic layers extracted into hexane (3 × 10 
mL). Organic layers were combined, dried over anhyd. MgSO4, filtered and concentrated in 
vacuo. Product purified by silica gel chromatography (PET ether/EtOAc 15:1) yielding the title 
compound as a white solid (25 mg, 38 %). Rf = 0.54 (hexane/EtOAc 9:1). MS: m/z (+ESI) exact 
mass calc’d for C22H32O3Si [M + Na]
+ 395.2013 found 395.2021. 1H NMR (400 MHz, 
Chloroform-d) δ 6.17 – 6.09 (m, 1H, C8-H), 6.09 – 6.00 (m, 1H, C9-H), 5.60 (ddt, J = 18.2, 
9.3, 7.0 Hz, 1H, C25-H), 5.04 – 4.95 (m, 2H, C26-H), 4.13 – 4.01 (m, 1H, C14-H), 3.53 – 3.42 
(m, 2H, C10-H/ C14-H), 3.02 (q, J = 2.0 Hz, 1H, C7-H), 2.98 – 2.89 (m, 1H, C5-H), 2.84 – 
2.65 (m, 1H, C24-H), 2.60 (t, J = 5.3 Hz, 1H, C23-H), 2.03 (dd, J = 9.0, 5.5 Hz, 1H, C23-H), 
1.87 (ddt, J = 14.7, 7.0, 1.3 Hz, 1H, C24-H), 1.51 – 1.38 (m, 1H, C11-H), 1.34 (t, J = 1.7 Hz, 
1H, C11-H), 1.33 – 1.20 (m, 1H, C2-H, under EtOAc peak), 0.88 (s, 9H, t-Bu), 0.06 (d, J = 
10.3 Hz, 6H, C17-H/ C19-H). 13C NMR (101 MHz, Chloroform-d) δ 209.11, 206.96, 138.38, 
136.90, 133.86, 117.89, 71.86, 60.03, 51.68, 51.57, 49.13, 45.51, 39.89, 36.33, 35.67, 26.06, 
18.52, 16.16, -5.40, -5.48.  
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7.2.23. (Ph2O route) 1-allyl-4-(((tert-butyldimethylsilyl)oxy)methyl)bicyclo[4.1.0]hept-3-
ene-2,5-dione (Compound 1.81) 
 
 
(25 mg, 0.06 mmol) of 1.80 was dissolved in Ph2O (5 mL) and heated to 140 ºC with 250 W 
microwave radiation with stirring for 15 min under an argon atmosphere. Reaction monitored 
by TLC (hexane/EtOAc 8:2). Upon completion, reaction mixture allowed to cool to ambient 
temperature and product purified by silica gel chromatography, initially with neat hexane 
followed by Hexane/EtOAc 8:2 yielding title compound as a clear oil (5 mg, 26 %). Rf = 0.82 
(hexane/EtOAc 8:2). MS: m/z (+ESI) exact mass calc’d for C17H26O3Si [M + Na]
+ 329.1543 
found 329.1555. 1H NMR (400 MHz, Chloroform-d) δ 6.58 – 6.48 (m, 1H, C5-H), 5.75 (ddt, 
J = 17.2, 10.6, 6.9 Hz, 1H, C20-H), 5.12 – 5.02 (m, 2H, C21-H), 4.60 – 4.49 (m, 1H, C9-H), 
4.37 – 4.22 (m, 1H, C9-H), 2.90 – 2.78 (m, 1H, C19-H), 2.40 (ddd, J = 8.8, 7.1, 5.1 Hz, 1H, 
C2-H), 2.28 – 2.18 (m, 1H, C19-H), 1.73 (t, J = 5.0 Hz, 1H, C18-H), 1.56 – 1.49 (m, 5H, C18-
H under water peak), 0.90 (d, J = 8.8 Hz, 9H, t-Bu), 0.11 – 0.01 (m, 6H, C13-H/ C14-H). 13C 
NMR (101 MHz, Chloroform-d) δ 196.01, 195.78, 148.35, 133.45, 132.21, 131.49, 129.45, 




7.2.24. (MeCN route) 1-allyl-4-(((tert-butyldimethylsilyl)oxy)methyl)bicyclo[4.1.0]hept-
3-ene-2,5-dione (Compound 1.81) 
 
 
A solution of 1.80 (12 mg, 0.032 mmol) was dissolved in MeCN (1 mL) and heated to 140 ºC 
with stirring with 200 W for 30 min. Reaction was monitored by TLC (hexane/EtOAc 4:1). 
When complete, the reaction mixture was filtered through a silica plug and washed through 
with diethyl ether. Filtrate was concentrated in vacuo yielding the title compound as a brown 
oil (9 mg, 0.029 mmol, 91 %). Rf= 0.56 (hexane/EtOAc 4:1). MS: m/z (+ESI) exact mass calc’d 
for C17H26O3Si [M + Na]
+  329.1543 found 329.1558. 1H NMR (400 MHz, Chloroform-d) δ 
6.58 – 6.48 (m, 1H, C5-H), 5.75 (ddt, J = 17.2, 10.6, 6.9 Hz, 1H, C20-H), 5.12 – 5.02 (m, 2H, 
C21-H), 4.60 – 4.49 (m, 1H, C9-H), 4.37 – 4.22 (m, 1H, C9-H), 2.90 – 2.78 (m, 1H, C19-H), 
2.40 (ddd, J = 8.8, 7.1, 5.1 Hz, 1H, C2-H), 2.28 – 2.18 (m, 1H, C19-H), 1.73 (t, J = 5.0 Hz, 1H, 
C18-H), 1.56 – 1.49 (m, 5H, C18-H under water peak), 0.90 (d, J = 8.8 Hz, 9H, t-Bu), 0.11 – 
0.01 (m, 6H, C13-H/ C14-H). 13C NMR (101 MHz, Chloroform-d) δ 196.01, 195.78, 148.35, 
133.45, 132.21, 131.49, 129.45, 118.46, 59.40, 36.72, 34.58, 32.86, 26.62, 25.97, 25.80, 18.42, 









Imidazole (606 mg, 8.9 mmol) was added to a solution of 1.60 (470 mg, 1.8 mmol) in dry DMF 
(9 mL). After 30 min of stirring, the mixture was cooled to 0 ºC and TBSCl (678 mg, 4.4 mmol) 
was added. The reaction was allowed to proceed for 4 h and progress was monitored by TLC 
(hexane/EtOAc 9:1). Upon completion, reaction was quenched with dH2O and the aqueous 
phase was extracted with hexane (3 × 5 mL). Organic layers combined, dried with MgSO4, 
filtered and concentrated under educed pressure. Product purified by silica gel chromatography 
(PET ether/EtOAc 15:1) yielding the title compound as a clear oil (571 mg, 83 %). Rf = 0.5 
(hexane/EtOAc 9:1); MS: m/z (+ESI) exact mass calc’d for C21H32O4Si [M + Na]
+ 399.1968 
found 399.1962. 1H NMR (400 MHz, Chloroform-d) δ 6.26 (dd, J = 5.7, 2.9 Hz, 1H, C11-H), 
6.13 (dd, J = 5.7, 3.2 Hz, 1H, C10-H), 5.73 – 5.58 (m, 1H, C16-H), 5.42 (d, J = 5.8 Hz, 1H, 
C3-H), 5.14 – 5.04 (m, 2H, C17-H), 4.89 (d, J = 10.6 Hz, 1H, C2-H), 3.90 (dd, J = 5.7, 1.4 Hz, 
1H, C13-H), 3.73 (dd, J = 10.5, 1.4 Hz, 1H, C13-H), 3.53 (s, 1H, C18-H), 3.34 (d, J = 2.9 Hz, 
1H, C12-H), 3.19 (dp, J = 5.1, 1.8 Hz, 1H, C9-H), 2.67 (ddt, J = 15.1, 6.6, 1.4 Hz, 1H, C8-H), 
2.44 (ddt, J = 15.1, 7.5, 1.2 Hz, 1H, C8-H), 2.31 (d, J = 3.5 Hz, 1H, C14-H), 1.53 (dt, J = 9.2, 
1.6 Hz, 1H, C15-H), 1.47 (dt, J = 9.2, 1.8 Hz, 1H, C15-H), 0.94 (s, 9H, tBu-H), 0.13 (d, J = 7.6 
Hz, 6H, C22-H/C23-H). 13C NMR (101 MHz, Chloroform-d) δ 207.89, 139.44, 136.37, 131.28, 










A solution of (diacetoxyiodo)benzene (16 g, 49.7 mmol) in dry MeOH (80 mL) was added 
dropwise over 2 h to a solution of 2-iodophenol (5.90 g, 26.8 mmol) in dry MeOH (43.7 mL) 
at 0 ºC with stirring under nitrogen. The reaction was monitored by TLC (hexane/EtOAc 8:2). 
Upon completion, the reaction mixture was filtered over a silica gel pad and concentrated under 
reduced pressure. The product purified by silica gel chromatography (PET ether/EtOAc 9:1) 
yielding the title compound as a brown/red oil (4.15 g, 55 %). Rf = 0.38 (hexane/EtOAc 8:2).  
MS: m/z (+ESI) exact mass calc’d for C8H9IO3 [M + Na]+ 302.9489 found 302.9491. 
1H NMR 
(400 MHz, Chloroform-d) δ 7.61 (d, J = 3.0 Hz, 1H, C3-H), 6.88 (dd, J = 10.3, 3.0 Hz, 1H, 
C6-H), 6.41 (d, J = 10.3 Hz, 1H, C5-H), 3.39 (s, 6H, (OCH3)2). 
13C NMR (101 MHz, 









A solution of (diacetoxyiodo)benzene (14.9 g/ 46.3 mmol) in dry MeOH (80 mL) was added 
dropwise over 2 h to a stirring solution of  2-bromophenol (3 mL/ 25 mmol) in dry MeOH (40 
mL) at 0 ºC over the course of 2 h under nitrogen. The reaction was monitored by TLC (hexane/ 
EtOAc 8:2). Upon completion, the reaction mixture was filtered through a silica gel pad and 
the reaction mixture was concentrated under reduced pressure. The product was purified by 
silica gel chromatography (PET ether/ EtOAc 9:1) yielding the title compound as a brown oil 
(2.72 g/ 46 %). Rf = 0.46 (hexane/ EtOAc 8:2). MS: m/z (+ESI) exact mass calc’d for C8H9BrO3 
 [M + Na]+ 254.9627 found 254.9629. 1H NMR (400 MHz, Chloroform-d) δ 7.34 – 7.15 (m, 
1H, C3-H), 6.85 (dd, J = 10.3, 3.0 Hz, 1H, C6-H), 6.39 (d, J = 10.3 Hz, 1H, C5-H), 3.39 (s, 













Anhydrous DME (35 mL) was added dropwise to 2.36 (2.72 g/ 11.6 mmol) at   -78 ºC. To the 
solution, BF3Et2O (1.45 mL/ 11.7 mmol) was added dropwise, followed by subsequent addition 
of ethylene glycol (3.2 mL/ 57 mmol). The reaction was stirred for 2 h with gradual raising to 
ambient temperature. The reaction was monitored by TLC (hexane/ EtOAc 3:1). When 
complete, the reaction was quenched with saturated NH4Cl (aq.) and the organic layer was 
extracted into DCM (3 × 20 mL) and dried over anhydrous MgSO4. The mixture was filtered 
and the crude mixture was concentrated under reduced pressure. The product was purified by 
silica gel chromatography (PET ether/ EtOAc 3:1) yielding the title compound as a red/ yellow 
powder (1.9 g/ 71 %). Rf = 0.35 (hexane/ EtOAc 3:1). MS: m/z (+ESI) exact mass calc’d for 
C8H7BrO3 [M + Na]+ 252.9471 found 252.9472. 
1H NMR (400 MHz, Chloroform-d) δ 7.06 
(d, J = 2.9 Hz, 1H, C6-H), 6.64 (dd, J = 10.0, 2.8 Hz, 1H, C9-H), 6.29 (d, J = 10.0 Hz, 1H, 
C10-H), 4.15 (s, 4H, C2/3-H). 13C NMR (101 MHz, Chloroform-d) δ 177.94, 143.88, 143.76, 









Triflic acid (14.1 mL, 0.2 M) in dry DCM was added dropwise to a solution of (R)-(+)-o-tolyl-
CBS oxazaborolidene in toluene (6.72 mL mL, 0.5 M) at -78 ºC and stirred for 15 minutes. A 
solution of 2.37 (4.26 g, 18.4 mmol) in dry DCM (26 mL) and freshly distilled cyclopentadiene 
(1.8 mL) were added dropwise to the stirring solution. Reaction monitored by TLC 
(hexane/EtOAc 3:1). Upon completion, reaction quenched with TEA (1 mL). Crude mixture 
was concentrated under reduced pressure. Product purified by silica gel chromatography (PET 
ether/ EtOAc 3:1) yielding the title compound as a yellow/ brown oil (4.02 g, 13.5 mmol 73 
%). Rf = 0.5 (hexane/EtOAc 3:1). [α]D
25 = 0.0 (c 1, CHCl3). MS: m/z (+ESI) exact mass calc’d 
for C13H13Br1O3 [M + Na]+ 318.9940, found 318.9950. 
1H NMR (400 MHz, Chloroform-d) δ 
6.75 (d, J = 1.3 Hz, 1H, C2-H), 6.08 (dd, J = 5.6, 2.9 Hz, 1H, C15-H), 5.87 (dd, J = 5.6, 2.8 
Hz, 1H, C14-H), 4.18 – 4.06 (m, 1H, C10/11-H), 4.06 – 3.90 (m, 3H, C10/11-H), 3.44 – 3.29 
(m, 1H, C5-H), 3.26 – 3.11 (m, 2H, C13/16-H), 2.96 – 2.78 (m, 1H, C4-H), 1.42 (dt, J = 8.7, 
1.8 Hz, 1H, C19-H), 1.32 (dt, J = 8.6, 1.5 Hz, 1H, C19-H). 13C NMR (101 MHz, Chloroform-





7.2.30. (Bromine route) 7'-allyl-1',4',4a',8a'-tetrahydro-8'H-spiro[[1,3]dioxolane-2,5'-




Pd(PPh3)4 (1.15 g, 7.5 mol%) and allyltributyl tin (8.2 mL, 26.7 mmol) were added to a solution 
of 2.38 (4.02 g, 13.5 mmol) in degassed THF (20 mL) under nitrogen. The reaction mixture 
was heated to 110 ºC with microwave radiation (150 W) and stirred for 20 min. The reaction 
monitored by TLC (hex/EtOAc 3:1). Upon completion, the reaction was cooled to ambient 
temperature and quenched with sat. NH4Cl (aq.). Organic layer extracted with EtOAc (3 × 10 
mL). Crude mix concentrated under reduced pressure. Product was purified by silica gel 
chromatography (PET ether/EtOAc 9:1) yielding the title compound as a brown oil (2.62 g, 
10.1 mmol, 75%). Rf = 0.5 (hexane/EtOAc 3:1). MS: m/z (+ESI) exact mass calc’d for 
C16H118O3 [M + Na]+ 281.1148, found 381.1152. 
1H NMR (400 MHz, Chloroform-d) δ 6.07 
– 5.98 (m, 2H, C2-H, C15-H), 5.79 (dd, J = 5.6, 2.9 Hz, 1H, C14-H), 5.77 – 5.61 (m, 1H, C20-
H), 5.11 – 5.05 (m, 1H, C21-H), 5.05 – 4.96 (m, 1H, C21-H), 4.13 – 4.05 (m, 1H, C10/11-H), 
4.05 – 3.90 (m, 3H, C10/11-H), 3.29 (dtt, J = 4.2, 2.6, 1.3 Hz, 1H, C13-H), 3.15 (dh, J = 3.4, 
1.7 Hz, 1H, C16-H), 3.05 (dd, J = 8.8, 4.3 Hz, 1H, C4-H), 2.86 (dq, J = 6.9, 1.4 Hz, 2H, C12-
H), 2.81 (ddd, J = 8.8, 3.7, 1.4 Hz, 1H, C5-H), 1.43 – 1.22 (m, 2H, C19-H).13C NMR (101 
MHz, Chloroform-d) δ 199.76, 141.92, 140.89, 135.68, 134.61, 133.55, 117.44, 104.64, 65.58, 










Acetone (5.46 mL) and H2SO4 (5.46 mL, 1 N) were added to a solution of 1.69 (1.18 g, 4.6 
mmol) in THF (5 mL) and the mixture was stirred for 30 min at ambient temperature. 
Monitored by TLC (hexane/EtOAc 3:1). When complete, organic layer was extracted into 
DCM (3 × 10 mL), dried over anhydrous MgSO4, filtered and concentrated under reduced 
pressure, yielding the title compound as a red/orange waxy solid (918 mg, 91 %) which was 
taken forward without further purification. Rf = 0.46 (hexane/EtOAc 3:1). MS: m/z (+ESI) 
exact mass calc’d for C14H14O2 [M + Na]+ 237.0891 found 237.0876.
1H NMR (400 MHz, 
Chloroform-d) δ 6.45 (t, J = 1.4 Hz, 1H, C2-H), 6.10 – 6.00 (m, 2H, C17-H), 5.77 – 5.69 (m, 
1H, C16-H), 5.20 – 5.07 (m, 2H, CH=CH), 3.55 (ddt, J = 5.6, 2.7, 1.4 Hz, 2H, C9-H/C12-H), 
3.24 (t, J = 2.6 Hz, 2H, C4-H/C5-H), 3.07 (dq, J = 6.8, 1.3 Hz, 2H, C8-H), 1.58 – 1.42 (m, 2H, 
C15-H).13C NMR (101 MHz, Chloroform-d) δ 199.27, 198.87, 153.39, 139.15, 135.47, 135.01, 








Imidazole (190 mg, 2.78 mmol) was added to a solution of 1.72 (148 mg, 0.56 mmol) in dry 
DMF (2.8 mL) and the mixture was stirred at ambient temperature for 30 min. The mixture 
was then cooled to 0 ºC and TBDMSCl (210 mg, 1.38 mmol) was added and the reaction was 
stirred for 4 h at 0 ºC. Monitored by TLC (hexane/EtOAc 9:1). When complete, reaction 
quenched with Milli-Q, organic phase extracted with hexane (3 × 5 mL), dried over anhyd. 
MgSO4, filtered and concentrated under reduced pressure. Product purified by silica gel 
chromatography (PET ether/EtOAc 15:1) yielding the title compound as a clear oil (165 mg, 
79 %). Rf = 0.4 (hexane/EtOAc 9:1). MS: m/z (+ESI) exact mass calc’d for C21H32O4Si [M + 
Na]+ 399.1968 found 399.1962. 1H NMR (400 MHz, Chloroform-d) δ 6.26 (dd, J = 5.7, 2.9 
Hz, 1H, C9-H), 6.13 (dd, J = 5.7, 3.2 Hz, 1H, C8-H), 5.73 – 5.58 (m, 1H, C15-H), 5.42 (d, J = 
5.8 Hz, 1H, C3-H), 5.14 – 5.04 (m, 2H, C16-H), 4.89 (d, J = 10.6 Hz, 1H, C2-H), 3.90 (dd, J 
= 5.7, 1.4 Hz, 1H, C17-H), 3.73 (dd, J = 10.5, 1.4 Hz, 1H, C17-H), 3.53 (s, 1H, OH), 3.34 (d, 
J = 2.9 Hz, 1H, C10-H), 3.19 (dp, J = 5.1, 1.8 Hz, 1H, C7-H), 2.67 (ddt, J = 15.1, 6.6, 1.4 Hz, 
1H, C14-H), 2.44 (ddt, J = 15.1, 7.5, 1.2 Hz, 1H, C14-H), 2.31 (d, J = 3.5 Hz, 1H, C5-H), 1.53 
(dt, J = 9.2, 1.6 Hz, 1H, C12-H), 1.47 (dt, J = 9.2, 1.8 Hz, 1H, C12-H), 0.94 (s, 9H, tBu-H), 
0.13 (d, J = 7.6 Hz, 6H, C21-H/C22-H). 13C NMR (101 MHz, Chloroform-d) δ 207.89, 139.43, 
136.37, 131.27, 119.00, 72.78, 69.95, 67.14, 63.31, 54.39, 50.42, 45.58, 43.94, 43.74, 31.76, 









Imidazole (13 mg, 0.19 mmol) was added to a solution of 1.74 (12 mg, 0.038 mmol) in dry 
DMF (2 mL) and the mixture was stirred for 30 min. The mixture was then cooled to 0 ºC and 
chloro(dimethyl)thexylsilane (18 µL, 0.095 mmol) added and the mixture was stirred for 4 h. 
Monitored by TLC (hexane/EtOAc 3:1). When complete, the reaction was quenched with 
dH2O and organic layers extracted with hexane (3 × 5  mL). The layers were combined, dried 
over MgSO4, filtered and concentrated in vacuo. Product purified by flash chromatography 
(hexane/EtOAc 3:1) yielding the title compound as a white oily solid (4 mg, 23 %). Rf = 0.2 
(hexane/EtOAc 3:1).MS: m/z (+ESI) calc’d for C24H40O6Si [M + Na]
+ 475.2492 found 
475.2504. 1H NMR (400 MHz, Chloroform-d) δ 6.50 (ddd, J = 8.3, 6.9, 1.6 Hz, 1H, C9-H), 
6.01 (q, J = 1.7 Hz, 1H, C18-H), 4.67 (d, J = 8.6 Hz, 1H, C3-H), 4.41 (t, J = 1.9 Hz, 2H, C19-
H), 3.72 (d, J = 3.0 Hz, 1H, C2-H),  2.95 (dd, J = 15.8, 8.0 Hz, 1H, C8-H), 2.70 – 2.62 (m, 1H, 
C8-H), 2.56 (d, J = 8.8 Hz, 1H, C11-H), 1.84 (d, J = 1.4 Hz, 3H, C14-H), 1.48 (s, 9H, C17-H), 
0.94 – 0.78 (m, 12H, C26-H/C27-H/C28-H/C29-H), 0.13 (d, J = 1.7 Hz, 6H, C22-H/C23-
H).13C NMR (101 MHz, Chloroform-d) δ 193.36, 167.36, 157.85, 133.39, 132.90, 120.61, 






2-oxo-7-oxabicyclo[4.1.0]hept-3-en-1-yl)-2-methylbut-2-enoate (Compound 2.64) 
 
 
Imidazole (10 mg, 0.15 mmol) was added to a solution of 1.74 (10 mg, 0.013 mmol) in dry 
DMF (2 mL) and the mixture was stirred at ambient temperature for 30 min. The mixture was 
cooled to 0 ºC and TBDPS (18 µL, 0.075 mmol) was added and the reaction mixture was stirred 
for 4 h. Monitored by TLC (hexane/EtOAc 3:1). When complete, the reaction was quenched 
with dH2O, organic layer extracted with hexane (3 × 5 mL), dried with MgSO4, filtered and 
concentrated in vacuo. Product purified by silica gel chromatography (PET ether/EtOAc 3:1) 
yielding the title compound as a white solid (1.5 mg, 6 %). Rf = 0.26 (hexane/EtOAc 3:1). MS: 
m/z (+ESI) exact mass calc’d for C32H40O6Si [M + Na]
+ 571.2492 found 571.2486. Shown to 









1.74 (38 mg, 0.1 mmol) was dissolved in a solution of p-toluene sulphonic acid in acetone (0.2 
mg/ mL, 3 mL) and stirred at 60 ºC for 1.5 h. Reaction monitored by TLC (hexane/ EtOAc 
3:1). Upon completion, the reaction was quenched with the addition of 1mL saturated NaHCO3 
(aq.) and the mixture was concentrated under reduced pressure. The residue was subsequently 
re-dissolved in DCM and washed with brine. The organic layers were extracted into DCM (3 
× 10 mL) and concentrated under reduced pressure. The product was purified by preparatory 
TLC (hexane/ EtOAc 1:1) yielding a yellow oil (6 mg, 20 %) which was subsequently purified 
by HPLC yielding a white solid (2 mg, 6 %). Rf = 0.44 (hexane/ EtOAc 3:1). MS: m/z (+ESI) 
exact mass calc’d for C19H26O6 [M + Na]
+ 373.1622, found 373.1617. 1H NMR (400 MHz, 
Chloroform-d) δ 6.50 (ddq, J = 8.5, 7.4, 1.5 Hz, 1H, C21-H), 5.71 (q, J = 1.7 Hz, 1H, C5-H), 
4.83 (dq, J = 3.2, 1.7 Hz, 1H, C3-H), 4.44 (q, J = 1.9 Hz, 2H, C11-H), 3.65 (d, J = 2.7 Hz, 1H, 
C2-H), 3.00 – 2.89 (m, 1H, C20-H), 2.68 (ddd, J = 15.9, 7.1, 1.1 Hz, 1H, C20-H), 2.17 (s, 1H 
(acetone)), 1.83 (q, J = 1.1 Hz, 3H, C24-H), 1.54 (s, 3H, C32/33-H), 1.53 – 1.44 (m, 12H, t-
butyl H, C32/33-H). 13C NMR (101 MHz, Chloroform-d) δ 193.15, 166.89, 152.81, 133.05, 









1.74 (26 mg, 0.08 mmol) was dissolved in a solution of p-toluene sulphonic acid in pentan-3-
one (0.4 mg/ mL, 4 mL) and stirred at 100 ºC overnight with stirring. The reaction was 
monitored by TLC (hexane/ EtOAc 1:1). Upon completion, the reaction was quenched with 
the addition of 1 mL of saturated NaHCO3 (aq.) and the mixture was concentrated under 
reduced pressure. The residue was subsequently re-dissolved in DCM and washed with brine. 
The organic layers were extracted into DCM (3 × 10 mL), dried with anhydrous MgSO4, 
filtered and concentrated under reduced pressure. The product was purified by preparatory TLC 
(hexane/ EtOAc 1:1) yielding a yellow oil (12 mg/ 15%). Rf = 0.80 (hexane/ EtOAc 1:1).MS: 
m/z (+ESI) exact mass calc’d for C21H30O6 [M + Na]
+ 401.1935, found 401.1939. 1H NMR 
(400 MHz, Chloroform-d) δ 6.50 (dddd, J = 10.0, 5.7, 2.8, 1.0 Hz, 1H, C13-H), 6.00 (q, J = 1.5 
Hz, 1 H, C5-H), 5.69 (q, J = 1.7 Hz, 1 H, C5-H*), 4.83 (dq, J = 3.4, 1.7 Hz, 1H, C3-H), 4.75 
(dt, J = 3.0, 1.3 Hz, 1H, C3-H*), 4.44 (ddt, J = 6.3, 3.1, 1.5 Hz, 2H, C8-H), 3.74 (d, J = 3.0 Hz, 
1H, C2-H), 3.66 (d, J = 2.7 Hz, 1H, C2-H*), 2.94 (ddd, J = 15.9, 8.3, 2.9 Hz, 1H, C12-H), 2.72 
– 2.62 (m, 1H, C12-H), 2.43 (q, J = 7.4 Hz, 2H, C25/C26-H), 1.87 – 1.79 (m, 4H, C16/25/26-
H), 1.74 (qd, J = 7.4, 3.2 Hz, 1H, C25/26-H), 1.48 (s, 9H, t-Bu), 1.06 (t, J = 7.3 Hz, 3H, C27/28-
H), 0.94 (dt, J = 18.8, 7.5 Hz, 3H, C27/28-H). 13C NMR (101 MHz, Chloroform-d) δ 192.93, 
156.83, 133.16, 132.64, 132.46, 120.93, 80.72, 80.64, 66.03, 65.14, 63.20, 61.42, 60.74, 59.34, 
56.41, 35.61, 28.24, 27.20, 27.12, 24.78, 12.98, 8.06, 7.84.  










1.74 (16 mg, 0.05 mmol) was dissolved in a solution of p-toluene sulphonic acid in 1,1-
dimethoxycyclohexane (0.4 mg/ mL in 3 mL) and heated to 60 ºC with stirring for 1.5 h. The 
reaction was monitored by TLC (hexane/ EtOAc 1:1). Upon completion, the reaction was 
quenched with the addition of 1 mL of saturated NaHCO3 (aq.) and concentrated under reduced 
pressure. The residue was subsequently re-dissolved in DCM and washed with brine, then 
organic layers were extracted into DCM (3 × 10 mL), dried with anhydrous MgSO4, filtered 
and concentrated under reduced pressure. The product was purified by preparatory TLC 
(hexane/ EtOAc 1:1) yielding the product as a yellow oil (9.2 mg, 0.018 mmol, 36%). Rf = 0.90 
(hexane/ EtOAc 1:1). MS: m/z (+ESI) exact mass calc’d for C22H30O6 [M + Na]
+ 413.1935, 
found 413.1937. 1H NMR (400 MHz, Chloroform-d) δ 6.50 (ddq, J = 8.6, 7.2, 1.5 Hz, 1H, 
C13-H), 6-5.99 (m, 0.1H, C5-H*) 5.69 (q, J = 1.6 Hz, 1H, C5-H*), 4.85 (dq, J = 3.2, 1.7 Hz, 
1H, C3-H), 4.75-4.74 (m, 0.1H, C3-H*), 4.53 – 4.36 (m, 2H, C8-H), 3.74-3.73 (m, 0.1H, C2-
H*), 3.66 (d, J = 2.7 Hz, 1H, C2-H), 2.99 – 2.89 (m, 1H, C12-H), 2.72 – 2.61 (m, 1H, C12-H), 
1.95 – 1.85 (m, 1H, cyclohexyl), 1.83 (q, J = 1.1 Hz, 3H, C16-H), 1.73 (td, J = 7.6, 7.0, 4.5 Hz, 
1H, cyclohexyl), 1.61 – 1.50 (m, 3H, cyclohexyl), 1.47 (s, 9H, t-Bu), 1.45 – 1.42 (m, 1H, 
cyclohexyl), 1.21 (s, 1H, cyclohexyl), 1.16 (s, 1H, cyclohexyl), 0.98 – 0.81 (m, 2H, 
cyclohexyl). 13C NMR (101 MHz, Chloroform-d) δ 193.35, 167.08, 153.16, 133.09, 132.65, 
117.95, 101.11, 80.63, 64.96, 61.32, 59.70, 56.42, 34.69, 31.56, 28.24, 27.09, 25.46, 22.90, 
22.82, 12.97. *Denotes diastereotopic protons in a 9:1 ratio.  
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